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Ubiquitination of proteins is essential for optimal functioning of almost every cellular 
pathway in eukaryotes. Post-translational modification of a protein with ubiquitin can 
be used to trigger different processes. During replication, the ubiquitination of PCNA at 
K164 is a crucial step in the regulation of several DNA damage tolerance pathways. This 
thesis studies the enzymes involved in the mono-ubiquitination of PCNA and how this 
specific mark is generated and removed. A combination of mechanistic and structural 
studies is used to get insight in the regulation of this process. To place it into context this 
introduction first describes the ubiquitination process followed by a brief introduction 
of the essential players involved in DNA damage bypass.
Ubiquitination is a post-translational modification which involves the attachment of 
ubiquitin on either the lysine residues or the N-terminus of target proteins. Ubiquitin 
modifications are extremely modular since ubiquitin itself has 7 lysine residues in 
addition to its N-terminus which allows for the formation of homotypic, heterotypic and 
branched ubiquitin chains apart from the simpler mono-ubiquitination marks. Examples 
are K-48 linked ubiquitin chains, which are the most abundant form of ubiquitination and 
lead to proteasomal degradation of the target protein whereas mono-ubiquitination and 
K63-linked chains are non-degradative signals involved in several cellular pathways, 
e.g. DNA damage pathways and innate immunity (Thrower et al, 2000; Hoege et al, 
2002; Galan & Haguenauer-Tsapis, 1997). Recently, many reports have identified new 
phenotypes for the lesser known atypical chains which highlights the incredible diversity 
of the ubiquitin system (Swatek & Komander, 2016).
Attachment of ubiquitin to target proteins is performed by the sequential action of 
enzymes belonging to the ubiquitin activating enzymes (E1), ubiquitin conjugating 
enzymes (E2) and the ubiquitin ligases (E3) respectively. In this process, the E3 ligases 
control catalytic efficiency and substrate specificity. On the other hand, the removal of 
ubiquitin is carried out by a class of proteases called deubiquitinating enzymes (DUBs) 
which carry the catalytic as well as the substrate binding component.
The large numbers of (de)-ubiquitination enzymes are necessary to direct a vast array of 
ubiquitin linkages to a diverse set of substrates while ensuring specificity. Their action 
leads to the timely attachment and removal of ubiquitin linkages which is essential for 
proper functioning of the respective pathways. Further regulation of these enzymes can 
add another layer of control. This is important, as unchecked activity can have disastrous 
consequences for the cell. Different forms of regulation, including PTMS, effects of the 
substrate and intra-enzyme allosteric regulation have been observed and described 
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in a number of review articles (Sahtoe & Sixma, 2015; Zheng & Shabek, 2017). In the 
following sections we will highlight the importance of E3 ligases and DUBs in catalyzing 
their respective reactions and dictating substrate specificity.
UBIQUITINATING ENZYMES
The ubiquitination cascade is initiated by an E1 enzyme which activates the C-terminal 
tail of ubiquitin by forming a thioester bond with its active site cysteine residue in an 
ATP dependent manner. This is followed by the transfer of ubiquitin to the active site 
cysteine of one of ~35 different E2 enzymes. E3 ligases then bind ubiquitin-loaded E2’s 
and mediate the transfer of ubiquitin to the substrate.
E3 ligases are divided in three classes with distinct mechanisms for ubiquitin transfer, 
the HECT (homologous to E6-AP carboxy terminus) ligases directly catalyze ubiquitin 
transfer through their own enzymatic activity whereas the RING (really interesting new 
gene) E3’s act as intermediates and enhance the rate of ubiquitin transfer from the E2 to 
the substrate (Metzger et al, 2014; Scheffner & Kumar, 2014; Deshaies & Joazeiro, 2009). 
The third class of E3 ligases called RBR’s (RING-IBR-RING) display a RING-HECT hybrid 
mechanism to facilitate ubiquitin transfer (Wenzel et al, 2011). RING mediated transfer 
of ubiquitin from E2 to substrate is the most commonly used mechanism as RING E3’s 
are the largest family of E3 ligases with over 600 members.
The RING E3’s are composed of a zinc binding domain called the RING domain which 
contains highly conserved cysteine and histidine residues that co-ordinate two zinc 
atoms within its central core in a cross braced manner (Deshaies & Joazeiro, 2009). 
This peculiar fold allows the RING domain to act as a central axis for protein-protein 
interactions which is essential for its activity since both the E2 and the charged ubiquitin 
interact through this domain. RING E3s are a diverse group where some are active as 
single subunit RINGs while others require RING dimerization to exhibit full activity. 
Dimerization has been shown to be important for ligase activity as the non-E2 binding 
RING monomer is important for preferential binding of the ubiquitin-loaded E2 and 
subsequent catalysis (Plechanovová et al, 2011). In monomeric RINGs like the Cbl family, 
an additional ubiquitin interacting component which is external to the RING domain is 
necessary for optimal transfer of ubiquitin from the charged E2 (Dou et al, 2013).
Several variants of the RING domain have been identified, some of these lack one or most 
of the conserved residues but retain a similar fold while others have a similar conserved 
amino acid pattern but lack the distinct RING fold (Borden & Freemont, 1996). One of 
the notable variants is the U-box domain which does not bind zinc but has a similar fold 
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Chapter 1
as the RING domain and is also able to independently recruit E2 enzymes (Aravind & 
Koonin, 2000; Vander Kooi et al, 2006). In addition to the RING domain, most RING E3’s 
also contains a substrate interaction domain but, in some cases, they reside in multi 
subunit complexes where specificity is dictated by another subunit of the complex.
The RING domain does not contain an active site but it enhances the rate of transfer 
of charged ubiquitin from E2 to target substrate by several folds. This activation 
occurs upon binding of the RING domain to both the E2 and ubiquitin which results 
in the immobilization of the previously flexible donor ubiquitin. The RING imposed 
conformational selection also positions the C-terminal tail of ubiquitin with respect to 
the E2 active site such that the thioester is now prone to attack from the target lysine 
(Plechanovová et al, 2012; Pruneda et al, 2012; Dou et al, 2012). RING E3 ligases share 
this mechanism of E2~Ub binding and activation among themselves but their mode of 
substrate recruitment is very diverse and thus far less understood. The mechanistic 
details of substrate specificity are understood for a few cases but these cannot be 
applied to such a broad class of enzymes until more research with different combinations 
of E3’s and substrates is carried out.
DEUBIQUITINATING ENZYMES (DUBS)
DUBs are isopeptidases that cleave ubiquitin or ubiquitin-like molecules from their target 
substrates. DUBs counteract the activity of ubiquitin ligases so their role is defined by the 
nature of the substrate and the type of modification being processed. They also play a 
role in maintaining the free ubiquitin pool and formation of mature ubiquitin monomers. 
There are nearly 100 DUBs encoded in the human genome and they are divided into seven 
families based on their sequence and catalytic fold. The ubiquitin-specific proteases 
(USPs), the ovarian tumor proteases (OTUs), the ubiquitin C-terminal hydrolases (UCHs), 
the Josephin’s, MINDY’s and ZUFSP are cysteine proteases while the seventh DUB family 
is the JAMM (JAB1/MPN/Mov34) domain zinc-dependent metalloprotease family 
(Mevissen & Komander, 2017; Hermanns et al, 2018; Kwasna et al, 2018).
DUBs can cleave ubiquitin modifications either directly from their target substrate or 
they can modify ubiquitin signals by trimming ubiquitin chains. Many DUBs including 
the USPs do not exhibit chain specificity for ubiquitin dimers and cleave all types of 
chains. However, a subset, e.g. the OTU family, has exquisite chain specificity, even at 
the dimer level. Moreover, most USPs that have been tested on longer chains displayed 
some level of chain selectivity. In addition to their catalytic domains, many DUBs carry 
domains which allows them to either recognize specific linkage type or the target from 
which the linkage needs to be cleaved. In some cases, these internal domains don’t 
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affect target recruitment but instead regulate DUB function by modulating their intrinsic 
catalytic activity.
Regulation of DUB activity by affecting target recruitment or catalytic activity can also 
be carried out by external proteins that associate with DUBs in multi subunit complexes 
(Sahtoe & Sixma, 2015; Leznicki & Kulathu, 2017). Multiple subunits of the SAGA DUB 
module act together to increase yeast USP Ubp8 activity while one subunit also facilitates 
substrate recognition (Lee et al, 2005; Morgan et al, 2016). UCH-L5 activity is regulated 
both positively and negatively by binding to RPN13 and INO80G respectively. Structural 
studies have shown how both these regulators affect UCH-L5 substrate binding leading 
to opposite outcomes (Sahtoe et al, 2015; VanderLinden et al, 2015). Another well know 
example is the activation of USP1/12/46 by WDR48 where binding leads to increased 
catalytic turnover of the USPs (Cohn et al, 2007). USP12 and USP46 also bind another 
activator called WDR20 which leads to further activation of these complexes (Kee et al, 
2010). Structures of DUBs from each subfamily have been reported in the past decade 
that highlight the distinct architecture and activity mechanism of each class. However, 
the mechanisms involved in allosteric regulation and substrate specificity are still poorly 
understood for most DUBs.
SUBSTRATE SPECIFICITY
The ubiquitin machinery performs its function on a broad group of substrates with a 
high degree of specificity. If (de)-ubiquitination enzymes were not acting specifically 
on their respective substrates then this would lead to a complete breakdown in cellular 
functioning. E3 ligases and DUBs are the principal determinants of target specificity 
for ubiquitin attachment and removal respectively. Over the past few decades many 
reports have emerged that describe the role of specific regions in recruitment of these 
enzymes to their respective substrates. These regions could either be specialized 
domains within the enzymes itself or they can be “external” proteins that interact with 
the enzyme (Zheng & Shabek, 2017). However, there is far less understanding of the 
mechanistic details involved in specific lysine targeting especially when there are other 
lysine’s also present in the vicinity of the ubiquitin thioester. Some breakthroughs have 
been achieved for a handful of RING E3’s as mechanisms describing the role of protein-
protein interactions with substrate in orienting the charged ubiquitin in the vicinity of 
the target lysine have been elucidated (McGinty et al, 2014; Streich & Lima, 2016). In 
case of DUBs, the first structure reported was of the SUMO specific SENP2 with its 
substrate RanGAP1-SUMO. The authors identified interaction surfaces on the protease 
that are important for RanGAP1 specific activity (Reverter & Lima, 2006). Recently, the 
structure of the SAGA-DUB module on ubiquitinated (K120) histone H2B highlighted 
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the molecular determinants for substrate specificity in yeast Ubp8 (USP22 in humans) 
(Morgan et al, 2016).
Many examples of substrates that show modification of specific lysine residues have 
emerged for e.g. ubiquitin modification of K164 in PCNA, K561 and K523 in FANCD2 and 
FANCI, K519 in SMAD4 etc (Mattiroli & Sixma, 2014). One of the best studied substrates 
for site specific (de)-ubiquitination is the nucleosome, more specifically the histone H2A. 
There are three distinct sites on H2A (K13/K15; K118/K119; K125/K127/K129) which are 
ubiquitinated specifically by three different E3 ligases which lead to different biological 
outcomes (Wang et al, 2004; Mattiroli et al, 2012; Gatti et al, 2012; Kalb et al, 2014). 
Conversely, the removal of ubiquitin from these three sites also seems to be performed 
by different DUBs as it has been reported that BAP1 (Scheuermann et al, 2010; Sahtoe et 
al, 2016) and USP16 (Joo et al, 2007) specifically deubiquitinate the K118/K119 site while 
USP44 (Mosbech et al, 2013) and USP51 (Wang et al, 2016) have been implicated in the 
deubiquitination of the K13/K15 site. Recently, USP48 was identified to be preferentially 
involved in counteracting the role of BRCA1/BARD1 ubiquitination of K125/K127/K129 
(Uckelmann et al, 2018). Another substrate that is selectively modified at a specific lysine 
residue is PCNA which is mono-ubiquitinated at K164 by the E2-E3 pair RAD6-RAD18 
(Hoege et al, 2002) and deubiquitinated by USP1 (Huang et al, 2006). In chapters 4 and 5, 
we have identified regions in both USP1 and RAD18 which play a role in PCNA interaction 
directly and also through their association with DNA.
PCNA (DE)-UBIQUITINATION
Proliferating cell nuclear antigen (PCNA) is a ring-shaped protein that orchestrates a 
large plethora of functions at the replication fork. It is also known as the sliding clamp 
since its architecture enables it to encircle the DNA and slide bi-directionally on it to 
perform multiple functions, primarily by recruitment of replication and repair factors. A 
5-protein complex called the replication factor complex (RFC) ensures efficient loading 
of PCNA on DNA in an ATP dependent manner (Yoder & Burgers, 1991). PCNA lacks any 
enzymatic activity by itself but it plays a role in varied processes by recruiting a wide 
range of proteins (Moldovan et al, 2007). PCNA interacts with a large number of proteins 
by binding to a conserved motif called the PCNA interacting peptide (PIP) motif. The 
consensus PIP sequence is Q-X-X-Ψ-X-X-ϑ-ϑ, in which Ψ is a moderately hydrophobic 
amino acid (L, V, I, or M) and ϑ is an aromatic residue (Y or F) (De Biasio & Blanco, 2013). 
Many proteins have different versions of the PIP which deviate from the consensus 
sequence as a result of which they can have different affinities for PCNA.
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The primary function of PCNA is in DNA replication where it tethers the polymerase to 
DNA which leads to an increase in replication processivity. The sliding clamp also plays 
a crucial role in non-replicative processes mostly dealing with DNA repair and genomic 
stability (Choe & Moldovan, 2017). One such process is the translesion synthesis (TLS) 
pathway where cells employ low fidelity polymerases (for eg; Pol η, Pol κ, Rev1) to 
bypass damaged lesions which cannot be processed by normal replicative polymerases. 
TLS is tolerated by the cell as it prefers the use of error prone polymerases instead 
of replication fork stalling which can lead to formation of more toxic double stranded 
breaks if replication is not restarted (Cipolla et al, 2016). In TLS, PCNA gets mono-
ubiquitinated at lysine 164 by RAD6-RAD18 upon fork stalling at DNA lesions (Fig.1), this 
leads to the recruitment of specialized TLS polymerases that allow for damage bypass 
and continuation of replication (Hoege et al, 2002; Watanabe et al, 2004; Kannouche et 
al, 2004). Since unchecked recruitment of these polymerase can be highly mutagenic, 
cells employ the deubiquitinase USP1 which removes the mono-ubiquitin mark from 
PCNA (Fig.2) and allows the entry of normal replicative polymerases resulting in more 






Fig.1) Structural model of RAD6_Ub-RAD18 bound to PCNA (PDB: 1AXC chains A,C,E) loaded on DNA. Model 
of RAD6_Ub-RAD18 is based on RNF4-RNF4-Ub~E2 (PDB: 4AP4), the RAD18 RING domain (PDB: 2Y43) was 
superimposed on RNF4 and RAD6 (PDB: 2YBF chain A) was superimposed on the E2 before removing the RNF4 
and E2 structures. The current model lacks the Zinc finger (ZnF) and SAP domain (shown here) along with the 
C-terminal region of RAD18 which contains the RAD6 and Pol η binding domain.
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RAD18 is a multi-domain RING E3 ligase that is active upon homodimerization mediated 
by its N-terminal RING domain. This domain is also important for RAD6 (E2) interaction 
along with another specialized RAD6 binding domain (R6BD) that is present at the 
C-terminus of RAD18. Additionally, RAD18 also contains a zinc-finger (ZnF) domain, SAP 
domain and a Pol η interaction domain (Hedglin & Benkovic, 2015). RAD6-RAD18 form 
a stable asymmetric complex where one RAD6 molecule binds one RAD18 homodimer 
(Bailly et al, 1997; Huang et al, 2011). RAD6 is capable of forming ubiquitin chains through 
non covalent interactions with the “backside” ubiquitin binding site but RAD18 binds 
to this site through its R6BD and prevents “backside” binding thereby inhibiting RAD6 
chain formation activity (Hibbert et al, 2011). The mono-ubiquitination activity of RAD6-
RAD18 is low on free PCNA but it is strongly stimulated when PCNA is loaded onto the 
DNA (Fig.1) (Garg & Burgers, 2005). The mechanistic details of this activation were still 
unknown so we have tried to address this by performing quantitative mono-ubiquitination 
assays on DNA-loaded PCNA in chapter 5.
In spite of the large number of ubiquitination enzymes, RAD6-RAD18 is essential for 
carrying out PCNA mono-ubiquitination. This ubiquitination mark acts as a trigger for 
TLS upon replication fork stalling. Stalling of the replication fork leads to a buildup 
of ssDNA which is quickly bound by the heterotrimeric RPA protein. This induces the 
recruitment of RAD6-RAD18 to the stalled replication fork by a direct interaction between 
RPA and RAD18 (Niimi et al, 2008). The binding of RAD18 to RPA takes place through its 
N- terminal region which includes the RING domain but not the ZnF or the SAP domain 
(Davies et al, 2008). However, RAD18 binds DNA through its SAP domain which has been 
shown to be important for its activity on PCNA (Notenboom et al, 2007; Tsuji et al, 2008; 
Nakajima et al, 2006). Altogether, this suggests that both DNA and RPA interactions 
are necessary for RAD18 ligase activity on PCNA. The interaction region for PCNA 
on RAD18 has been broadly mapped to the N-terminal region spanning from residue 
16-366 but the exact residues involved are not known. This leads us to the important 
question of how several of these RAD18 interactions co-operate to achieve specific 
PCNA mono-ubiquitination at K164 (Fig.1). In Chapter 5, we identify several molecular 
features within RAD18 that allow for activity on DNA-loaded PCNA and uncover new 
mechanisms involved in RAD18 activity.
USP1 AND ITS PARALOGS
USP1 acts as a negative regulator of TLS by deubiquitinating monoubiquitinated PCNA 
(PCNA-Ub) thereby preventing the unscheduled recruitment of TLS polymerases (Fig.2) 
(Huang et al, 2006). USP1 also acts as a negative regulator of another DNA repair 
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pathway i.e. the Fanconi Anemia pathway where it deubiquitinates monoubiquitinated 
FANCD2 (Nijman et al, 2005). The USP1 knockout mice show a severe Fanconi Anemia 
phenotype with defects in homologous recombination and heightened PCNA-Ub levels 
confirming the importance of USP1 in genomic stability (Kim et al, 2009). Due to its 
role in DNA repair, USP1 has emerged as an attractive drug target in cancer research 
and several studies have shown that inhibition of its enzymatic activity can reverse the 
chemoresistance of non-small cell lung cancer cells to cisplatin which is a commonly 
used anticancer drug (Chen et al, 2011). Recently, USP1 mediated PCNA deubiquitination 
in TLS was shown to be important for maintaining replication fork stability in the absence 
of BRCA1. This gives rise to an interesting synthetic lethal relationship and suggests 
that USP1 inhibitors might help in treatment of BRCA1 deficient tumors (Lim et al, 2018). 
Additionally, USP1 has been proposed to have an important role in stabilizing a number 
of proteins involved in diverse cellular pathways like autophagy, cell division, antiviral 
immunity, AKT signaling, β-catenin signaling and stem cell maintenance (Raimondi et 
al, 2019; Jung et al, 2016; Yu et al, 2017; Zhang et al, 2012; Ma et al, 2019; Williams et 
al, 2011). The various USP1 functions and its clinical potential make it an interesting 
member of the USP family to study mechanistically.
USP1 is a multi-domain protein of 785 amino acid residues and belongs to the largest 
family of DUBs called the USPs. This family of DUBs has cysteine protease activity in a 
conserved catalytic domain. The USP catalytic domain can be divided into 3 subdomains 
which are known as the finger, palm and thumb domains. Its catalytic center has a 
catalytic triad involving a cysteine (Cys), a histidine (His) and an aspartate or asparagine 
(Asp or Asn). In some USPs the third catalytic residue (Asp or Asn) is missing but the 
regions containing the Cys and His residues are highly conserved among all family 
members. The mode of catalysis in USPs is similar to that observed in the Papain 
protease families where an acyl intermediate is formed between the catalytic Cys and 
C-terminal glycine of ubiquitin which is hydrolyzed upon nucleophilic attack by a water 
molecule (Komander et al, 2009). Alternatively, it was proposed that USP1 activity takes 
place through general base catalysis which is different from the mode of action of the 
papain family (Villamil et al, 2012a).
The catalytic triad of USPs is located at the interface of the palm and thumb subdomains 
while the finger domain binds the ubiquitin molecule that is linked via its C-terminus to a 
lysine residue of a target protein or another ubiquitin molecule. Several structures of USP 
catalytic domains with and without ubiquitin have been solved which not only highlight 
the conservation of the catalytic fold but also demonstrate unique structural features 
among USPs. In these structures, some USPs are found in an inactive conformation in 
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the Apo form, where either the catalytic residues are misaligned or the ubiquitin binding 
region is blocked. These USPs achieve a catalytic competent state upon binding of 
ubiquitin or specialized domains (internal or external) to the USP catalytic domain. One 
such example is that of USP7 where binding of ubiquitin leads to changes in several 
structural elements surrounding the catalytic cleft which realigns the active site residues 
(Hu et al, 2002). There is no structural information of the USP1 protein as of now but 
it is very likely that its catalytic domain would be similar to that of other members of 
this family (Fig.2). However, the presence of large inserts within its catalytic domain 
makes the overall structure of USP1 very interesting as it can inform us on the specific 
positioning and role of these inserts in USP1 activity.
USP1 activity is regulated at multiple levels since it is a crucial regulator of important 
cellular pathways. It has been proposed that exposure to UV irradiation leads to an 
autocleavage event within USP1 resulting in loss of activity and thus a prolonged TLS 
(Huang et al, 2006). Importantly, USP1 activity is regulated by a WD40 repeat protein 
called UAF1 (USP1-associated factor) which binds and enhances USP1 catalytic activity. 
UAF1 is a WD40 domain containing protein which is composed of an N-terminal 8-bladed 
β-propeller and two C-terminal domains namely, SLD1 and SLD2. The N-terminal 
β-propeller region is responsible for binding to USP1 that leads to a several fold increase 
in kcat while there is no significant change in KM on a minimal substrate. This suggests 
that UAF1 binding results in increased catalytic turnover of USP1 and no change in 
affinity for ubiquitin (Cohn et al, 2007). It was later shown that UAF1 activates USP1 by 
realigning the active site residues into a productive confirmation (Villamil et al, 2012a). 
The C-terminal domains of UAF1 have also been implicated in USP1 function on both 
PCNA-Ub and FANCD2-Ub. The SLD2 domain of UAF1 binds to the SIM motif on FANCI 
and hElg1 which ensures targeted recruitment of USP1 to FANCD2-Ub and PCNA-Ub 
respectively (Yang et al, 2011).
UAF1 binds and activates two other USPs which are paralogs of USP1 namely, USP12 
and USP46 (Cohn et al, 2009). Both these USPs are much smaller than USP1 as they 
are mainly composed of the USP catalytic domain and lack the large inserts found in 
USP1. USP12 and USP46 share high sequence similarity (88%) with each other and 31% 
sequence similarity with USP1. The cellular substrates of USP12 and USP46 are not well 
defined with multiple reports implicating them in divergent cellular pathways. USP46 
plays an important role in neurobiology as studies have linked it to behavioral phenotypes 
in mice and in the regulation of AMPA receptors which are crucial for brain function 
(Imai et al, 2013; Zhang et al, 2011; Huo et al, 2015). USP46 has also been shown to be 
essential for proliferation of HPV transformed cells making it a target for the treatment 
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of HPV induced cancers (Kiran et al, 2018). On the other hand, USP12 acts on the T cell 
receptor (TCR) adaptor proteins LAT and Trat1 thereby regulating TCR expression at the 
cell surface (Jahan et al, 2016). It is also proposed to promote LPS induced macrophage 
responses and act as a negative regulator of the Notch signaling pathway (Kumar et 
al, 2017; Moretti et al, 2012). Additionally, some reports have identified considerable 
overlap in USP12 and USP46 function which is to be expected due to the high degree of 
similarity. Both USP46 and USP12 have been implicated in deubiquitination of histone 
H2A and H2B in Xenopus, in the regulation of Akt phosphatases (PHLPP and PHLPPL1) 
and in the regulation of immune response upon exposure to the Epstein Barr virus (Joo 
et al, 2011; Gangula & Maddika, 2013; Li et al, 2013; Ohashi et al, 2015).
The activation of USP12 and USP46 by UAF1 takes place solely by an increase in kcat 
which is similar to what is observed in USP1. But USP12 and USP46 undergo a second 
activation step upon binding another WD40 repeat protein called WDR20 (Kee et al, 
2010). WDR20 is composed of a 7 bladed β-propeller domain and together with UAF1 
stimulates the catalytic activity of USP12 and USP46 to its maximum state. Interestingly, 
USP1 lacks WDR20-mediated hyperactivation presumably due to its inability to bind this 
protein which suggests significant differences in USP1 activity regulation compared 
to USP12 and USP46. Several structures of USP12 and USP46 with and without their 
activators have been solved in the last few years. These have shed more light on the 
mechanistic details of this activation (Yin et al, 2015; Li et al, 2016; Dharadhar et al, 
2016). In chapter 3, we present the structure of USP12-Ub+UAF1 and show that UAF1 
has a secondary binding site on USP12 which is conserved among its paralogs, USP46 
and USP1.
Our structure is identical to the USP46-Ub+UAF1 structure where the authors also 
observed the second UAF1 binding but did not pursue it as the second UAF1 binding does 
not affect the catalytic activity of these USPs. Altogether, these structures highlighted 
the mechanistic details of UAF1 binding in this subfamily of USPs and revealed the 
interfaces involved in catalytic activation. The USP12 and USP46 showed no structural 
changes with and without UAF1 as all these structures were bound to ubiquitin suicide 
probes which trap the USP in an active conformation. However, it was observed that 
these USPs get activated when UAF1 binds to the finger sub-domain which is very distant 
from the active site suggesting an allosteric activation mechanism. In another study, the 
apo structures of USP12 and USP12+UAF1 were solved which when compared to each 
other showed subtle rearrangements of various structural elements within the USP12 
catalytic domain upon UAF1 binding. Additionally, the same study also presented the 
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structure of the USP12+UAF1+WDR20 complex showing that WDR20 binds the palm 
domain of USP12 which is still very distant from the catalytic center (Li et al, 2016).
Understanding the mechanistic details of USP1 activation by UAF1 has proven to be 
elusive so far due to lack of any structural information of USP1 itself. However, the 
structures of its paralogs with and without UAF1 do reveal the activation interface on 
USP1 along with the understanding that the activation mechanism is highly dynamic in 
this sub class of USPs. Further correlation of the findings in USP12/USP46 to USP1 is 
complicated since USP1 is a much larger protein due to its inserts which are interspersed 
within its catalytic domain. Additionally, USP1 does not have a secondary activation 
step upon interaction with WDR20 like its paralogs which indicates that certain distinct 
mechanisms might be employed by USP1 upon UAF1 binding. In Chapter 4, we describe 
the role of USP1 inserts in regulating its intrinsic activity and reveal how this regulation 
is closely linked to UAF1 mediated activation.
Apart from UAF1-mediated activation of USP1 there are other external factors that have 
been proposed to play a role in USP1 regulation. Phosphorylation of serine 313 located in 
the large insert of USP1 seemed essential for UAF1 recruitment and activation (Villamil 
et al, 2012b) but this does not explain why USP1 lacking this region can still bind to 
and get activated by UAF1. Moreover, USP12 and USP46 lack this region within their 
corresponding insert and still bind UAF1 and mutational analysis suggests that binding 
is conserved within this sub-family of USPs (Yin et al, 2015; Li et al, 2016). Another 
factor that was recently reported to regulate USP1 activity was DNA binding to the 
large insert of USP1. DNA binding was reported to stimulate USP1-UAF1 activity three-
fold by enhancing ubiquitin binding and catalytic turnover (Lim et al, 2018). Since USP1 
deubiquitinates a number of DNA bound substrates this kind of regulation seems feasible 
but the total activation is small and we could not reproduce it (chapter 4). In Chapter 4, 
we present a detailed analysis of the effect of both DNA binding and phosphorylation 
on USP1 activity against a minimal substrate.
The regulation of USP catalytic activity has been mostly studied on minimal substrates 
which are mainly composed of a ubiquitin molecule attached to a fluorophore at the 
C-terminus. These kind of activity assays do not allow us to study the role of substrates 
in regulation of USP intrinsic activity. Furthermore, recognition of molecular determinants 
within USPs for their respective substrates is also not possible with this experimental 
setup. Many USPs have multiple natural substrates thus identifying specific interaction 
motifs will help in targeted inhibition of USP function rather than inhibiting all catalytic 
activity which is the most commonly used method of targeting USPs. Biochemical and 
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structural studies of USPs with their natural substrates is an exciting area of research 
which can help answer a lot of these questions and can aid in the development of a 
new class of specific USP inhibitors. This avenue is currently technically challenging 
to explore as it requires the production of a well-defined singly modified substrate. 
Additionally, several other factors have to be considered which have been explained in 
detail along with an example of studying USP activity on natural substrate in Chapter 






Fig.2) Structural model of USP1-UAF1 bound to PCNA (PDB: 1AXC chain A,C,E) loaded on DNA. A homology 
model of USP1-UAF1 was created based on the USP12-UAF1 structure (PDB: 5K1C chain A,B); USP1 has three 
inserts, i.e. L1, L2 (not shown here) and L3, these inserts are absent in USP1 paralogs USP12 and USP46.  
USP1 has gained interest for clinical applications due to its role in two essential DNA 
repair pathways i.e. Fanconi Anemia pathway and Translesion synthesis pathway. USP1 
deubiquitinates monoubiquitinated FANCD2 and PCNA respectively in these pathways 
and both these substrates can be purified in large amounts biochemically. This presents 
an opportunity to uncover mechanistic details of USP1 function on its natural substrate 
which will not only aid in the development of specific inhibitors but also answer some 
basic concepts of substrate mediated catalysis in USP function. The activity of USP1 
on FANCD2 has been examined in significant detail and FANCD2 recognition elements 
have been identified in USP1 (Arkinson et al, 2018). Moreover, it was also shown that 
DNA is an essential cofactor for efficient FANCD2 deubiquitination by USP1-UAF1 where 
the activation is solely dependent on the DNA binding role of UAF1 (Liang et al, 2019). 
1
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Similar analysis of USP1 activity on PCNA has not yielded any new insights and the role 
of DNA loading of PCNA on deubiquitination has not been explored yet. This is most likely 
due to the technical challenges in the loading of PCNA-Ub on DNA and the subsequent 
purification of this complex for biochemical analysis. In Chapter 4, we describe a protocol 
for large scale purification of DNA-loaded PCNA-Ub and uncover a secondary activation 
step in USP1 which takes place upon interaction with DNA-loaded PCNA-Ub.
This thesis brings to light several aspects involved in the allosteric regulation of USP1 
both by its activator UAF1 and its natural substrate DNA-loaded PCNA-Ub. It also 
highlights the role of DNA-loaded PCNA on regulating activity of RAD6-RAD18 and 
identifies PCNA interacting regions on both RAD18 and USP1. Altogether, this helps in 
understanding basic mechanisms of substrate mediated catalysis in E3’s and DUB’s and 
provides new hotspots for specific targeting of this important pathway.
OUTLINE OF THE THESIS
Chapter 2 provides a detailed framework for quantitative characterization of USP 
activity with complete protocols for purification of USPs and their kinetic analysis on 
both minimal and more natural substrates. The advantages and limitations of various in 
vitro binding assays that could be used for studying USP interactions are also discussed.
In Chapter 3 we report the crystal structure of the USP12-Ub/UAF1 and show that the 
USP12/UAF1 complex has a 1:2 stoichiometry in solution with a two-step binding that is 
conserved in USP1 and USP46. We also show that the high affinity interface is essential 
for UAF1 mediated activation in USP12 while the low affinity interface does not affect 
catalytic activity.
In Chapter 4 we describe the mechanistic details of USP1 activation by UAF1 and show 
how UAF1 binding alone brings USP1 to an activated state that resembles WDR20 
activation in USP12/USP46. We also discover a secondary activation step within USP1 
that is triggered only upon interaction with DNA-loaded PCNA-Ub. Moreover, we identify 
the region within USP1 responsible for DNA and PCNA interaction and show that these 
are necessary for the secondary activation of USP1.
In Chapter 5 we perform a biochemical analysis of RAD6-RAD18 activity on DNA-loaded 
PCNA and identify molecular motifs that are important for its activity in the presence 
and absence of DNA. We propose that activation on DNA-loaded PCNA is solely due 
to DNA binding of RAD18 and also that the interface for ubiquitin transfer in RAD18 is 
unique from what is observed in other RING ligases.
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Chapter 6 closes the thesis with a general discussion of the results presented here along 
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Ubiquitin-specific proteases (USPs) are an important class of deubiquitinating 
enzymes (DUBs) that carry out critical roles in cellular physiology and are regulated at 
multiple levels. Quantitative characterization of USP activity is crucial for mechanistic 
understanding of USP function and regulation. This requires kinetic analysis using in vitro 
activity assays on minimal and natural substrates with purified proteins. In this chapter 
we give advice for efficient design of USP constructs and their optimal expression, 
followed by a series of purification strategies. We then present protocols for studying 
USP activity quantitatively on minimal and more natural substrates, and we discuss 
how to include possible regulatory elements such as internal USP domains or external 
interacting proteins. Lastly, we examine different binding assays for studying USP 
interactions and discuss how these can be included in full kinetic analyses.
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INTRODUCTION
Ubiquitination of proteins has become one of the most widely studied aspects of 
cellular physiology in eukaryotes. This is due to its crucial role in regulating a plethora 
of cellular pathways ranging from DNA damage responses to cell migration. The (de)-
ubiquitinating enzymes orchestrating the ubiquitination cycle were first described in 
the 1980’s (Hershko, Heller, Elias, & Ciechanover, 1983; Pickart & Rose, 1985), and since 
then considerable progress has been made in understanding their role as essential 
components of many, if not all cellular pathways. Deubiquitinating enzymes (DUBs) are 
proteases that cleave ubiquitin from their target substrates, and sometimes can also 
remove closely-related ubiquitin-like proteins such as NEDD8. They play a role in the 
formation of mature ubiquitin monomers by processing C-terminally extended ubiquitin 
precursors, and they maintain a free ubiquitin pool by recycling unanchored polyubiquitin 
chains into free ubiquitin. Apart from being important for ubiquitin maintenance, DUBs 
also cleave ubiquitin marks from their target proteins, which counteracts the activities 
of ubiquitin-ligating enzymes. This leads to distinct roles for DUBs depending on the 
type of ubiquitin modification and the nature of substrate being cleaved. Cleavage 
of Lys-48 linked ubiquitin chains prevents proteasome-mediated degradation of the 
target proteins, while cleaving “non-degradative” ubiquitin linkages turns off the signal 
created by particular ubiquitin-substrate attachments. Finally, DUBs can also partially 
trim ubiquitin chains, which leads to modification of ubiquitin chain architecture and 
changes in downstream signaling (Reyes-Turcu, Ventii, & Wilkinson, 2009).
There are approximately 100 DUBs encoded in the human genome, which are subdivided 
into smaller families based on their sequences and catalytic mechanisms (Leznicki & 
Kulathu, 2017). Seven families of DUBs are characterized by structurally distinct catalytic 
folds, six of which are cysteine proteases and one a metalloprotease, the so-called 
JAMM domain (Mevissen & Komander, 2017; Hermanns et al., 2018; Hewings et al., 2018; 
Kwasna et al., 2018). The Ubiquitin-Specific Proteases (USPs) form the largest family of 
DUBs, and in this chapter we focus on this group.
USPs contain a conserved catalytic core which has a papain-like fold that is comprised 
of approximately 350 residues. This catalytic domain adopts a conformation which 
resembles an extended open hand, subdivided into fingers, palm and thumb subdomains 
(Hu et al., 2002). USPs have a catalytic triad composed of cysteine, histidine and 
aspartate/asparagine residues that come from regions remote in the primary sequence. 
Many USPs have insertions of various sizes in their catalytic domains (Ye, Scheel, 
Hofmann, & Komander, 2009), as well as substantial N- and C-terminal extensions. These 
additional regions can play major roles in the catalysis and regulation of the USPs. A well-
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studied example is USP7 in which an N-terminal TRAF domain is crucial for interaction 
with its substrates (Holowaty, Sheng, Nguyen, Arrowsmith, & Frappier, 2003; Sheng et 
al., 2006), while the C-terminal region is important for regulating its catalytic activity as 
well as substrate binding (Fernández-Montalván et al., 2007; Faesen et al., 2011; Cheng 
et al., 2015; Pfoh et al., 2015).
The physiological functions of USPs are slowly emerging. Many USPs are involved in 
pathways that are dysregulated in human diseases such as cancer and neurodegenerative 
diseases. (Clague, Coulson, & Urbe, 2012; Heideker & Wertz, 2015). For example, USP1, 
USP3, USP11, USP16, USP28, USP47, USP48 are involved in DNA damage repair pathways; 
USP2, USP4, USP15, USP34 participate in Wnt signaling; and USP8, USP15, USP30, USP32 
are implicated in the autophagy of mitochondria (mitophagy) (Fraile, Quesada, Rodríguez, 
Freije, & López-Otín, 2012; Bingol et al., 2014; Cornelissen et al., 2014; Durcan et al., 2014; 
Wang et al., 2015). How most USPs select their respective substrates is unclear, which 
makes it hard to infer any specific function from their sequence or structure; this is 
further complicated by their tendency to function on multiple substrates. A quantitative 
analysis of USP activity on different substrates (especially natural substrates) can yield 
deeper insights into how specific USP targets are selected.
Since USPs are essential biological regulators, they themselves have to be tightly 
regulated to ensure proper functioning. Different modes of regulation exist, affecting 
catalytic activity, subcellular localization, or cellular abundance of these enzymes. 
Regulation can be orchestrated by internal factors (domains within the USPs), external 
factors (binding partners, substrate, post-translational modifications) as well as 
transcriptional control; many different modes of regulation may contribute to activity 
of a single USP (Sahtoe & Sixma, 2015; Leznicki & Kulathu, 2017; Mevissen & Komander, 
2017). Continuing with the example of USP7, substrate binding and catalytic activity 
are regulated by its internal domains but it can be further modulated by an external 
protein called GMPS that enhances its activity and affects its subcellular localization 
(Van Der Knaap et al., 2005; Faesen et al., 2011; Reddy et al., 2014). There are many 
examples where multiple modes of regulation are employed for a single USP and these 
have been extensively reviewed elsewhere (Sahtoe & Sixma, 2015; Leznicki & Kulathu, 
2017; Mevissen & Komander, 2017).
To understand how internal and external regulatory factors modulate catalytic activity of 
USPs it is important to perform quantitative analysis of USP activity. In vitro analysis can 
be very valuable here, as it allows separating individual functions by performing assays 
in the presence and absence of the regulatory elements. These kinds of analyses shed 
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light on the mechanism of activity modulation and in some cases inform us on how 
concerted action of multiple regulatory elements brings about changes in USP function.
In this chapter we give a detailed workflow for quantitative analysis of USP function. 
We discuss expression systems and present a series of examples of USP purification. 
We then describe how USP catalytic activity can be quantitatively analyzed on different 
substrates, i.e., minimal substrates and natural substrates. We also present a detailed 
workflow for generating fluorescently labelled ubiquitinated substrate for quantitative 
analysis of DUB activity. Furthermore, we review the use of activity assays to study 
how internal and external factors modulate USP catalytic activity. Finally, we discuss 
the importance of studying USP interactions with their substrates and/or cofactors 
quantitatively in vitro and highlight the advantages and limitations of commonly used 
binding assays.
PURIFICATION OF USPS
For the in vitro characterization of USPs it is important to carefully purify the USP in 
question. The first step is expression of the protein, but as yields vary in a protein-
specific manner we do not present a general protocol, but rather suggest testing different 
expression systems. As USPs are intracellular proteins, either bacteria or insect cells 
usually work well for expression. In bacterial expression, there will be no eukaryote-
specific post-translational modifications taking place, whereas this may happen 
during expression of USPs in insect cells. As these may affect activity, this needs to 
be carefully examined. Moreover, DUBs purified from insect cells may bind tightly to 
regulatory proteins that are hard to remove; a notable example is USP1, that carries along 
its activator UAF1 (WDR48). A related problem occurs when purifying the activators: it 
is difficult to purify GMPS from insect cells without carrying along a fraction of USP7.
To efficiently test different affinity tags and expression systems we make use of a 
coherent set of ligation-independent expression vectors (Luna-Vargas et al., 2011), 
most of which are available from Addgene (www.addgene.org). Unless post-translational 
modifications are important, we prefer bacteria for expression as procedures are faster. 
Therefore, we first test if the protein of interest can be expressed in bacteria in small-
scale expression tests under a set of different conditions. In these assays we vary the 
choice of affinity tag, expression strain, growth medium, and induction conditions. If 
none of these conditions yield soluble protein, then we try insect cells, where we again 
start with small scale tests. Expression is read out after the initial affinity purification by 
analysis on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
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If specific protein domains have to be expressed, or if soluble full-length protein is not 
expressed in any of the tested conditions, one needs to design the specific region to 
be expressed. In the following sections we will reflect on the design of the expression 
construct that can aid in obtaining pure USP proteins or protein fragments and describe 
three case studies to show what a USP purification protocol can look like.
Determination of a well behaved USP catalytic domain construct
Protocol
1. Look up the USP of interest in e.g. UniProt. Here protein sequences are stored, 
including splicing variants, as well as additional information from the literature: 
scroll through the page and follow links to published papers or second party 
websites. Especially when there is structural information known, we recommend 
checking the linked page of the Protein Databank (PDB) and if applicable the 
accompanying paper(s) for expression constructs and domain information.
2. If the literature assessment has not yielded defined construct boundaries, we highly 
recommend looking at the sequence analysis by Ye et. al. (Ye et al., 2009). Here the 
catalytic domains (CDs) of all (human) USPs have been aligned and annotated in 
the supplemental information. Search for the USP of interest and note the active-
site residues as well as the presence of any zinc-binding motifs. This information 
is useful for the actual purification and analysis.
3. The alignment in Ye et. al.,2009 shows boundaries for the catalytic core. These 
boundaries have been obtained by sequence comparison and in our experience, 
they give a good starting point to design a construct that yields a soluble catalytic 
domain. However, the actual domain boundaries vary more than expected from the 
sequence alignments alone and may require optimization.
4. We use sequence conservation and secondary structure to define the borders of 
the constructs. As a tool we make use of the Crystallographic Construct Designer 
(CCD, https://ccd.rhpc.nki.nl) (Mooij, Mitsiki, & Perrakis, 2009) as this shows the 
results from multiple analyses and suggests potential cloning primers.
5. Usually the N-terminal end of the catalytic construct does not need a lot of 
adaptation, but the C-terminal boundaries may vary. We generally extend the 
construct by up to forty residues as this can improve heterologous expression. 
As an example, USP7 has a large α-helix just C-terminal of the CD. Inclusion of 
this region was helpful for soluble bacterial expression (Kim, Dijk, & Sixma, 2016). 
As an extra check, one can run a protein structure prediction program on the 
final construct (e.g. Phyre2 (Kelley, Mezulis, Yates, Wass, & Sternberg, 2015)). 
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The designed construct should yield the USP domain, possibly with small N- and 
C-terminal extensions.
6. Order primers and clone the designed constructs into expression vectors. We 
recommend testing several constructs, with varying start and end points.
7. Using a codon-optimised sequence should also be considered. Codon-optimisation 
can increase the chances of successful heterologous expression. It can be done for 
multiple expression systems through various suppliers (e.g. GenScript, Integrated 
DNA technologies).
Note: Remember that any protease used to cleave off an affinity tag requires an 
unobstructed recognition sequence: a slightly extended N- or C-terminus in the construct 
can help this.
General purification protocol for USPs
For the expression and purification of the designed USP constructs we refer the 
reader to the many handbooks available (eg. Strategies for Protein Purification by GE 
Healthcare, etc.). In general, the protocols supplied by manufacturers suffice for initial 
purification trials, and optimization is done from this starting point. Here we describe 
three case studies to give examples of purification of USPs in bacteria, insect cells and 
co-purification of a USP with its regulator in insect cells.
Note: The practical guidelines mentioned in the notes should be applied for all the 
purification protocols described in this chapter.
Note: Since USPs are cysteine proteases, it is important that all purification buffers should 
contain reducing agents because oxidation by reactive oxygen species (ROS) has been 
shown to inactivate a large number of USPs (Cotto-Rios, Békés, Chapman, Ueberheide, 
& Huang, 2012; Lee, Baek, Soetandyo, & Ye, 2013).
Case Study– a) Expression of a USP in E. coli: USP7
The full length codon-optimized USP7 sequence is cloned into a pGEX-6p vector 
containing a 3C protease-cleavable N-terminal GST tag (Faesen et al., 2011). Transform 
the sequence-verified expression construct into Escherichia Coli BL21 Rosetta2 (DE3) 
T1R cells and grow the transformed cells in 4 liters of Terrific Broth growth medium, which 
allows growing to high density. When cells reach an O.D.600nm of 1.8 add 0.2 mM IPTG to 
induce and incubate overnight at 18°C.
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o Lysis buffer - 50 mM HEPES (pH 7.5) + 150 mM NaCl + 1 mM EDTA + 1 mM DTT + 
0.1 mM PMSF + DNase I (Roche)
Note: DNAse should be omitted if the USP will be tested for binding or activity against DNA.
o GST Wash buffer - 50 mM HEPES (pH 7.5) + 250 mM NaCl + 1 mM EDTA + 1 mM 
DTT
o GST Elution buffer - 50 mM HEPES (pH 7.5) + 250 mM NaCl + 1 mM EDTA + 1 mM 
DTT + 15 mM glutathione
o IEX buffer A - 10 mM HEPES (pH 7.5) + 50 mM NaCl + 1 mM DTT
o IEX buffer B - 10 mM HEPES (pH 7.5) + 1 M NaCl + 1 mM DTT
o Gel filtration buffer - 25 mM HEPES (pH 7.5) + 100 mM NaCl + 1 mM DTT
Protocol
1. Harvest cells by centrifugation at 5300 x g for 15 minutes and resuspend in Lysis 
buffer. For expressions in TB we use 30 mL of buffer per expressed liter.
2. Lyse the resuspended cells by homogenization using a cell homogenizer (e.g. 
Avestin Emulsiflex-C5 ) which is precooled to 4°C.
Note: We use the emulsiflex and sonicator both. Results are mostly interchangeable, but 
occasionally a protein seems to respond better to one or the other treatment.
3. Spin down the lysed cell suspension at 53000 x g for 40 mins in a pre-cooled 
centrifuge at 4°C and collect the supernatant. Collect samples of the supernatant 
and pellet and dilute them tenfold for analysis by SDS-PAGE along with samples 
from step 6-7.
4. Add 5 ml of GST-Sepharose beads (GE Healthcare) to a gravity flow column (Bio-
Rad) and equilibrate with 5 column volumes (CV) of GST Wash buffer at 4°C. 
Determine the amount of GST beads to use based on protein yields from the first 
small scale prep. We use 1 ml of GST beads for 10 mg of GST tagged protein but 
this might differ for individual proteins depending on their size.
5. Add the lysate and incubate by rotating at 4°C for 30 minutes.
6. Allow the lysate to pass through the column by gravity flow and collect the 
flowthrough. Take a sample of the flowthrough for SDS-PAGE analysis.
7. Wash the column with 20 CV of Wash buffer and elute with 5 x 0.8 CV of Elution 
buffer. Collect wash and elution fractions and take samples for SDS-PAGE.
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8. Perform SDS-PAGE with all the collected samples to determine which fractions 
contain USP7. If all the steps are performed properly then protein should be in the 
elution fractions.
9. Pool elution fractions containing USP7 and set aside a sample for comparison with 
the 3C protease post-cleavage sample by SDS-PAGE.
Note: Estimate the absolute amount of protein after every step during the purification. This 
will help in identifying if unusual amounts of protein are lost in any step.
10. Add 3C protease to the pooled USP7 sample and transfer the mixture to a dialysis 
tube, Incubate at 4°C while dialyzing overnight against 2 liters of IEX buffer. Make 
sure the molecular weight cut-off does not allow the 3C protease to go through 
(MWCO < 20 kDa).
Note: Cleavage times can vary depending on the sample and the amount of enzyme added; 
it is usually most convenient to incubate the sample overnight. Adding 1 μg of 3C protease 
for 100 μg of protein is sufficient for complete cleavage under these conditions.
11. Equilibrate a 10 ml POROS Q anion exchange column with sequential washes of 
2 CV IEX buffer A, 2 CV IEX buffer B and 2 CV IEX buffer A at 4°C. The size of the 
column can vary depending upon the purification scale.
12. Check if 3C protease cleavage is complete by analyzing samples from before and 
after cleavage on SDS-PAGE. If it is already known that cleavage is complete under 
these conditions, then this step can be skipped.
13. Spin down the cleaved protein sample and load the supernatant on the column 
followed by washing with 3 CV of IEX buffer A.
14. Elute USP7 by using a salt gradient of 20 CV from 50 mM to 1 M NaCl; full-length 
human USP7 typically elutes around 150-250 mM NaCl.
15. Collect samples corresponding to all the significant peaks as measured by UV 
absorbance at 280 nM (UV280) and analyze them by SDS-PAGE.
16. Equilibrate a Superdex 200 10/300 size exclusion column (GE Healthcare) with Gel 
filtration buffer at 4°C. The size of column is based on the amount of protein being 
purified (for e.g. if USP7 ≥ 10 mg then we use the 16/60 column and for ≤ 10 mg we 
use the 10/300 column).
Note: If a larger column is used, then make sure that equilibration is started earlier so that 
it is ready to use as soon as the sample is concentrated.
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17. Concentrate the pooled fractions from the anion-exchange column at 4°C using 
a Amicon Ultra-15 centrifugal filter unit with a 30 kDa cutoff (Merck) until a final 
volume of 500 μl is reached.
18. Load the concentrated sample on the pre-equilibrated size exclusion column.
19. Collect samples corresponding to the UV280 peaks and analyze them by SDS-PAGE.
20. Combine fractions containing pure USP7 (128 kDa) and concentrate at 4°C in 
a Amicon Ultra-15 centrifugal filter unit with a 30 kDa cutoff (Merck) to a final 
concentration of 10 mg/ml.
21. Aliquot the concentrated protein and flash freeze in liquid nitrogen for long term 
storage at -80°C. If protein is to be used for functional studies, then make aliquots of 10 
μl; if protein is to be used for crystallography, then make aliquots of 40 μl.
Note: It is not recommended to refreeze the protein aliquot after assays as this can 
influence the activity and stability.
Case Study – b) Expression of a USP in insect cells: USP46
Many USPs are not expressed in bacteria or have very low expression and solubility 
levels. In such cases, expression and purification in insect cells can be a good alternative, 
frequently improving expression levels as well as solubility. We employ Spodoptera 
frugiperda (Sf9) insect cells for protein expression using the baculovirus expression 
system. Sf9 cells are more sensitive to variations in culture conditions compared to 
bacterial cells; our reproducibility improved when we appointed a single person to 
maintain the insect cell cultures. This helps to avoid contamination, makes it possible 
to efficiently expand cultures for protein expression, and ensures that new stock cultures 
are started before the passage limit is reached.
Production of recombinant bacmids and baculoviruses is carried out based on protocols 
in the Invitrogen manual (Bac-to-Bac® Baculovirus Expression Systems) for insect cell 
expression. The titre of the P1 viral stock is not calculated and it is assumed to be in the 
range of 1 x 106 to 1 x 107. Optimal infection conditions for large-scale expression vary for 
each recombinant baculovirus. Therefore, small-scale expression tests are performed, 
varying virus amounts. Additionally, different expression times are tested at constant 
virus levels and only after determining these two parameters is large-scale expression 
initiated.
The full length USP46 cDNA is cloned into a pFastbac vector with a cleavable N-terminal 
His tag. Transform the sequence-verified construct into DH10Bac bacterial cells for 
bacmid preparation. Purify the recombinant bacmid and use it for transfection of Sf9 
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insect cells to produce the recombinant baculovirus. We don’t normally determine virus 
titer, but rather rely on small-scale expression tests to decide on the necessary amount 
of USP46 P2 viral stock to add. Here we use 4 ml of the P2 virus per 2 liters of Sf9 culture 
at 2 x 106 cells/ml and harvest after 72 hours.
Buffers
o Lysis buffer – 50 mM Tris-HCl (pH 7.5) + 200 mM NaCl + 2 mM Tris(2-carboxyethyl)
phosphine (TCEP) + Pierce™ Protease Inhibitor Mini Tablets, EDTA Free (1 tablet/50 
ml)
o His wash buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP + 50 mM 
Imidazole (pH 8.0)
o His elution buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP + 500 
mM Imidazole (pH 8.0)
o IEX dilution buffer - 50 mM Tris-HCl (pH 7.5) + 50 mM NaCl + 2 mM TCEP
o IEX buffer A - 20 mM Tris-HCl (pH 7.5) + 50 mM NaCl + 2 mM DTT
o IEX buffer B - 20 mM Tris-HCl (pH 7.5) + 1 M NaCl + 2 mM DTT
o Gel filtration buffer – 20 mM HEPES (pH 7.5) + 150 mM NaCl + 2 mM DTT
Protocol
1. Harvest Sf9 cells by spinning them down at 750 x g for 15 minutes at room 
temperature and resuspend the cells in 50 ml of Lysis buffer.We generally use 25 
ml of Lysis buffer to harvest 1 liter of Sf9 cells (2 x 106 cells/ml).
2. Add the resuspended cells to a 125 ml metal beaker immersed in ice, and lyse 
by sonicating with a pre-cooled sonicator (Qsonica Q700 with 12.7 mm probe) . 
The lysis conditions are as follows, Amp -50; Pulse on -15 seconds; Pulse off - 45 
seconds; Total Time – 2 minutes.
3. Spin down the lysed cell suspension at 53000 x g for 40 mins in a pre-cooled 
centrifuge at 4°C and collect the supernatant. Collect and dilute samples of the 
supernatant and pellet for analysis by SDS-PAGE along with samples from step 6-7.
4. Add 2 ml of Ni2+-Sepharose beads (GE Healthcare) in a gravity flow column and 
equilibrate with 4 CV of Lysis Buffer (without protease inhibitors) at 4°C.
Note: Nickel and Talon beads are most commonly used for His affinity purification. They 
have somewhat different affinity and this can be optimized for individual constructs.
Note: The amount of beads used depends on the estimated yields based on small scale 
expression tests. It is important to note that Nickel and Talon beads can act as ion 
exchangers and can bind to random proteins. It is therefore important to limit the quantity 
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of beads and better to underestimate than to overestimate. This may result in not binding 
all the protein of interest, but what is purified is much cleaner.
5. Add the lysate and incubate with rotation at 4°C for 30 minutes.
6. Allow the lysate to pass through the column by gravity flow and collect the 
flowthrough. Take a sample of the flowthrough for SDS-PAGE analysis.
7. Wash the column with 50 CV of Wash buffer and elute with 5 x 0.8 CV of Elution 
buffer. Collect wash and elution fractions and take aliquots for SDS-PAGE.
Note: Some His-tagged proteins start eluting at 50 mM imidazole therefore always check 
if this is the case before using 50 mM imidazole in the wash buffers.
8. Perform SDS-PAGE with all the collected samples to determine which fractions 
contain USP46.
9. Equilibrate a 10 ml POROS Q anion exchange column with sequential washes of 2 
CV IEX buffer A, 2 CV IEX buffer B and 2 CV IEX buffer A at 4°C.
10. Pool elution fractions containing USP46 and dilute the pooled sample with an equal 
volume of IEX dilution buffer.
Note: The final salt concentration of the buffer should be significantly lower than the salt 
concentration at which the protein is expected to elute from the column. Don’t dilute more 
than necessary as some proteins might precipitate.
11. Load the diluted USP46 sample on the column followed by washing with 3 CV of 
IEX buffer A.
12. Elute USP46 by using a salt gradient of 20 CV from 50 mM to 1 M NaCl.
13. Collect samples corresponding to all the significant UV280 fractions and analyze 
them by SDS-PAGE. USP46 typically elutes around 200-300 mM NaCl.
14. Equilibrate a Superdex 200 16/60 size exclusion column (GE Healthcare) with Gel 
filtration buffer at 4°C.
15. Concentrate the pooled fractions at 4°C using a Amicon Ultra-15 centrifugal filter 
unit with a 10 kDa cutoff (Merck) until a final volume of 500 μl is reached.
16. Load the concentrated sample on the pre equilibrated size exclusion column. A 
single UV280 peak with a leading shoulder will be obtained. The shoulder contains 
USP46 bound to its interacting proteins from insect cells such as UAF1.
17. Collect fractions corresponding to the shoulder and peak for analyzing them by 
SDS-PAGE.
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18. Combine peak fractions containing pure USP46 and concentrate at 4°C in a Amicon 
Ultra-15 centrifugal filter unit with a 10 kDa cutoff (Merck) to a final concentration 
of 10 mg/ml.
19. Aliquot the concentrated protein and flash freeze in liquid nitrogen for long term 
storage at -80°C. If protein is to be used for activity assays, then make aliquots of 
10 μl, and if protein is to be used for crystallography, then make aliquots of 40 μl.
Case Study – c) Co expression of a USP with a regulatory protein in insect cells: USP1-
UAF1
USP1 was cloned into a pFastBac vector with a cleavable N-terminal His tag, UAF1 into a 
pFastBac vector with a cleavable N-terminal Strep II tag. Transform the sequence-verified 
constructs separately into DH10Bac cells for bacmid preparation. Purify the recombinant 
USP1 and UAF1 bacmids and use each for transfection of Spodoptera frugiperda (Sf9) 
insect cells to produce recombinant baculoviruses. Perform small-scale expression tests 
with different ratios of USP1 and UAF1 viruses and check if both proteins are expressed 
equally. Based on the small-scale expression tests, select appropriate amounts of P2 
viral stock. Here we use 4 ml of USP1 P2 viral stock and 2 ml of UAF1 P2 viral stock in 
2 liters of Sf9 culture at 2x106 cells/ml and harvest after 72 hours.
Buffers
o Lysis buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP + Pierce™ 
Protease Inhibitor Mini Tablets, EDTA Free (1 tablet/50 ml)
o His wash buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP + 50 mM 
Imidazole (pH 8.0)
o His elution buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP + 500 
mM Imidazole (pH 8.0)
o Strep wash buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP
o Strep elution buffer – 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 2 mM TCEP + 2.5 
mM Desthiobiotin
o Gel filtration buffer – 20 mM HEPES (pH 7.5) + 150 mM NaCl + 2 mM DTT
Protocol
1. Harvest cells by spinning them down at 750 x g for 15 minutes at room temperature 
and resuspend the cells in 100 ml of Lysis buffer.
2. Add the resuspended cells to a 125 ml metal beaker immersed in ice, and lyse by 
sonicating with a pre-cooled sonicator (Qsonica Q700 with 12.7 mm probe). We use 
lysis conditions as follows, Amp -50; Pulse on -15 seconds; Pulse off - 45 seconds; 
Total Time – 2 minutes.
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3. Spin down the lysed cell suspension at 53000 x g for 40 mins in a pre-cooled 
centrifuge at 4°C and collect the supernatant. Collect and dilute samples of the 
supernatant and pellet for analysis by SDS-PAGE along with samples from step 7-8.
4. Add 2 ml of Ni2+-Sepharose beads (GE Healthcare) to a gravity flow column (Bio-
Rad) and equilibrate with 4 CV of Lysis Buffer (without protease inhibitors) at 4°C.
5. Load the lysate and incubate by rotating at 4°C for 30 minutes.
6. Allow the lysate to pass through the column by gravity and collect the flowthrough. 
Take a sample of the flowthrough for SDS-PAGE analysis.
7. Wash the column with 50 CV of His wash buffer and elute with 5 x 0.8 CV of His 
elution buffer. Collect wash and elution fractions and take aliquots for SDS-PAGE.
8. Perform SDS-PAGE with all the collected samples to determine which fractions 
contain USP1-UAF1.
9. Add 5 ml of Streptactin sepharose beads (IBA Life Sciences) to a gravity flow column 
and equilibrate with 5 CV of Strep wash buffer at 4°C. The amount of beads used 
depends on the estimated protein yields. Generally 1 ml of Streptactin sepharose 
beads bind up to 100 nmol of strep-tagged protein.
10. Combine and load the USP1-UAF1 fractions on the column without disturbing the 
Streptactin beads. Allow the sample to pass through the column slowly by gravity 
and reload the flowthrough at least once on the column. Collect the flowthrough 
and take a sample for SDS-PAGE.
11. Wash the column with 2 CV of Strep wash buffer and elute with 6 x 0.8 CV of Strep 
elution buffer.
Note: Excessive washing of the Streptactin column should be avoided as contaminating 
proteins get easily washed away in 1-2 CV due to lack of nonspecific interactions. More 
importantly, excessive washing will lead to loss of the strep tagged protein since the 
affinity between the strep tag and the streptactin beads is in the low micromolar range.
12. Perform SDS-PAGE with all the collected samples to determine which fractions 
contain the USP1-UAF1 complex.
13. Combine the elution fractions and take a sample for comparison with the post-
cleavage sample by SDS-PAGE.
14. Add His-tagged 3C protease to the pooled USP1-UAF1 sample and incubate 
overnight at 4°C. Save a sample and check for cleavage on SDS-PAGE.
15. Add 4 ml of Ni2+-Sepharose beads (GE Healthcare) to a gravity flow column and 
equilibrate with 4 CV of Lysis Buffer (without protease inhibitors) at 4°C.
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16. Perform a reverse Ni2+-affinity purification by adding the cleaved sample to the 
column. The cleaved USP1-UAF1 should not bind, while the His-tagged protease 
will bind to the column.
17. Allow the sample to go through the column slowly by gravity flow and reload the 
flowthrough at least once on the column. Collect the flowthrough and take a sample 
for SDS-PAGE.
18. Wash the column with 5 x 1 CV of His wash buffer and elution is done with 3 x 0.8 
CV of His elution buffer.
19. Perform SDS-PAGE with all the collected samples to determine which fractions to 
collect for the next step; pure USP1-UAF1 should be in the flowthrough and wash 
fractions.
20. Equilibrate the Superdex 200 10/300 size exclusion column (GE Healthcare) with 
Gel filtration buffer at 4°C.
21. Pool and concentrate the fractions at 4°C using a Amicon Ultra-15 centrifugal filter 
unit with a 50 kDa cutoff (Merck) until a final volume of 500 μl is reached.
22. Load the concentrated sample on a pre-equilibrated size exclusion column.
23. Collect fractions corresponding to the UV280 peak and analyze them by SDS-PAGE.
24. Combine fractions containing pure USP1-UAF1 and concentrate at 4°C in a Amicon 
Ultra-15 centrifugal filter unit with a 50 kDa cutoff (Merck) to a final concentration 
of 5 mg/ml.
25. Aliquot the concentrated protein and flash freeze in liquid nitrogen for storage at 
-80°C.
CHARACTERIZATION OF USPS
After purification of the USP of interest, or a USP domain or USP-regulator complex, 
one would like to assess the quality of the particular protein preparation. Methods to 
assess protein stability and stoichiometry have been described extensively elsewhere 
(Wen, Arakawa, & Philo, 1996; Senisterra & Finerty, 2009); for this analysis of USPs, we 
focus on the enzymatic activity.
Besides using an activity assay for quality control, these assays can also provide insight 
into the mechanisms of USP activity by yielding key enzymatic parameters. Here we 
describe our protocols to determine parameters such as KM and kcat, using a minimal 
substrate and a more “realistic” one. Furthermore, we indicate how these activity assays 
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USP activity on a minimal substrate
Ubiquitin-specific proteases specifically cleave ubiquitin (Ub) from targets, with ubiquitin 
being the minimally recognized entity as a substrate. As such the minimal substrate to 
use in activity assays consists of ubiquitin with its C-terminus conjugated to a readout 
molecule, usually a quenched fluorophore that increases in fluorescence when released 
or a moiety that can trigger a secondary, luminescent signal (Orcutt, Wu, Eddins, Leach, 
& Strickler, 2013). For an activity assay, the ubiquitin needs to have a peptide(-like) 
linkage to the C-terminal leaving group to allow processing by the USP. One possibility 
is assessment using a fluorescence polarization assay (FP, see section 3.4.4) in which 
the release of fluorescently tagged ubiquitin from a substrate is measured by the change 
in polarization.
Here we use two commonly used quenched fluorophores, rhodamine (Rho) or 7-amino-4-
methylcoumarin (AMC), which are conjugated to ubiquitin. Ubiquitin rhodamine (UbRho) 
or Ubiquitin 7-amino-4-methylcoumarin (UbAMC) are commercially available and often 
used in the DUB-field (Hassiepen et al., 2007). As the released compound from these 
model substrates is a direct readout of cleaved product, we can use the time-resolution 
of a plate reader to determine the enzymatic parameters.
Here, we use a PheraStar plate reader (BMG LabTech), but other machines could 
be suitable as well. Make sure that the plate reader has the required filters or 
monochromators to measure rhodamine (Rho) or 7-amino-4-methylcoumarin (AMC) 
fluorescence and that it can measure the fluorescence intensity (FI) over an extended 
period of time. Some plate readers, like the PheraStar, also have an injection option, 
which sometimes can be useful. The injector allows detection of early events of the 
reaction, which is necessary for very active USPs or when they display unexpected 
behavior ((Clerici, Luna-Vargas, Faesen, & Sixma, 2014; Haahr et al., 2018); Kim et al, 
2019). For enzymes with normal Michaelis-Menten behavior, the procedure described 
here, where we prepare the plates manually, leaving a delay time between the addition 
of substrate or enzyme and the start of the measurement, is sufficient.
Deubiquitination assay as a quality control step
For a simple check of deubiquitinating activity for a new protein construct, one would 
simply add the newly purified enzyme to the minimal substrate and monitor the 
fluorescence increase. If this is a new purification of an already analyzed USP, take into 
account the assay conditions (concentration, buffer) already established for the protein 
(see 3.1.3).
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Materials
- Freshly thawed protein, make sure it has reduced cysteines
Note: Using fresh DTT ensures the cysteines (including the active site) are reduced, which 
is essential for the enzyme to be active.
Note: Try not to refreeze enzymes as they lose activity. It is better to make small aliquots 
and thaw only once.
- UbRho (from e.g. Boston BioChem (US), or UbiQ Bio (Europe)); for these quality 
control assays, we use an 8 µM stock.
Note: Upon 1:1 dilution in the assay, this will result in an end concentration of 4 µM, which 
is around the KD for many USPs.
- Protein storage buffer: the exact composition depends on the USP of interest. 
Generally a buffer containing 20 mM HEPES (pH 7.5); 150 mM NaCl and 1 mM DTT 
suffices.
- Low Volume 384-Well Black Flat Bottom Polystyrene NBS™ Microplate (Corning, 
catalogue number: 3820)
Protocol
1. Add 10 µL UbRho to two wells of the plate.
2. At the plate reader, check the settings and the program, take care to select the 
proper wells. Time-wise the result of the experiment will be clear within 10 minutes, 
but we usually measure longer.
Note: Rhodamine: excitation maximum- 485 nm, emission maximum- 530 nm. AMC: 
excitation maximum- 380 nm, emission maximum- 480 nm.
3. Add 10 µL buffer to one well (blank) and 10 µL of protein solution to the other.
4. Insert the plate and start the program, monitoring the fluorescence increase over 
time.
5. If correct, the blank will show a steady, low baseline fluorescent signal over time, 
indicating no cleavage is taking place. The other well will show, if there is an active 
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Preparatory analysis for quantitation of UbRho cleavage
To convert the obtained fluorescence units into concentration (µM) a calibration curve 
for the batch of UbRho has to be determined. Keep in mind that such a calibration curve 
differs with the machine and ‘gain’ settings used. We use the same machine with one 
particular gain setting per batch of minimal substrate.
Determine optimal gain
1. Decide on the highest concentration of UbRho you are planning to use. 30 µM is 
generally sufficient for KM determination for most USPs.
2. Prepare UbRho at this concentration and add a known active DUB, preferably at 
a high concentration so hydrolysis proceeds quickly. We generally use USP7, but 
other very active USPs such as USP21 will work too and are available at reasonable 
price from a supplier such as Boston BioChem.
3. Add the sample to a micro well plate and measure fluorescence in the plate reader.
4. If the signal reaches the detection limit, restart the measurement using a lower gain 
setting. Wait until the signal increase levels off, all substrate is now hydrolyzed.
5. Use the plate reader’s auto-gain function, setting the FI signal of the well to 90%.
6. Make a note of the gain setting, or alternatively save this in a method file to be used 
by the plate reader.
Note: UbRho concentrations higher than 30 µM are tricky to work with. It can give unreliable 
readings, possibly due to aggregation of the fluorophore.
Determine a calibration curve of Rhodamine fluorescence as a function of substrate 
concentration
Once the optimal gain has been determined, one can run the calibration that gives the 
conversion factor to calculate product concentrations from the fluorescence readings.
1. Make a dilution range of your UbRho stock in the range of 0.25-30 µM.
2. Add an active DUB to each well.
3. Monitor the fluorescence using the plate reader and wait until the signal is stable.
Note: The optimal gain can also be determined here by using the plate readers auto-gain 
function on the highest concentration of substrate once the fluorescence signal is stable. 
Alternatively, one can also use a stock of free rhodamine to determine the optimal gain.
4. After the measurements, assess the reactions using a spectrophotometer (e.g. 
Nanodrop) at their excitation wavelength. Using Beer’s law and the extinction 
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coefficient of the cleaved fluorescent product, one can determine the product (and 
thus the starting substrate) concentration.
5. Get the FI readings of the plateau (in AU) for each UbRho dilution and plot them 
against the used substrate concentration.
6. Fit the points linearly to get a conversion factor, converting AU to µM.
Optimal USP concentration for kinetic analysis of enzyme activity
In order to quantify USP kinetics, the experiment must be performed under optimal 
sample conditions. To determine enzyme parameters such as KM and kcat, the enzyme 
and substrate concentrations have to be within the Michaelis-Menten domain ([E]<<[S]; 
(Michaelis & Menten, 1913)). In general, this means that the enzyme concentration should 
be at least two orders of magnitude lower than the substrate concentration. Due to 
the detection limits of the released fluorophore, the substrate concentration must be 
between 100 nM and 30 µM. This places initial constraints on the enzyme concentration 
in the assay. Moreover, the assay needs to sample the full range of activity, if there is 
too much enzyme, we cannot get the initial velocity (V0) of the reaction; if there is too 
little enzyme it will take too long before the signal appears.
Materials
- The purified protein, with a known concentration (UV280 or Bradford assay)
- UbRho, for this optimization assay we use an 8 µM stock
- Protein storage buffer
Note: Make sure to have fresh reducing agent in both the buffer and protein stock.
- Low Volume 384 Well Black Flat Bottom Polystyrene NBS™ Microplate (Corning, 
catalogue number: 3820)
- PCR tubes, preferably in a strip for easy use with a multichannel pipette
Protocol
1. Make a concentration range of the USP protein in an 8 strip of PCR tubes. We usually 
make a ten-fold dilution range going down from 2 µM to 2 nM or even pM with very 
active enzymes.
2. For every concentration to be tested add 10 µL UbRho stock into a well.
3. At the plate reader, check the settings and the program, take care to select the 
proper wells. We generally run this experiment for 1 hour.
4. Using a multichannel pipette, add 10 µL of the protein samples into the wells.
5. Insert the plate and start the measurement.
2
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6. Observe the FI increase over time. For the highest concentration the signal will 
probably level off within seconds: with this concentration no V0 can be determined. 
Try to find the curve with the optimal protein concentration; this curve will preferably 
reach a plateau right before the end of your measurement (see note).
7. Note down the optimal concentration or fine-tune it by repeating the experiment 
with a narrower dilution range.
Note: If the signal reaches a plateau it gives you an internal experiment control within this 
one measurement. When converting the plateau value (in AU) to µM using the calibration 
curve (3.1.2), it should yield the used UbRho concentration.
Determining steady-state enzymatic parameters using minimal substrate
Here we describe steady-state kinetic analysis of USP7 activity on a minimal substrate. 
The protocol can be used for other USPs as well, but buffer conditions and protein 
concentrations may have to be optimized (see 3.1.3).
Materials
- Reaction buffer: 20 mM HEPES 7.5; 100 mM NaCl; 1 mM DTT; 0.05% Tween-20
- UbRho stock (1 mM, in DMSO)
- USP7 protein stock
- Low Volume 384 Well Black Flat Bottom Polystyrene NBS™ Microplate (Corning, 
catalogue number: 3820)
- PCR tubes, preferably in a strip for easy use with a multichannel pipette
- Data fitting software: GraphPad Prism 7
Protocol
1. Prepare reaction buffer, using fresh DTT.
Note: Using fresh DTT ensures the cysteines (including the active site) are reduced, which 
is essential for the enzyme to be active. The Tween-20 is included to prevent proteins or 
compounds from sticking to the walls of the plate.
2. Thaw stocks and determine the protein concentration (For USP7: 1 OD280 = 7.96 
µM).
3. Make a 2 nM USP7 stock. Make sure to make enough volume-wise, for one single 
measurement, we make 100 µL.
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Note: Do NOT take too large dilution steps. We usually do sequential dilutions starting 
with a 1 µM dilution (measure for certainty using a NanoDrop), then dilute 25-fold (40 nM) 
and then 20-fold (2 nM). This helps prevent aggregation.
4. Make serial two-fold dilutions of UbRho (starting at 16 µM) in an 8-strip of PCR 
tubes. Make sure the minimal amount is 10 µL for each reaction. E.g. make 25 µL 
of 16 µM UbRho, then do a serial dilution transferring 12.5 µL to the next well with 
12.5 µL buffer.
5. Add 10 µL of 2 nM USP7 into the wells of the assay plate - note down the wells.
6. At the plate reader, check the settings and the program, take care to select the 
proper wells.
Note: Rhodamine: excitation maximum- 485 nm, emission maximum- 530 nm. AMC: 
excitation maximum- 380 nm, emission maximum- 480 nm. Gain setting as determined 
in 3.1.2.
7. Using the multichannel pipette, add 10 µL of the substrate into the wells.
8. Start the program, and monitor the fluorescence increase.
Analysis
9. Get the data from the machine (.xls or .csv file) and copy them into Prism 7.
10. Using the determined conversion rate (section 3.1.2), convert the AU values into µM 
and plot them (as converted substrate vs time).
11. Examine the plot to assess the quality of the experiment. Are there curves where 
the signal increase does not seem to follow the dilution steps and do the plateaus 
reached (see note in 3.1.3) match the substrate concentrations used? Also find the 
time range to determine the initial velocity (V0); this range encompasses the linear 
part of the curve right after the start.
12. If the linear range cannot be properly determined, look into optimizing the 
experiment (section 3.1.3).
13. Use the determined time range to linearly fit that part of the data and acquire the 
V0 for each substrate concentration tested. Then plot these velocities against 
substrate concentration to obtain a Michaelis-Menten plot. The data can also be 
fitted using the built-in Michaelis-Menten equation to obtain the KM and Vmax.
Note: Modern computers do not require linearization of the data for fitting Michaelis-
Menten data. Linearization creates large artefacts and should be avoided.
2
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14. The curve and the fit statistics will indicate whether you have sufficient plateaus 
at the top and bottom of the curve. Take this into account in the next experiments 
for the tested enzyme, extending the substrate dilution range if necessary.
15. Convert the Vmax value to kcat by dividing it with the enzyme concentration used and 
calculate the catalytic efficiency kcat/KM.
Measuring deubiquitination of a natural target
Minimal substrates such as ubiquitin-AMC or ubiquitin-rhodamine are convenient for 
initial enzymological characterization of DUBs. However, activities on minimal substrates 
do not always translate directly to activities on a physiological target (Uckelmann et al., 
2018; Kim et al.,provisionally accepted), and substrates may affect the reaction itself. 
Since regulation of deubiquitinating enzymes is often achieved through modulating their 
activities (Sahtoe & Sixma, 2015; Mevissen & Komander, 2017), it is ultimately necessary 
to study the enzymology of DUBs on their physiological targets. The identification of 
physiological targets for some DUBs and advanced tools for modelling enzyme kinetics 
allow one to study target-specific deubiquitination in some systems.
Quantitative analysis is assisted by a well-defined singly modified substrate. To make 
such a substrate, requires a properly characterized ubiquitination site, known to be used 
in vivo, knowledge of the natural ubiquitin modification (monomer or polymer and if 
the latter what linkages), and a way to consistently produce labelled substrate. In our 
USP7 case study (Kim et al., provisionally accepted), we investigated its interaction with 
p53, for which the ubiquitination sites and USP7 recognition sites were well defined 
in literature. This protein sequence and the advanced methods in chemical ubiquitin 
synthesis allowed the generation of a fluorescently labelled, homogeneous, peptide 
substrate. We could use this tool, along with the kinetic modelling program KinTek 
(Johnson, Simpson, & Blom, 2009), to quantitatively study the effect of target recognition 
on the enzyme kinetics of USP7.
Here we describe a different approach to measuring substrate-specific deubiquitination. 
We employ a gel-based setup, enzymatically ubiquitinated target proteins (H2A in 
nucleosomal core particles) with a fluorescently labelled ubiquitin and a laser-based 
fluorescence gel scanner for quantification of the signal. In this experimental system we 
exploit the fact that ubiquitination of H2A by BRCA1/BARD1 is unusually site-specific. 
This allows tracking of H2A deubiquitination by the BRCA1-site-specific DUB USP48. 
The three steps necessary for measuring specific deubiquitination of nucleosomes are 
described in detail:
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1. Labelling of ubiquitin
2. Generation of the ubiquitinated nucleosome substrate
3. Measurement of site-specific deubiquitination
Note: Here we make use of a well characterized system that allows tracking specific 
ubiquitination and deubiquitinating events. For every new experimental system, it is worth 
considering some very basic questions:
What exactly constitutes the substrate?
- Are there different distinct ubiquitination sites (different lysines ubiquitinated) on 
the target protein?
- Should different sites be treated as distinct targets?
- Can the experimental setup distinguish between different sites?
- Are the sites mono-ubiquitinated or will ubiquitin chains be formed?
Once the substrate is identified, can it be produced in high purity?
- Can the ubiquitinated substrate be produced synthetically or enzymatically?
- Are there side products of the ubiquitination reaction that need to be considered (e.g. 
formation of nonspecific ubiquitin chains)?
- Can the product be purified after the ubiquitination reaction?
- Will substrate preparation yield a homogeneous substrate?
Finally, does the selected assay readout report on the deubiquitination of the site of 
interest?
Labelling ubiquitin
To enable labelling of ubiquitin with cysteine-reactive fluorescent dyes, a mutant ubiquitin 
construct carrying a cysteine as the second residue (Cysubiquitin) is used; ubiquitin has 
no native Cys residues. Any dye carrying a cysteine-reactive moiety can in principle be 
used. In the following example we used a tetramethylrhodamine dye (TAMRA) with a 
Cys-reactive maleimide moiety to generate TAMRAubiquitin which was suitable for our 
specific purpose and economical when considering the large amounts of fluorophore 
used in the study.
Purification of Cysubiquitin
The CysUbiquitin construct is cloned into the pETNKI-His-SUMO2-kan vector (Luna-Vargas 
et al., 2011). Transform the sequence-verified expression construct into Escherichia Coli 
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BL21 (DE3) T1R cells and grow the transformed cells in 1 liter of Lysogeny Broth (LB) 
growth medium. When cells reach an O.D.600nm of 0.8 add 0.2 mM IPTG to induce and 
incubate at 37°C for 4 hours.
Buffers
o Lysis buffer - 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 1 mM TCEP + 5 mM 
Imidazole + Pierce™ Protease Inhibitor Mini Tablets, EDTA Free (1 tablet/50 ml)
o Wash buffer - 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 1 mM TCEP + 20 mM 
Imidazole
o Elution buffer -50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 1 mM TCEP + 350 mM 
Imidazole
o Dialysis buffer 1 - 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 1 mM TCEP
o Dialysis buffer 2 - 50 mM Ammonium Acetate (pH 4.5) + 1 mM DTT
o IEX buffer A - 50 mM Ammonium Acetate (pH 4.5) + 2 mM DTT
o IEX buffer B - 50 mM Ammonium Acetate (pH 4.5) + 500 mM NaCl + 2 mM DTT
o GF buffer - 50 mM Tris-HCl (pH 7.5) + 150 mM NaCl + 5 mM DTT
Protocol
1. Spin down cells at 5300 x g for 15 minutes at room temperature and resuspend in 
50 ml lysis buffer.
2. Lyse cells by sonicating with a pre-cooled sonicator (Qsonica Q700 with 12.7 mm 
probe) . The lysis conditions are as follows, Amp -80; Pulse on -15 seconds; Pulse 
off - 45 seconds; Total Time – 4 minutes.
3. Centrifuge the lysate at 53000 x g for 30 minutes at 4 °C.
4. Add 8 ml chelating sepharose beads (Roche) charged with Ni2+ to the supernatant, 
load onto a sealed gravity-flow column (Bio-Rad), let the beads settle by force of 
gravity, then open the column and let the supernatant flow through.
5. Wash the beads with 3 x 80 ml of wash buffer.
6. Elute the sample in 25 ml of elution buffer.
7. Add His-tagged SENP2 protease to a final concentration of 3 µg/ml, transfer sample 
to a 3500 – 5000 Da cutoff Spectra/Por dialysis tube (Spectrum) and dialyze 
against 2 x 2 L of dialysis buffer 1 at 4 °C. After 4 hours replace the buffer with 2 L 
of fresh dialysis buffer 1 and let this second dialysis step proceed overnight.
8. To remove the His-SUMO, uncleaved protein and SENP2, add 8 ml chelating 
sepharose beads charged with Ni2+ to the dialysed sample and load on a gravity-
flow column. Let the beads settle by force of gravity and collect the flow-through 
containing ubiquitin (His-SUMO, uncleaved SUMO-CysUbiquitin and His-SENP2 will 
551327-L-bw-Dharadhar
Processed on: 30-12-2020 PDF page: 53
53
Quantitative analysis of USP activity in vitro
remain bound to the beads). Wash beads with 8 ml of dialysis buffer 1 and collect 
in the same tube.
9. While stirring the sample on ice, add perchloric acid dropwise until a final 
concentration of 2 % v/v is reached. Most proteins will precipitate at this stage, 
while CysUbiquitin will stay in solution.
10. Centrifuge at 53000 x g at 4 °C for 30 minutes and collect the supernatant.
11. Dialyze the supernatant against 2 L Dialysis Buffer 2 overnight at 4 °C.
12. Load sample on a 5 ml HiTrap SP HP ion exchange column (GE healthcare) in IEX-
buffer A at 4 °C.
13. Elute sample using a linear gradient ranging from 0 % IEX-buffer B to 100 % IEX-
buffer B in 12 column volumes.
14. Combine fractions containing CysUbiquitin and gel filter on a Superdex 75 16/60 
column (GE healthcare) .
15. Combine fractions containing CysUbiquitin, concentrate in an Amicon Ultra-15 
centrifugal filter unit with a 3 kDa cutoff (Merck) to a concentration of ~1 mM, 
snap-freeze 50 µl aliquots in liquid nitrogen and store at -80 °C.
Materials
- Fresh DTT
- Labelling buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl
- Purified Cysubiquitin
- TAMRA-maleimide
- Storage buffer: 25 mM HEPES, 150 mM NaCl, 1 mM DTT
- Spectra/Por 3500 – 5000 D cutoff dialysis tubing (Spectrum)
Protocol
Note: Throughout the protocol, wherever possible, keep the fluorophore and the 
fluorescently labelled protein protected from direct light.
1. Thaw the desired amount of Cysubiquitin to be labelled.
2. Add 5 mM of fresh DTT to the sample to reduce the cysteine residue for labelling.
Note: It is critical the cysteine residues are reduced, otherwise labelling will not be 
possible.
3. Dialyze reduced Cysubiquitin against at least three changes of 2 L labelling buffer to 
remove residual DTT which would interfere with labelling. Ideally the second dialysis 
step should be carried out overnight.
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Note: Removal of residual DTT is critical as it would otherwise react with the maleimide 
group and compete with cysteine labeling. TCEP should not interfere with maleimide-
dependent labelling reactions as it does not contain thiols. However, we have never tested 
labelling in the presence of TCEP and the reader is advised to conduct their own pilot 
experiments if the reducing agent is to be changed. For faster removal of DTT, a buffer 
exchange column or desalting spin column can be used.
4. For the labelling reaction, add a 5-fold molar excess of TAMRA-maleimide over 
ubiquitin and incubate for 2 hours at room temperature, followed by overnight 
incubation at 4°C.
Note: The ratio of fluorophore over ubiquitin is critical for high labelling efficiency. The 
optimal ratio can vary between batches of protein and fluorophore. When feasible, the 
reader is advised to conduct small-scale pilot experiments, varying the ratio incrementally 
between 2:1 and 8:1 and assess labelling efficiency as described later on. Similarly, 
different incubation times and temperatures can be tested. We had good success with 
the suggested ratios and incubation.
5. Quench the labelling reaction with a 3-fold molar excess of DTT over fluorophore.
6. Centrifuge the sample at 20000 x g to remove aggregated material and collect the 
supernatant.
7. Dialyze the supernatant against three changes of 2 L storage buffer to remove 
excess dye.
8. To remove residual dye that might be present even after extensive dialysis, purify 
the sample on an appropriate size-exclusion column (Superdex S75 or comparable) 
using FPLC or a commercially available dye-removal spin column.
Note: Removal of residual dye is a crucial step in order to be able to estimate concentrations 
of labelled ubiquitin accurately. The suggested procedure using FPLC allowed us to obtain 
exceptionally pure sample. If purification by FPLC is not an option, or if the protocol needs 
speeding up, commercially available dye-removal spin columns are a good alternative. 
High amounts of free fluorophore might necessitate the use of two successive column 
steps.
9. If using FPLC, be aware that fluorescent dyes can be very sticky and adhere to the 
column resin, especially when present in high concentration during size exclusion 
chromatography. Extensive column washes are necessary to remove residual dye.
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10. Concentrate sample to the desired concentration;. the concentration is best 
calculated using the fluorophores absorbance at 542 nm and the corresponding 
extinction coefficient of 101000 cm-1M-1
Note: This combination of maximum absorbance and extinction coefficient is true for the 
particular fluorophore used in this study. Make sure you use the right absorbance and 
extinction coefficient for the fluorophore you are using. This might differ from the stated 
values here, even if the fluorophore is a TAMRA-based fluorophore.
11. Assess labelling efficiency by determining concentration of dye and protein. To 
determine the dye concentration measure absorption at the appropriate wavelength. 
Estimation of ubiquitin concentration is best done on a SDS gel. As a standard, run a 
titration series of known amounts of unlabelled ubiquitin. To determine the ubiquitin 
concentration in your labelled sample, run several dilutions on the same gel and 
compare to the standard. Divide this estimate of the ubiquitin concentration by the 
dye concentration to estimate the labelling efficiency.
12. Flash freeze sample aliquots and store at -80°C.
Note: The labelled ubiquitin can be used not only for measuring deubiquitination, but is 
equally suited for E3 ligase ubiquitination reactions. It can further be used for binding 
assays reliant on fluorescence polarization.
Generating ubiquitinated nucleosomes
We describe here the ubiquitination of nucleosome core particles (NCPs) using 
truncated BRCA1/BARD1 as the E3 ligase. If other E3-substrate combinations are used, 
concentrations of components may vary and pilot experiments need to be conducted 
to establish reaction conditions. However, in our experience, the stated conditions are 
appropriate for all H2A-specific E3 ligases and should provide a reasonable starting 
point for other systems as well.
Materials
- E1: hUBA1 purified from E.Coli (Uckelmann et al., 2018), also commercially available 
(Boston Biochem)
- E2: UBCH5C purified from E.Coli (Uckelmann et al., 2018), also commercially 
available (Boston Biochem)
- E3: BRCA11-306/BARD126-302 purified from E.Coli (Uckelmann et al., 2018)
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- Purified 147 bp DNA for nucleosome reconstitution (Vasudevan, Chua, & Davey, 
2010)
- Labelled ubiquitin
- EDTA, pH 8 (500 mM)
- ATP, pH 7.5 (100 mM)
- Ubiquitination reaction buffer: 25 mM HEPES (pH 7.5) + 150 mM NaCl + 3 mM MgCl2 
+ 1 mM DTT (fresh)
- Gel filtration buffer: 25 mM HEPES (pH 7.5) + 150 mM NaCl + 1 mM DTT
- 50 kDa cutoff Amicon ultra-15 centrifugal filter unit (Merck)
Protocol
Note: Throughout the protocol, wherever possible keep the fluorophore and the 
fluorescently labelled protein protected from direct light.
1. Reconstitute recombinant nucleosome core particles (NCP) according to a 
previously published protocol (Luger et al., 1999).
2. For the ubiquitination reaction, combine 0.5 μM of hUBA1, 1 μM UBCH5C, 1 μM 
BRCA11-306 / BARD126-302, 5 μM NCP and 40 μM TAMRAubiquitin in Ubiquitination 
reaction buffer.
3. Start the reaction by adding ATP to a final concentration of 3 mM.
4. Incubate at 30°C for 45 minutes.
5. Stop the reaction by putting the sample on ice and adding EDTA to a final 
concentration of 5 mM.
6. Purify the ubiquitinated nucleosomes by size exclusion on a Superose 6 increase 
column (GE Healthcare) in gel filtration buffer.
Note: This step removes excess ubiquitin, ATP, E1 and E2 enzymes but ubiquitinated NCP 
cannot be resolved from non-ubiquitinated NCP. However, the reaction conditions of the 
ubiquitination reaction have been optimized to yield a mix of mono- di- and triubiquitinated 
NCP and a negligible amount of non-ubiquitinated NCP. This heterogeneous mix of 
different ubiquitination states is appropriate for the following USP48 analysis as mono-, 
di-, and triubiquitinated species can be resolved on a SDS-PAGE gel, which allows to 
discern individual catalytic rates for different ubiquitination states.
7. Check for ubiquitination by running a SDS-PAGE gel and combine fractions that 
contain ubiquitinated nucleosomes. Concentrate sample to ~10 μM using a 50 kDa 
cutoff concentrator.
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8. Ideally the ubiquitinated nucleosomes are used immediately. However, storage of 
up to a week at 4°C leads to only minor deterioration in sample quality. Never freeze 
reconstituted nucleosomes.
Quantitative analysis of USP activity: Deubiquitination of Nucleosome core particles by 
USP48
To enable quantitation of kinetic parameters, full data sets are needed under Michaelis-
Menten conditions. However, an interesting alternative approach is the modelling of 
kinetic parameters (with e.g., Kintek explorer (Johnson et al., 2009)) based on reaction 
velocities while sampling over a wide range of substrate and enzyme concentrations. 
A 4 x 3 grid of enzyme and substrate concentrations (Table 1) was sufficient to reliably 
estimate kinetic parameters for NCP deubiquitination by USP48. It will become obvious 
during the fitting process how much data is necessary for proper restraint of the model 
parameters for the particular system studied (for details see (Johnson et al., 2009)).
Table 1: Combinations of enzyme and substrate concentrations used to determine kinetic 

























For the sake of clarity, we describe the experimental setup used to record a single time 
course for only one combination of enzyme and substrate concentration (25 nM USP48, 
2000 nM NCP). For the complete grid of different combinations, the reader is referred 
to Table 1.
Material
- Full length USP48 purified from Sf-9 insect cells (Uckelmann et al., 2018); 80 µM
- Purified NCP ubiquitinated with TAMRAubiquitin; 15 µM
- DUB-reaction buffer: 25 mM HEPES, 150 mM NaCl, 2 mM DTT (fresh)
- 4x Laemmli sample buffer
Protocol
Note: Throughout the protocol, wherever possible keep the fluorophore and the 
fluorescently labelled protein protected from direct light.
2
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1. Prepare a 30 μl aliquot containing 50 nM USP48 in DUB-reaction buffer.
2. Prepare a 27.5 μl aliquot of 4 μM ubiquitinated NCP (NCPUb) in DUB-reaction buffer.
Note: Make sure DTT in the reaction buffer is added freshly
3. Pre-warm USP48 and NCPUb to 30°C.
Note: Assays are best done using thin-walled PCR tubes and a PCR machine set to 
incubate at 30°C.
4. Time points will be taken after 0, 1, 2, 4, 8, 16, and 45 minutes. The reaction will be 
stopped at each time point by transferring 5 μl of the reaction to a tube pre-filled 
with 1.7 μl of 4x Laemmli sample buffer. While samples are pre-warming, prepare 
“stop-tubes” for each time point by adding 1.7 μl 4x Laemmli sample buffer to 200 
μl PCR-tubes.
5. For the time point 0, add 2.5 μl reaction buffer and 2.5 μl of the pre-incubating NCPUb 
dilution to the appropriate stop-tube.
6. Start the reaction by adding 25 μl from the USP48 dilution to the now 25 μl of the 
NCPUb dilution and incubate at 30°C.
Note: In experimental systems where the fluorophore tends to aggregate and form 
precipitate, addition of 0.05 % TWEEN20 v/v can help prevent aggregation
7. At each time-point, take 5 μl from the reaction mixture and add to the appropriate 
stop-tube.
Note: Several reactions can easily be streamlined by using a multichannel pipette so that 
different enzyme-substrate combinations can be recorded simultaneously.
8. Boil the samples and run 5 μl on a 4-12% gradient SDS-gel.
9. For quantitative readout a laser-based fluorescence gel scanner is suggested.
10. Quantify the bands in each lane using programs such as ImageJ. Each band 
represents a fraction of the total concentration of labelled ubiquitin (and thus 
ubiquitinated substrate) used in the reaction. Note, however, that this represents 
the molar amounts of ubiquitin present in each band. If the interest lies with the 
molar amounts of substrate, the quantification needs to be corrected for the number 
of ubiquitins present on each substrate species. For example, to calculate molar 
amounts for the species corresponding to di-ubiquitinated H2A, the molar amounts 
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quantified from the fluorescence signal need to be divided by two, as there are two 
ubiquitins on the di-ubiquitinated H2A.
Note: More details on analysis and interpretation of the kinetic data generated this way 
can be found in ((Johnson et al., 2009; Uckelmann et al., 2018); Kim et al., in revision)
Regulation of USP activity
USPs are usually large multi-domain proteins where the accessory domains can play a 
vital role in regulation of the USPs either by modulating their catalytic rates or by altering 
their affinity for ubiquitin or their natural substrates. Additionally, USP activity can be 
regulated upon binding to regulatory proteins in trans. To investigate the potential effects 
of any regulatory element on DUB activity, a first step is to assess differences in USP 
activity in the presence and absence of the regulatory element.
Estimation of KD based on activity assays
For determining kinetic parameters of USP activity in the presence of regulatory factors 
it is important to estimate the KD between the USP and the regulatory factor. This gives 
us an idea of the concentration required to saturate the binding so that the effect caused 
by this regulatory binding can be observed. Here we describe a general protocol for 
estimating KD that is based on change in USP catalytic activity upon binding to its 
regulator.
Note: Activation assays done with domains added in trans will yield an apparent KD for the 
in trans interaction, in a covalently linked setting the affinities can differ.
Materials
- Purified regulatory protein (e.g. UAF1 ) or a domain (e.g. UBL domains of USP7)
- Purified USP full length or catalytic domain
- UbRho (8 µM stock)
- Reaction Buffer (20 mM HEPES (pH 7.5) + 100 mM NaCl + 5 mM DTT + 0.05% Tween 
20)
- Low Volume 384 Well Black Flat Bottom Polystyrene NBS™ Microplate (Corning, 
catalogue number: 3820)
Protocol
1. Determine the protein concentration of the USP and the regulatory protein.
2. Prepare a USP stock (refer to 3.1.3) in reaction buffer.
2
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3. Prepare a two-fold dilution series of the regulatory protein in reaction buffer. Each 
dilution should have a volume of 10 μl.
4. Add 10 μl of the USP stock to each dilution and let the sample incubate for 10-15 
minutes at room temperature.
5. Prepare an 8 μM stock of UbRho in reaction buffer.
6. Add 10 μl of USP + regulator into the wells; each dilution goes into a separate well.
7. Using a multichannel pipette, add 10 µL of the substrate into the wells.
8. Start the program, and monitor the fluorescence increase.
9. If the regulatory effect is saturated at the lowest concentrations of regulator or 
if saturation is not reached even at the highest concentration then adjust the 
concentration range of the regulator and perform the experiment again.
10. Determine the apparent KD by calculating the initial rates and plotting them against 
the concentration of regulator.
Note: Since this assay includes ubiquitin, the KD obtained here could be different for 
the ubiquitin-USP intermediate then for the USP alone. For non-ubiquitin-based affinity 
experiments refer to section 3.4.
Quantitative assessment of activity modulation
Here we describe the case study of USP1-UAF1, in which we determine the steady-state 
kinetic parameters for this complex. The protocol can be used for other USP complexes 
as well, although the buffer and protein concentrations may have to be optimized (see 
3.1.3).
Materials
- Purified USP1 (65 µM) and UAF1 (75 µM)
- UbRho stock (1 mM, in DMSO)
- Reaction Buffer (20 mM HEPES 7.5 + 100 mM NaCl + 5mM DTT + 0.05% Tween 20)
- Low Volume 384 Well Black Flat Bottom Polystyrene NBS™ Microplate (Corning, 
catalogue number: 3820)
- PCR tubes, in a strip
- Data fitting software: GraphPad Prism 7
Note: Follow the same guidelines for sample and buffer preparation provided in the notes 
of section 3.1.4.
Protocol
1. Determine the concentration of USP1 and UAF1.
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2. Prepare a 40 nM USP1 stock and a 400nM UAF1 stock in reaction buffer. Make at 
least 60 μl of each stock solution.
Note: The KD for USP1-UAF1 binding is around 10 nM, but we still use 10 times more 
UAF1 to USP1 to ensure all of the USP1 is bound. For every USP complex, perform the 
experiment at varying concentrations of regulator (3.3.1) to determine the concentration 
of regulator to use.
3. Mix 50 μl of the USP1 stock with 50 μl of the UAF1 stock, and incubate at room 
temperature for 10 minutes.
4. Make a two-fold dilution range of UbRho (starting at 60 µM) in an 8-strip of PCR 
tubes. Make sure the minimal amount is 10 µL for each reaction. For example, 
prepare 25 µL of 60 µM UbRho, then do a serial dilution transferring 12.5 µL to the 
next well containing 12.5 µL buffer.
5. Add 10 µL of USP1/UAF1 stock solution into the wells of the assay plate – note 
down the wells.
6. At the plate reader, check the settings and the program, take care to select the 
proper wells.
7. Using the multichannel pipette, add 10 µL of the substrate into the wells.
8. Start the program, and monitor the fluorescence increase.
9. Analyze the data by following the analysis protocol outlined in section 3.1.4.
Case study: mapping substrate recognition sites on USP with effects on activity assays.
Whilst the activation assay is designed for use with a minimal ubiquitin substrate 
(UbRho), some domains within a USP could aid specifically in the recognition or cleavage 
of a physiological ubiquitinated target. By omitting the domain of interest in the protein 
construct, one can investigate its effect in comparison to the full-length protein. We have 
used such a system to study the effect of the TRAF domain of USP7 on the recognition 
and activity of USP7 toward a ubiquitinated p53-peptide, which mimics a physiological 
substrate of the enzyme (Kim et al., provisionally accepted).
Quantitative USP interaction analysis
Large scale proteomic studies carried out specifically on DUBs have uncovered large 
protein interaction networks (Sowa, Bennett, Gygi, & Harper, 2009). These DUB interaction 
networks can be examined and simplified further by using in vitro binding assays to 
identify and quantify protein interactions. Most USPs are part of multiprotein complexes 
where the members of the complex are either substrates of the USP or regulators of USP 
function. Binding studies can be used to simplify these complicated interaction networks 
2
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by examining which members are responsible for direct interactions with the USP in 
question. Furthermore, once the binding partner has been identified, the stoichiometry 
of binding can also be determined using certain binding assays. Additionally, the 
equilibrium dissociation constant (KD) and binding kinetics data obtained from such 
analyses give an indication of the lifetime of a protein interaction with its binding partner. 
This can then be compared with its other binding partners to obtain relative abundance 
of protein complexes for the protein in question. This kind of information is very useful 
for understanding mechanisms of USP regulation, especially when multiple regulatory 
factors are involved. For example, information obtained from binding studies can be 
used in activity assays to quantitatively analyze the effect of interactors on USP activity 
(refer to section 3.3.2).
Here we describe a number of in vitro binding assays which can be performed to study 
protein – protein interactions. We do not go into the details of any of these assays as 
they are available in the published literature. Instead, we highlight the important features 
and limitations of each binding assay so that an informed decision can be made by the 
reader before performing these assays.
In Vitro pull-down assays
In vitro pull-down assays are a fast and inexpensive way of identifying protein - protein 
interactions as these experiments do not require highly specialized instrumentation or a 
large amount of material. Pull-down assays are a type of affinity purification where one 
of the proteins is immobilized to a surface using a specific antibody or an affinity tag. 
The potential binding partner is incubated with the immobilized protein and interaction 
is confirmed if both proteins co-elute from the surface. Many proteins interact non-
specifically with the immobilization surface which leads to false positive results. Thus, 
control experiments should be performed to confirm lack of non-specific interactions. 
Pull down assays are usually not quantitative and low affinity interactions or interactions 
with a fast off rate cannot be detected using this method. Additionally, if the interacting 
region on the immobilized protein is masked by the surface then no binding will be 
observed.
Analytical gel filtration
This technique is an easy way of determining if two proteins interact with each other. The 
biggest advantage here is that the proteins don’t have to contain any tag and also the 
amount of protein required is relatively low. The time required for a typical size exclusion 
run means that complexes with fast off-rates will be poorly detected. This technique is 
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primarily used for qualitative purposes, but multiple runs at varying concentrations, with 
sensitive read-out (e.g. western blot) would allow quantification of binding parameters.
Surface Plasmon Resonance
Surface plasmon resonance (SPR) is a spectroscopic method which is used to detect 
protein interactions by immobilizing the ligand on a thin metal film and measuring 
the change in refractive index upon binding of the analyte. SPR experiments allows 
quantification of the KD, and if the binding process is well defined, also makes it possible 
to determine kinetic parameters (kON and kOFF). High-affinity interactions of less than 1 
nM (depending on the system) and low-affinity interactions upto 500 μM can both be 
analyzed in this label-free setup with the only requirement being that one of the proteins 
has to be tagged so that it can be immobilized on a complementary surface. The starting 
material required to carry out binding measurements is not very high unless the affinity 
is very low, in which case the amount of analyte required will increase considerably. The 
disadvantage of this system is that one of the protein partners has to be immobilized on 
a solid surface which can prevent binding due to steric hindrance or in some cases lead 
to more binding than what is actually observed in solution. Moreover, the instrument and 
sensors are expensive and running the instrument requires some expertise.
Fluorescence polarization
Fluorescence polarization (FP) measures protein binding based on change in polarization 
of emitted light upon excitation of a fluorescent molecule with plane-polarized light. 
Therefore, when an interacting protein binds to the fluorescently labelled protein there 
is a change in the polarization of emitted light due to slower tumbling of the fluorescent 
molecule. FP is a quantitative technique and the amount of sample required for these 
assays is lower compared to SPR but that again depends on the affinity of the interaction 
being measured. FP depends on the size of the interacting proteins; thus, it usually 
only works well when the size of the labelled protein is much smaller compared to 
the interacting protein. The other limitation of FP arises when measuring low-affinity 
interactions because for such cases the concentration of the unlabelled protein is very 
high which can lead to artificial crowding effects. Finally, the choice of label can also 
lead to non-specific interactions as some of the labels are very hydrophobic.
Microscale Thermophoresis
Microscale thermophoresis (MST) measures protein interactions in solution based on 
the diffusion of a fluorescently labelled molecule along a laser-induced local temperature 
gradient (Wienken, Baaske, Rothbauer, Braun, & Duhr, 2010). This technique requires 
labelling of one protein but unlike FP there is no limitation on the relative size of the 
2
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labelled and unlabelled proteins. Other advantages of MST are that the amount of sample 
required for obtaining a KD is lower than any of the techniques described here and also 
the range of binding affinities that can be measured is very high. MST is a very sensitive 
method and because of that small changes in buffer or sample preparation can lead to 
changes in signal which hamper reproducibility. Additionally, kinetic parameters cannot 
be determined with this method and hydrophobicity of the label can lead to non-specific 
interactions.
Isothermal Titration Calorimetry
Isothermal Titration Calorimetry (ITC) measures the heat generated in an interaction. 
Upon titration of one of the partners in the interaction, it allows determination of 
the thermodynamic properties of protein interactions in solution and gives KD and 
stoichiometry. This is a robust method which gives very solid data. It enables measuring 
protein interaction in a label-free environment. The biggest disadvantage of this method 
is the large sample quantities required, and this is particularly important in the case 
of USPs because many of these enzymes are not easily produced in large quantities. 
Other disadvantages of ITC are that measurement times are longer, it requires high 
concentrations, it requires stirring of the sample, and also that it does not measure 
kinetic parameters of binding.
Table 2: Features of commonly used binding assay for studying protein-protein interactions
CONCLUSIONS
The prerequisite for in vitro characterization of USPs is pure and stable protein. USPs 
are usually large proteins and often with several unstructured regions which makes their 
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expression and purification difficult. Purification of USPs from bacterial and insect cells 
presents distinct challenges which have been discussed in this chapter. The purification 
protocols outlined in this chapter serve as a starting point for purification of any USP 
but they might require modifications depending on the choice of expression construct 
and the USP being purified.
In vitro activity studies are a great way for studying USP function. These assays are 
also used to probe the role of regulatory factors in modifying USP catalytic activity. 
Similarly, when performing binding assays all the quality control measures mentioned 
above should be taken into consideration. The protocols described in this chapter in 
combination with several quality control measures will enable one to obtain reliable 
quantitative data on USP activity and regulation.
2
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Regulation of deubiquitinating enzyme (DUB) activity is an essential step for proper 
function of cellular ubiquitin signals. UAF1 is a WD40 repeat protein, which binds and 
activates three important DUBs, USP1, USP12 and USP46. Here, we report the crystal 
structure of the USP12-Ub/UAF1 complex at a resolution of 2.8 Å and of UAF1 at 2.3 
Å. In the complex we find two potential sites for UAF1 binding, analogous to what was 
seen in a USP46/UAF1 complex. In line with these observed dual binding states, we 
show here that USP12/UAF1 complex has 1:2 stoichiometry in solution, with a two-step 
binding at 4 nM and 325 nM respectively. Mutagenesis studies show that the finger sub-
domain of USP12 interacts with UAF1 to form the high affinity interface. Our activation 
studies confirm that the high affinity binding is important for activation while the second 
UAF1 binding does affect activation. Nevertheless, we show that this two step binding is 
conserved in the well-studied USP12 paralog, USP1. Our results highlight the interfaces 
essential for regulation of USP12 activity and show a conserved second binding of UAF1 
which could be important for regulatory functions independent of USP12 activity.
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INTRODUCTION
Ubiquitination of proteins is a reversible post-translational modification that is critical 
for almost any cellular process. The control of these crucial pathways lies in the precise 
regulation of ubiquitinating and deubiquitinating enzymes (DUBs). DUBs are carefully 
regulated intra-cellular peptidases that cleave ubiquitin from target substrates. There 
are approximately 90 DUBs in the human genome, in 5 different families (Clague et al., 
2013; Komander et al., 2009). The most abundant are the ubiquitin specific proteases 
(USPs) with 60 members that share a conserved USP catalytic domain, in which the 
ubiquitin core is held by the “fingers” while the catalytic centre lies between the “palm” 
and “thumb” subdomains. Despite this common catalytic core, the USP family members 
have many different modes of regulation (Sahtoe and Sixma, 2015).
Such regulation can take place in different ways and at different sites. USPs are regulated 
by changes in the catalytic domain, where the catalytic triad may be misarranged (Hu et 
al., 2002), via additional domains within the protein itself (Clerici et al., 2014; Faesen et 
al., 2011a), via post translational modifications (Nicassio et al., 2007), or by sub-cellular 
localization (Row et al., 2007). An interesting form of regulation is seen in a small sub-
family of USPs, that includes USP1, USP12 and USP46. These three proteins are activated 
by complex formation with a WD40 repeat protein called UAF1 (USP1 associated factor, 
also known as WDR48) that leads to increased catalytic turnover for these enzymes 
(Cohn et al., 2007).
USP12 and USP46 are small proteins (370 and 366 residues respectively) with a highly 
conserved catalytic domain and high sequence similarity (88% identity). The related 
paralog USP1 (31% identity) is much larger (785 residues), due to additional inserts 
within its catalytic domain. The USP12/UAF1 and USP46/UAF1 complex can be further 
activated by binding to a second WD repeat protein, WDR20. This hyper-activation is not 
observed for the USP1/UAF1 complex (Kee et al., 2010). The lack of hyper-activation 
in USP1 could be due to the presence of the long inserts which might prevent it from 
interacting with WDR20. All three enzymes have low intrinsic activity in isolation and 
binding to UAF1 leads to activation which was shown to be due to an increase in kcat 
with no drastic change in the KM (Cohn et al., 2007; Faesen et al., 2011b; Villamil et 
al., 2012a). The exclusive kcat activation is unusual for DUBs as most intermolecular 
activators (except GMPS) affect substrate binding (Faesen et al., 2011b).
The UAF1 regulation of this subfamily of DUBs has attracted considerable attention due 
to the biological importance of the enzymes involved. USP1 is important in DNA repair, 
where it acts on mono-ubiquitinated FANCD2 and PCNA in DNA cross-link repair and 
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DNA-damage avoidance pathways (Huang et al., 2006; Nijman et al., 2005). It is also 
found to deubiquitinate the ID family of transcriptional regulators (Williams et al., 2011). 
Due to these important functions, USP1 is considered a major possible drug target (Liang 
et al., 2014). USP46 plays important roles in neurobiology, as a small deletion mutation 
in USP46 leads to neurological effects in mice, including anxiety and changes in learning 
and memory (Imai et al., 2013; Zhang et al., 2011). The molecular basis for these effects 
is not yet clear. For USP12 several possible roles have been described. It is involved 
in stabilizing the Akt phosphatases resulting in decreased levels of pAkt (Gangula 
and Maddika, 2013). It has also been reported that USP12 and USP46 deubiquitinate 
histone H2A and H2B thereby playing a role in Xenopus development (Joo et al., 2011). 
Recently USP12 was shown to stabilize the T-cell receptor complex at the cell surface 
by deubiquitinating TCR adaptor proteins LAT and Trat1 (Jahan et al., 2016).
 Several studies have tried to uncover the detailed mechanism of USP1/12/46 activation 
by UAF1 and also the interfaces involved in the formation of this complex. It was 
suggested that UAF1 binding modulates the active site conformation of USP1 resulting 
in a productive catalytic triad and also that phosphorylation of Ser313 is necessary for 
its interaction (Villamil et al., 2012a, 2012b). Other studies have shown that the regions 
in and around the finger domain of USP1 might be necessary for UAF1 binding (Olazabal-
Herrero et al., 2015). Recently the crystal structure of the USP46-Ub and its complex with 
UAF1 were determined. In these structures two possible interfaces for UAF1 binding and 
activation were identified. The authors used mutational analysis to show that Interface 
1 is critical for UAF1 binding and activation (Yin et al., 2015).
Here we present the structure of USP12-Ub/UAF1580 complex which was solved at a 
resolution of 2.8 Å and compare it to the UAF1 structure alone. Intriguingly, we find 
that these structures resemble the USP46/UAF1 complex structure (Yin et al., 2015), 
including the presence of the second binding site. We then show that in solution USP12 
can bind to a second molecule UAF1, but with lower affinity. We confirm for USP12 that 
Interface 1 at the fingers site is the high affinity interface while the second low affinity 
interface could be at the backside of the ubiquitin binding cleft. Moreover, mutagenesis 
studies suggest that the first binding event at the fingers is responsible for activation 
while the second binding does not influence activity.
MATERIALS AND METHODS
Plasmids and cloning
Human USP12, USP46, USP1 and UAF1 constructs were obtained from Martin Cohn. 
The USPs were cloned into pFastbac-HTb vector and UAF1 was cloned into pFastbac1 
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(N-terminal Strep tag) for insect cell expression. The sequence verified insert containing 
pFastbac vectors were transformed into DH10Bac cell for bacmid preparation. The 
recombinant bacmid was used for transfection of Spodoptera frugiperda (sf9) insect 
cells to produce the recombinant baculovirus. USP12WT (24-370) and USP46 (8-366) 
were also cloned into the pGEX and pET bacterial expression vectors of the NKI LIC 
suite, respectively (Luna-Vargas et al., 2011). All USP12 mutants were made using the 
QuikChange site directed mutagenesis method on pGEX USP12 bacterial construct.
Protein expression and purification
N-terminal His-tagged USP1 (21-785) and USP12FL were expressed using Baculovirus 
expression in sf9 insect cells. After 72 hours of infection the cells were harvested in 
20 mM Tris (pH 8.0) + 200 mM NaCl + 2 mM TCEP + protease inhibitor (lysis buffer) 
and lysed by sonication. The lysed cells were spun down (21000 rpm for 1 hour) and 
the lysate was loaded on a His-affinity column (GE, USA). The column was washed 
with lysis buffer supplemented with 50mM Imidazole (pH 8.0) followed by elution with 
lysis buffer supplemented with 500 mM imidazole. The His-USP1 elution fractions 
were concentrated and loaded on a size exclusion chromatography column (Superdex 
200, GE, USA) equilibrated in GF buffer (20 mM HEPES (pH 7.5) + 150 mM NaCl + 2 
mM DTT) following which the protein fractions were concentrated upto 4.5 mg/ml and 
stored in -80⁰C. The USP12FL and USP46FL fractions were incubated with TEV protease 
and dialyzed overnight in lysis buffer without imidazole. The dialysed protein sample 
was then loaded on a His-affinity column where the protein was obtained in the wash 
fractions. The protein containing fractions were then concentrated and loaded on a size 
exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer 
following which protein fractions were concentrated upto 6 mg/ml and stored in -80⁰C.
N-terminal GST-tagged USP12WT and mutants were expressed in E. coli. The cells were 
induced with 0.2 mM IPTG at 18⁰C for 10-12 hours followed by which they were harvested 
in lysis buffer and lysed by sonication. The lysate was loaded on a GST-affinity column 
and washed with lysis buffer followed by elution with lysis buffer supplemented with 20 
mM Glutathione. The protein containing fractions were then concentrated and loaded 
on a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF 
buffer following which protein fractions were concentrated upto 15 mg/ml and stored 
in -80⁰C.
N-terminal His-tagged USP46 (8-366) was expressed in E.coli. The cells were induced 
with 0.5 mM IPTG at 20⁰C for ~16hrs followed by which they were harvested in 20 mM 
Tris (pH 7.5), 150 mM NaCl, 10 mM Imidazole (pH 8.0) and 5 mM beta-mercaptoethanol 
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(lysis buffer) and lysed by sonication. The lysate was loaded on a Ni-affinity column 
and washed with lysis buffer supplemented with 50 mM imidazole followed by elution 
with lysis buffer supplemented with 500 mM imidazole. USP46 was incubated with TEV 
protease and dialysed overnight in lysis buffer without imidazole. The dialysed protein 
sample was then loaded on a His-affinity column where the protein was obtained in 
the wash fractions. USP46 was loaded on a size exclusion chromatography column 
(Superdex 200, GE, USA) equilibrated with 20 mM Tris (pH 7.5), 150 mM NaCl and 2 mM 
DTT.
UAF1FL and UAF1580 were also purified from sf9 insect cells and were lysed in similar 
conditions as the USP purifications. The UAF1 lysates were loaded on a Strep-affinity 
column (IBA life sciences) and washed with 50 mM Tris (pH 8.0) + 150 mM NaCl + 2 
mM TCEP (wash buffer). The strep-UAF1 protein was then eluted using wash buffer 
supplemented with 2.5 mM Desthiobiotin. The protein containing fractions were 
concentrated and loaded on a size exclusion chromatography column (Superdex 200, GE, 
USA) equilibrated in GF buffer. The fractions corresponding to the peak were collected. 
UAF1 samples were treated with 10 mM iodoacetamide to prevent background DUB 
activity due to minute amounts of co-purified insect cell DUBs. Following iodoacetamide 
treatment the protein fractions were re-purified using size exclusion chromatography 
(Superdex 200, GE, USA). The protein fractions were then concentrated up to 10 mg/ml 
and stored in -80⁰C.
The USP/UAF1 complexes were co-expressed in baculovirus infected sf9 insect cells. 
USP/UAF1 complexes were purified by first carrying out a His-affinity purification 
followed by Strep-tag (IBA life Sciences) affinity purification as described above. The 
protein fractions were then concentrated and loaded on a size exclusion chromatography 
(Superdex S200, GE, USA) equilibrated in GF buffer. The protein containing fractions 
were concentrated upto 5 mg/ml and stored at -80⁰C.
Covalent complexes of USP46 and USP12FL/UAF1580 with Ub-VME and Ub-PRG 
respectively were generated under reducing conditions at 4⁰C for 12-16 hrs. The USP46 
reaction was very slow and only 50% of the enzyme reacted to Ub-VME whereas 
approximately 80% of the USP12FL/UAF1580 complex reacted to the Ub-PRG probe. 
The reacted USPs were then purified from the excess probe by using a size exclusion 
chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer. The purified 
USP-Ub complex was then concentrated and stored at -80⁰C.
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Crystallization and structure determination
USP12 and UAF1 crystals were obtained by sitting drop vapour diffusion experiment 
at 20°C using equal ratio of protein and mother liquor solution. UAF1580 was setup for 
crystallization at 8 mg/ml and crystals were obtained in 20% PEG3350, 200 mM Tri-
Sodium Citrate, Bis-Tris Propane pH 6.5. USP12FL-Ub-PRG/UAF1580 was setup at 5 mg/
ml and crystals were obtained in 3.2% PEG4000, 0.1 mM MMT pH 6.5 and 0.1 mM TCEP. 
The crystals were cryo-protected by brief washing in mother liquor solution with 30% 
glycerol prior to flash freezing in liquid nitrogen. Diffraction data was collected at the 
Swiss Light Source beamline PXIII at 100K.
USP46-Ub-VME at 8 mg/ml was set up for crystallization by sitting drop vapour diffusion 
experiment at 20°C. Crystals were obtained in 0.96 M Sodium Citrate pH 7.5 and 0.1 
mM ZnCl2 with protein: precipitant ratio 1.5 : 1. The crystals were cryo-protected by 
brief washing in mother liquor solution with 20% glycerol prior to flash freezing in liquid 
nitrogen. Diffraction data was collected at the European Synchrotron Radiation Facility 
(ESRF) beamline ID14-1 at 100K.
Crystallographic data were processed with XDS (Kabsch, 2010) or iMOSFLM (Battye et 
al., 2011) and scaled using XSCALE (Kabsch, 2010) or Aimless from the CCP4 suite (Winn 
et al., 2011). The USP46-Ub-VME structure was solved by molecular replacement using 
the USP2-Ub model (PDB 2IBI) in Phaser (McCoy et al., 2007) followed by automated 
model building using ARP/WARP (Langer et al., 2008).The UAF1 (9-580) structure was 
solved by molecular replacement (PDB-1VYH) in Phaser (McCoy et al., 2007) followed 
by automated model building using ARP/Warp (Langer et al., 2008). The USP12FL-Ub/
UAF1580 structure was solved by molecular replacement using the USP46, UAF1580 and 
ubiquitin structures as search models in Phaser. All structures were refined by Phenix 
(Adams et al., 2010), autoBUSTER (Smart et al., 2012), Refmac (Murshudov et al., 1997), 
PDB_REDO (Joosten et al., 2014) and models were built using COOT (Emsley et al., 2010). 
Interface analysis was performed with PISA (Krissinel and Henrick, 2007). All structure 
figures were generated using PyMOL (Schrödinger, LLC).
Size exclusion chromatography Multi Angle Laser Light Scattering (SEC-
MALLS)
The SEC-MALLS experiments were performed using the miniDawn Tristar light scattering 
detector (Wyatt technologies, USA) in line with size exclusion chromatography. After 
equilibration of the Superdex 200 10/300 GL and the Superose 6 increase 10/300 GL 
(GE, USA) in buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 2 mM DTT, the 
USP12FL-Ub/UAF1580 (8 µM) and the USP1/UAF1FL complex (6 µM) were loaded on the 
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Superdex 200 10/300 GL while the USP12FL-Ub/UAF1FL sample (42 µM) was loaded on 
the Superose 6 increase 10/300 GL (GE, USA). Molecular weight estimation was done by 
using the refractive index signal as measure of the concentration with the Astra software 
(Wyatt Technologies, USA).
Size exclusion chromatography - Small Angle X-ray Scattering (SEC-SAXS)
USP12FL-Ub/UAF1FL purified from insect cells was concentrated upto 38 µM. The buffer 
used for the size exclusion chromatography was also used for SEC-SAXS experiment 
on the BM29 SAXS beamline at the ESRF. Following equilibration, 30 µl of the purified 
USP12FL-Ub/UAF1FL was loaded on the Superdex 200 5/150 GL (GE, USA) and 1500 
successive 1 s frames were collected through the protein elution peak. The data were 
normalized to the intensity of the transmitted beam and radially averaged; the scattering 
of the solvent-blank (derived from the buffer run) was subtracted. Data were analysed 
using the ATSAS software package (Svergun et al., 2001). A moving set of 10 or 20 
frames was analysed across the high-intensity peak to estimate molecular weight from 
various methods (DATPOROD (Konarev et al., 2006), excluded volume from DAMMIF 
model (Franke and Svergun, 2009) and SAXS MoW2 (Fischer et al., 2010)) and fit the data 
to the crystallographic structures in CRYSOL (Svergun et al., 1995). Frames prior to 670 
and frames latter than 910 were considered too noisy or weak for analysis. OLIGOMER 
(Konarev et al., 2003) was used to perform a fit to the experimental curve from different 
possible models of the complex and determine volume fractions of each component. 
Several OLIGOMER runs were performed using the 2:1 complex, both 1:1 complexes and 
UAF1 alone as models in different combinations.
Ub-Rhodamine enzymatic assays
Enzymatic activity was followed as release of fluorescent rhodamine from the quenched 
Ub-Rho substrate, providing a direct readout for DUB activity. The fluorescent intensity 
was measured using Pherastar plate reader (BMG LABTECH GmbH, Germany). Activity 
of USP12WT at varying concentrations of UAF1FL (20-1250 nM) was tested at 100 nM 
of USP12WT and at a single substrate concentration of 1 µM. Activity was quantified 
by calculating the initial rates and plotted as a function of UAF1FL concentration. 100 
nM of enzyme was used against different concentrations of the minimal substrate (32 
µM to 0.25 µM) for the Michaelis Menten analysis. The initial rates were then plotted 
against substrate concentration and fitted with a Michaelis Menten model using non-
linear regression in GraphPad Prism 6 software (GraphPad Software Inc, USA).
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Binding assays
Surface Plasmon Resonance experiments were carried out to test binding of His-USP1 
and Gst-USP12WT to UAF1FL in the Biacore T200 system (GE, USA). The SPR buffer for 
Gst-USP12WT and mutants consisted of 20 mM HEPES 7.5, 150 mM NaCl, 20% glycerol, 
0.05% Tween-20, 2 mM TCEP (Tris (2-carboxyethyl) phosphine hydrochloride) and 1 mg/
ml dextran. The SPR buffer for His-USP1 had 300 mM NaCl to neutralize any unspecific 
interaction with Ni on the chip surface and the rest of the components were identical. The 
Gst-USP12 was immobilized via goat anti-GST antibody that was pre immobilized to the 
CM5 chip using amine coupling. The His-USP1 was directly immobilized to the surface 
of NTA chip via His-tag. The binding experiments were carried out in the single cycle 
kinetics mode with 5 sequential injection of UAF1FL in each cycle. An initial experiment 
with 5 injections from 1 nM to 10 µM and a more detailed assay with 15 injections from 
0.56 nM to 2.56 µM were carried out. Data from a reference flow cell, run in parallel 
with an empty chip (in case of NTA immobilization) or with GST (in case of anti-GST 
immobilization) were subtracted from the signal using the Biacore T200 Evaluation 
Software. Final analysis and the figures were done using GraphPad Prism 6 (GraphPad 
Software Inc, USA).
RESULTS
Crystal structures of USP46, UAF1580 and USP12FL-Ub/UAF1580 complex
To study how the regulator UAF1 modulates the activity of USPs, we purified the human 
USP46, human USP12 and several constructs of the human UAF1. We refer to UAF1 (9-
580) as UAF1580 and to UAF1 (9-677) as UAF1FL (Fig.1a). By reaction of USP46 and USP12 
with suicide inhibitors of ubiquitin, Ub-VME and Ub-PRG respectively, we could create 
covalently linked USP-Ub complexes, which were used for crystallization attempts.
We generated well diffracting crystals for USP46-Ub (1.85 Å), USP12FL-Ub/UAF1580 (2.8 
Å) and UAF1580 (2.3 Å). All three crystal structures were solved by molecular replacement 
where the covalent USP2-Ub complex model (2IBI) was used for the USP46-Ub structure 
and the protein PAF-AH (1VYH) was used as a model for UAF1580. The resulting structures 
of USP46-Ub and UAF1580 were used as models for the USP12FL-Ub/UAF1580 complex. 
All three structures were refined to acceptable R-factors and good geometry (Table.1).
The crystal structure of USP46-Ub reveals the canonical USP domain with a catalytic 
centre in the catalytically proficient state (Fig.1b). The crystallization contained only 
50% of the Ub-bound form, but the crystal was fully modified, indicating a preferential 
crystallization of the ubiquitin-bound form. This structure is in good agreement with the 
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recently published structure of USP46 ((5CVM), RMSd on 308 Cα: 0.3 Å).The structure of 
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Fig.1 - Crystal structure analysis shows two possible binding options for USP12.
A) Constructs used for the present study. B) Crystal structure of USP46-Ub-VME in cartoon representation. C) 
Crystal structure of UAF1580 coloured in a rainbow representation. D) Crystal structure of USP12FL-Ub/UAF1580 
showing UAF1580 bound to Interface 1.) E) Zoomed Interface 1 between UAF1580 and USP12FL-Ub showing the 
interface residues. F) Crystal structure of USP12FL-Ub/ UAF1580 showing UAF1580 bound to Interface 2. G) Zoomed 
Interface 2 between UAF1580 and USP12FL-Ub showing the interface residues. (Colours in panel B,D-G: Ub in 
yellow, other proteins as in A).
WD40 domain predictions obtained from the protein sequence predicted 8 blades. The 
first N-terminal residues (13-24) are present in the ancillary domain and the following 
residues from 25-360 form the 7 bladed β-propeller. The predicted eighth blade (361-
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400) forms the expected 4-stranded sheet but is located in the ancillary domain where 
it sits on top of a β sheet in which the N-terminal residues form an integral part. The 
UAF1580 structure is very similar to the recently published structure of UAF1 ((5CVL), 
RMSd on 517 Cα: 1.2 Å).
In the crystal lattice of the USP12FL-Ub/UAF1580 complex, the asymmetric unit contains 
one molecule of USP12 and one molecule of UAF1. However, USP12 makes two possible 
interfaces with UAF1 in these crystals, one on the fingers sub-domain (Interface 1) 
(Fig.1d,e) and the other on the backside of the ubiquitin binding cleft (Interface 2) (Fig.1f,g). 
The interactions in Interface 1 are dominated by hydrophilic and charged interactions, 
with 794 Å2 and 698 Å2 buried surface area on USP12 and UAF1580 respectively (Fig.1e). 
The Interface 2 is mostly hydrophobic and buries a surface area of 1030 Å2 and 1111 Å2 
on USP12 and UAF1580 respectively (Fig.1g). Intriguingly the same crystal packing was 
seen for the USP46/UAF1 complex (PDB code: 5CVN) that was published during the 
refinement of our structures (Yin et al., 2015). In that publication the authors confirmed 
by mutational analysis that Interface 1 is the relevant interface for activation. USP46/
UAF1 was crystallized in the same space group, with similar cell dimensions, which is 
not surprising since USP12 and USP46 have 88% sequence similarity, although neither 
interface is fully conserved. A second crystal form for USP46/UAF1FL was determined in 
a different crystal lattice (C2), with different packing, but even in this crystal lattice, the 
USP still has maintained both interfaces (PDB code: 5CVO). The striking similarity and 
conservation of these two USP/UAF1 interfaces among three different crystal structures 
suggested that this was not due to a crystal packing artefact and further analysis of the 
second interface would be worthwhile (Supp.Fig.1a).
A superposition of our USP46 structure on USP12 in complex with UAF1580 revealed no 
significant conformational change in the USP moiety (RMSd on 309 Cα: 0.9 Å). When 
the UAF1 moieties are compared by superposition of the UAF1580 onto the USP12FL-Ub/
UAF1580 complex, no conformational change is observed in UAF1580 close to Interface 
1 (Supp.Fig.1b), whereas a large shift is observed in the extended loop of blade 3, the 
region where UAF1580
 forms Interface 2 (Supp.Fig.1c). This conformational change due 
to interaction of UAF1580 at Interface 2 is also observed in the USP46/UAF1 structure 
upon UAF1 binding (Yin et al., 2015). Since the conformational change as well as the 
presence of two UAF1 interfaces seems to be conserved between USP46 and USP12, 
we wondered what stoichiometry the USP12/UAF1 complex has in solution.
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Table 1. Crystallography Details
Data Collection
USP46-UbVME UAF1580 USP12-UbPRG/UAF1580
Wavelength (Å) 0.93 0.92 1.00
Resolution (Å) 28.41-1.85 (1.90-1.85) 48.97-2.30 (2.35-2.30) 47.41-2.79 (2.92-2.79)
Space Group C 2 2 21 P 2 21 21 I 2 2 2
Unit Cell a, b , c (Å) 91.95 104.66 135.31 73.30 131.60 148.67 103.68 152.82 182.93
CC1/2 0.999 (0.720)* 0.999 (0.585) 0.995 (0.638)
Rmerge 0.12 (0.84) 0.05 (1.0) 0.08 (0.72)
Rpim 0.04 (0.84) 0.06 (0.57)
I/σI 17.68 (2.0) 16.1 (1.4) 10.4 (1.6)
Completeness (%) 98.8 (99.7) 99.6 (95.9) 99.3 (94.8)
Redundancy 3.56 (3.3) 4.5 (4.1) 4.5 (4.3)
Refinement
Unique Reflections (nr) 55291 64580 36148
Atoms total (nr) 3442 8586 7290
Protein atoms (nr) 3192 8195 7266
Solvent atoms (nr) 250 391 24
B-factors 31.9 58.3 72.4
TLS groups 4 4 4
Rwork/Rfree (%) 16.6/19.4 18.5/22.4 20.8/25.9
Rmsd bond lengths (Å) 0.017 0.007 0.014




Molprobity score 1.01 0.82 1.77
PDB code 5L8H 5L8E 5L8W
 High Resolution shell in parentheses; (*- Reprocessed with aimless)
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The USP12/UAF1 complex has 1:2 stoichiometry
To study relative amounts of USP12 and UAF1 in solution we carried out size exclusion 
chromatography coupled with multi-angle laser scattering (SEC-MALLS) of the purified 
USP12FL-Ub/UAF1580 complex which was used for obtaining the crystal structure. The 
molecular weight obtained from the MALLS experiment was approximately 166 KDa 
which is much closer to the calculated mass for 1:2 complex (180 KDa) than for a 1:1 
complex (115 KDa). The calculated molecular weight was not constant within the peak, 
which suggests a dynamic equilibrium between the 1:2 and 1:1 complexes (Fig.2a).
Next, we carried out small angle X-ray scattering (SAXS) experiments coupled to size 
exclusion chromatography. At the high concentration necessary for SAXS experiments 
higher order species are observed (Fig.2b). The purified complex of USP12FL with 
covalently bound Ub-PRG and UAF1FL was used for these experiments. Frames 
corresponding to the different parts of the peak were averaged and analysed separately 
(Supp.Fig.1d). Molecular weight estimation of the data (898-909) from the latter half 
of the peak was consistent, when carried out using different methods (Porod volume 
(Konarev et al., 2006), excluded volume from DAMMIF model (Franke and Svergun, 2009), 
and SAXS MoW2 (Fischer et al., 2010)), where we observed that USP12FL-Ub/UAF1FL has 
a molecular weight of 190 KDa corresponding to a 1:2 stoichiometry of the complex. 
Additionally, Porod analysis of the frames in the early half of the peak corresponded to 
a molecular weight of 390 KDa indicating formation of high molecular weight species 
which fits well with the MALLS data (Fig.2b).
Moreover, we compared the experimental SAXS profile of frames (898-909) with 
calculated scattering curves based on the crystal structure either with one UAF1FL bound 
(in either of the two sites), or with two UAF1FL molecules bound. We obtained a much 
worse fit with the 1:1 profile (Fig.2c,e) compared to the possible 1:2 profile (Fig.2d). To 
further analyze these data, we tested whether the OLIGOMER algorithm would change 
the fit. Other possible options did not improve the fit, but when testing for the 1:2 profile, 
we found an improved fit (Fig.2f) with volume fractions of 81% for the 1:2 complex (81%) 
and a smaller fraction for UAF1FL (19%). In principle such a fraction was expected to be 
a mixture of the 1:1 complex and UAF1FL. It is possible that the computational analysis 
selects against this complex mixture when fractions are small.
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Fig.2 - USP12/UAF1 has 1:2 stoichiometry.
A) SEC-MALLS analysis of USP12FL-Ub/UAF1580 (8 µM) shows a molecular weight corresponding to a 1:2 com-
plex. B) SEC-MALLS analysis of USP12FL-Ub/UAF1FL at high concentration (42 µM) shows a dynamic equilibrium 
between high molecular weight species and the 1:2 complex in agreement with the SAXS data. C,D,E) Experimen-
tal SEC-SAXS curve of USP12FL-Ub/UAF1FL fits better with the scattering curve based on the structure of the 1:2 
complex as compared to the 1:1 complex at either of the two interfaces. F) OLIGOMER fit of the Experimental 
SEC-SAXS curve of USP12FL-Ub/UAF1FL.
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UAF1 binds USP12 in two distinct steps with different affinities
We investigated if the two binding events indicative of the 1:2 stoichiometry could be 
observed in an in-vitro binding experiment. Therefore, we analysed the binding of UAF1FL 
to GST-USP12WT by surface plasmon resonance (SPR) and indeed observed two distinct 
binding events (Fig.3a). We found a high-affinity binding (Kd = 4 nM) with an extremely 
low off-rate, which saturated at 100 nM. Moreover, when we added higher concentrations 
of UAF1FL, a second binding event could be observed (Kd =325 nM) (Fig.3b) with faster 
binding and dissociation. In conclusion, we observed two binding events for UAF1FL 
binding to USP12WT with different binding characteristics.
Table 2. Michaelis Menten analysis of USP12WT with UAF1
Protein Kcat (x 10
-2s-1) KM (µM) Kcat/ KM (M
-1 s-1)
USP12WT(100 nM) 0.076 50  0.15 x 10
2
USP12WT+UAF1(100 nM) 2.6 50  5.20 x 10
2
USP12WT+UAF1(1250 nM) 3.3 64  5.15 x 10
2
We tested which of these events contributed to activation. We performed an enzymatic 
assay against the minimal substrate ubiquitin rhodamine (Ub-Rho), as a function of 
activator concentration. We could see a clear activation that correlates with the 
high-affinity binding site. In contrast, the second binding event does not affect the 
activation status, as no further activation is observed when the UAF1FL binds the 
second site (Fig.3c,d). We then performed a kinetic analysis of USP12 activity, either at 
equal concentration to UAF1 (1:1) or when an excess of UAF1 is present (Fig.3e). The 
Michaelis Menten parameters Kcat and KM did not change with higher UAF1 concentration, 
confirming that only Interface 1 is important for UAF1 mediated USP12 activation (Table 
2).
The Finger sub-domain in USP12 is crucial for binding and activation by UAF1
We validated the role of Interface 1 by making a series of mutations. In line with their 
role in the USP46/ UAF1 interface (Yin et al., 2015), a triple mutant made on UAF1 
(UAF13X =K214E+W256A+R272D) and a reciprocal mutant (E190K) on USP12 interfered 
with high affinity binding (Fig.4a,b). The high affinity binding could be partially rescued 
by combining the USP12E190K with the UAF13X mutant, in a similar fashion to what was 
observed for USP46 and UAF1 binding (Fig.4c)(Yin et al., 2015). Additionally, the binding 
of the USP12E190K to the low affinity site remained unchanged. On comparing the binding 
characteristics of these mutants with USP12WT, we noted that the UAF13X mutant only 
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binds at very high concentrations and does not release easily, while the USP12E190K 
mutant binds with a fast release (Fig.4a). We also made a series of mutations at Interface 
2 on USP12WT, by either reversing charges (R217D or R285E) or changing the hydrophobic 
interface (F287A) but none of them could disrupt binding of UAF1 to this site (Fig.4g,h).
 
Fig.3 - UAF1 binds USP12 in two steps with different affinities.
A) Qualitative SPR analysis of five successive injections of UAF1FL on immobilized USP12WT, raw data show 
how initial injections show slow kinetics, and binding at higher concentrations displays fast off-rates. B) Fit-
ting quantitative SPR analysis of UAF1FL to USP12WT, obtained from 15 successive injections of UAF1FL. Curve 
is fit to a two-step binding model with KD as indicated. C) Cleavage of Ub-Rhodamine by USP12WT at different 
concentrations of UAF1FL(10 nM-1250 nM). D) Initial rates of USP12WT plotted as a function of UAF1FL concen-
tration shows the importance of high affinity site for activation. E) Michaelis Menten analysis of USP12WT (100 
nM) alone and in two different concentrations of UAF1FL (100 nM, 1250 nM) shows that the second binding of 
UAF1 leads to no further activation.
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We then carried out an in-vitro Ub-Rho assay to analyse the effects of these mutations on 
USP12 activation and compare it with previously published findings for USP46 (Yin et al., 
2015). Wild type UAF1 was unable to activate USP12E190K to similar levels as compared 
to USP12WT (Fig.4d,e) and similarly, the UAF13X mutant did no longer activate. However, 
as shown previously for USP46/UAF1 (Yin et al., 2015), the combination of these 
complementary mutants rescues the activation (Fig.4f), highlighting the importance of 
the finger sub domain in USP12 and USP46 (Yin et al., 2015) activation by UAF1.
Fig.4 - Interface 1 is the high affinity site and is responsible for activation by UAF1
A) Comparing Qualitative SPR analysis of five successive injections of UAF1FL and UAF13X on immobilized US-
P12WT and USP12E190K shows differences in binding characteristics. B) Semi-quantitative SPR analysis of UAF1FL 
to USP12WT and USP12E190K mutant highlights weaker binding of the mutant to the high affinity interface. C) 
Semi-quantitative SPR analysis of UAF13X to USP12WT and USP12E190K, curves show disruption of binding in 
USP12WT which is rescued by the USP12E190K mutant. D) Cleavage of Ub-Rhodamine by USP12E190K at different 
concentrations of UAF1FL shows loss in activation by UAF1FL. E) Comparison of initial rates of USP12WT and 
USP12E190K at different UAF1FL concentrations shows that when high affinity interaction is lost the activity is 
impaired. F) Comparison of initial rates of USP12WT and USP12E190K at different concentrations of UAF13X shows 
the rescue of activation by the USP12E190K mutant. G) Comparing Qualitative SPR analysis of five successive 
injections of UAF1FL on immobilized USP12WT and USP12 interface 2 mutants shows no significant change 
in binding characteristics. H) Semi-quantitative SPR analysis of UAF1FL to Interface 2 mutant USP12RRFR and 
USP12WT shows identical binding.
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The two-step binding is conserved in USP1
Some aspects of USP1 regulation are different from the USP12 and USP46, as USP1 is a 
much larger enzyme, and it cannot be hyper-activated by WDR20. We therefore wondered 
whether the 1:2 stoichiometry is also conserved in this important DNA repair enzyme. We 
carried out SEC-MALLS of the purified USP1/UAF1 complex and the molecular weight 
obtained was approximately 220 KDa which closely corresponds to the 1:2 complex 
(235 KDa) rather than a 1:1 complex (160 KDa). Similar to the USP12/UAF1 MALLS data 
(Fig.2a), the molecular weight was not constant within the peak suggesting a dynamic 
equilibrium between the two states of the complex (Fig.5a). We then performed the UAF1 
binding assay with His-USP1 on the SPR chip (Fig.5b, c). Again, we observed a two-step 
binding, and although the high RU values for the second step suggests an additional 
unexplained background process, the fitting identified similar affinities for USP1 to those 
observed for USP12. Thus from our SPR result in addition to the MALLS data, we could 
confirm the presence of this unusual regulatory step in USP1.
Fig.5 - The two step UAF1 binding is conserved in USP1.
A) SEC-MALLS analysis of USP1/UAF1FL (6 µM) shows a molecular weight corresponding to the 1:2 complex. B) 
Qualitative SPR analysis shows that USP1 has conserved the two-step binding to UAF1FL, with similar kinetics. 
C) Fitting of quantitative SPR analysis of UAF1FL to USP1 obtained from 15 successive injections of UAF1FL to 
quantify the KD values. Curve is fit to a two-step binding model with affinities as indicated. D) UAF1 binds USP12 
at the fingers sub-domain which activates USP12 and then UAF1 also binds on the backside of the ubiquitin 
binding cleft.
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DISCUSSION AND CONCLUSIONS
Here we present a series of structures that contribute to the understanding of regulation 
of DUBs by non-substrate partners. In our analysis we identified two possible binding 
sites for UAF1 on USP12-Ub (Fig.5d), that are conserved from USP46. The two UAF1 
binding sites are distant from the catalytic centre and binding of UAF1 did not induce 
significant rearrangements in the USP structure. Thus it is very hard to envision from 
these structures how USP12 is activated by UAF1, especially when the activation is due to 
an increase in kcat and not KM. It is possible that UAF1 binding stabilizes the flexible USP12 
“finger”, transforming it into a catalytically proficient state and this may not be visible 
since we compare it to a ubiquitin-bound USP structure. Therefore an apo-structure of 
USP12 could shed more light on this issue.
The binding analysis shows that Interface 1 provides the high affinity interaction that 
is responsible for the activation of the USP. We measure a binding affinity in the order 
of 4 nM with extremely slow dissociation. The affinity is less tight than the 0.1 nM 
observed for USP46 by Yin et al, 2015, most likely due to differences in the experimental 
setup. Their lowest concentration of UAF1 used was far above the reported KD (7-fold), 
and the KD was estimated based on very slow dissociation constant derived from the 
global kinetic fit. Overall, the structure of USP12-Ub/UAF1580 and the UAF1 mediated 
activation through Interface 1 bears close resemblance to the published data on USP46 
(Yin et al., 2015), again highlighting the high degree of conservation between these 
USPs. The Interface 1 has a relatively small surface area, with a predominance of 
charged interactions. For such a small interface, even the observed affinity of 4 nM is 
rather surprising since such strong binding between two proteins is rarely mediated by 
interfaces having less than 1000 Å2 buried surface area (Chen et al., 2013). However, 
previous reports have suggested the importance of the finger domain for UAF1 binding 
and activation (Olazabal-Herrero et al., 2015). It is still unclear how S313 phosphorylation 
which is present in the long insert of USP1 could play a role in UAF1 binding (Villamil 
et al., 2012b), as the (shorter) corresponding region on USP12 is not involved in UAF1 
binding for either of the interfaces.
In the USP12/UAF1580 complex we observe a conserved second interface (Interface 2) 
at the backside of the ubiquitin binding cleft. The buried surface area of this interface 
is larger than for Interface 1, and the contact is more hydrophobic, indicating that its 
properties are very different. Our binding data confirm the presence of a secondary 
interaction, with an affinity of ~300 nM and fast kinetics. Unfortunately we were unable 
to validate this interface by mutational analysis. It is possible that this is due to the large 
surface area involved in this binding. Additionally the surface shape complementarity 
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between the extended loop in USP12 and the relatively concave architecture of ancillary 
domain and β-propeller in the UAF1 molecule could contribute to the interaction primarily 
by backbone interactions.
The two binding interfaces on UAF1 seem independent of each other as they reside in 
distant parts of the protein. Thus mutating residues on Interface 1 is unlikely to affect 
binding to Interface 2 or vice-versa. Our binding studies with the UAF13X mutant showed 
binding to the high affinity site at very high concentrations and no binding to the low 
affinity site. This could mean that UAF1 can only bind the low affinity site once the high 
affinity site has been fully occupied. It is possible that high overall flexibility in USP12 
in the unbound state prevents binding to the low affinity site, thereby making the high 
affinity binding mandatory for binding the second UAF1.
During revision of this manuscript, a structure for the USP12/UAF1/WDR20 complex 
was published (Li et al., 2016). In this structure WDR20 binds to a number of structural 
elements at the palm domain of USP12 with an affinity of 7 nM. Interestingly, the 
binding interface for WDR20 partially overlaps with the second binding site of UAF1 
on USP12 (Supp.Fig.1d), but the contacts are very different, explaining how a F287A/
V279D mutation can disrupt WDR20 binding whereas F287A does not affect the UAF1 
interface, which is dominated by backbone interactions in this area. The partial overlap 
of the binding interfaces and the high affinity of WDR20 suggests that WDR20 binding to 
USP12/UAF1 can either prevent binding of the second UAF1 molecule or it can actively 
compete out UAF1 if it is bound to the USP12/UAF1 complex. The partial overlap of this 
interface could hint towards a possible regulatory role for the second UAF1 binding.
The second binding of UAF1 to USP12 does not seem to play a role in the activation of 
USP12 on a minimal substrate. Meanwhile the effect of the second UAF1 binding on the 
catalytic activity of USP12 against one of its natural substrates remains to be tested 
and this could yield more insight on the possible function of this regulatory event. In 
any case, the conservation of the 1:2 stoichiometry and the two step binding of UAF1 in 
this small family of USPs highlights the importance of the second binding and implies 
that the binding could be important for functions which are independent of activation 
on a minimal substrate.
All available data (Cohn et al., 2009; Sowa et al., 2009) and the high affinity with slow 
off-rates indicate that USP12/UAF1 form a constitutive complex in cells. In contrast, the 
fast kinetics of the second binding site indicates that it could play a role in regulation. 
This is in line with the recent quantitative analysis of protein abundance in HeLa cells 
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that place the concentration of USP12 and UAF1 at 2 and 77 nM, respectively (Hein et al., 
2015). At that concentration the first interface would be fully saturated, and a significant 
fraction of the USPs would start to bind a second molecule. This means that the second 
binding could potentially play an important regulatory role.
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A) Superposition of USP12-Ub/UAF1 (colours as indicated earlier) with USP46-Ub/UAF1 
(Colours; USP46 – as in Fig 1b, Ubiquitin – Light Brown, UAF1 – Orange) (PDB code – 5CVN).
B, C) Superposition of free UAF1580 (Dark Pink) on USP12FL-Ub/UAF1580 (UAF1580 in green) 
structure at Interface 1 and 2 respectively.
D) Superposition of WDR20 (Dark Pink) with UAF1580 (light green) bound at Interface 2 on 
USP12-Ub/UAF1580 (colours as indicated earlier).
E) Io is plotted on the y-axis against the corresponding frame number on the x-axis, frames 670-
704 and 898-909 were analysed separately for the high molecular weight species and the 1:2 
complex respectively.
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During DNA replication, the deubiquitinating enzyme USP1 limits the recruitment of 
translesion polymerases by removing ubiquitin marks from PCNA to allow specific 
regulation of the Translesion synthesis (TLS) pathway. USP1 activity depends on an 
allosteric activator, UAF1 and this is tightly controlled. In comparison to paralogs USP12 
and USP46, USP1 contains three defined inserts and lacks the second WDR20 mediated 
activation step. Here we show how insert L1 and L3 together limit intrinsic USP1 
activity and how this is relieved by UAF1. Intriguingly, insert L1 also conveys substrate-
dependent increase in USP1 activity through DNA and PCNA interactions, in a process 
that is independent of UAF1-mediated activation. This study establishes insert L1 as an 
important regulatory hub within USP1 necessary for both substrate mediated activity 
enhancement and allosteric activation upon UAF1 binding.
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INTRODUCTION
Dynamic regulation of ubiquitination on proteins involved in DNA repair pathways is 
essential for proper functioning of these pathways. (De)-Ubiquitination enzymes that 
control these processes have gained a lot of attention, as these are attractive targets 
to attenuate DNA repair pathways. USP1 is a deubiquitinase (DUB) that acts on mono-
ubiquitinated PCNA and FANCD2, making it crucial for the regulation of translesion 
synthesis and the Fanconi anaemia pathway respectively (Nijman et al, 2005; Huang et 
al, 2006). Recently, it was also shown that USP1 inhibition resulted in replication fork 
destabilization and decreased viability of BRCA1-deficient cells indicating a synthetic 
lethal relationship (Lim et al, 2018). To target USP1 effectively it would be important to 
know how its catalytic activity is regulated.
USP1 belongs to the ubiquitin specific protease (USP) family of DUBs and it forms a 
small sub-family with two other USPs, USP12 and USP46 (Mevissen & Komander, 2017). 
These USPs bind a common co-factor called UAF1 (also known as WDR48), which leads 
to activation of these enzymes by an increase in the catalytic turnover (kcat) (Cohn et 
al, 2007, 2009). Relative to these paralogs, USP1 is much larger, primarily due to the 
presence of three inserts within its well conserved USP catalytic domain (Fig 1a, Fig 
EV1a). It also lacks the binding site for another activator, WDR20, which binds USP12 
and USP46, leading to further activation (Kee et al, 2010). In contrast, it was reported 
recently that USP1 activity is further enhanced upon binding DNA and this interaction 
is mediated by insert L1 of USP1 (Lim et al, 2018). Insert L1 was also shown to be the 
site of multiple phosphorylations (Villamil et al, 2012; Olazabal-Herrero et al, 2015) and 
it has been reported to carry two nuclear localization signals that are important for its 
translocation to the nucleus (Garcia-Santisteban et al, 2012).
So far there is no structural information available for USP1 alone or the USP1-UAF1 
complex, but crystal structures of the paralogs with and without the activators have 
been solved (Yin et al, 2015; Li et al, 2016; Dharadhar et al, 2016). Based on these USP12 
and USP46 structures it is clear that UAF1 binds USP1 on the ‘finger’ sub-domain of the 
catalytic domain (Yin et al, 2015). It has also been shown that UAF1 activation of USP12 
is mainly caused by a series of subtle structural rearrangements in various parts of the 
enzyme. One such region is the proximal knuckle (PK) helix and its preceding loop called 
the PK loop which also form a part of the WDR20 interface (Li et al, 2016). Interestingly, 
USP1 has a small insertion of 20 amino acids in the PK loop and this insert is located 
in the WDR20 binding interface of USP12 and USP46 (Insert L3, Fig EV1b). Whether 
this small insert of USP1 plays any role in its activation by UAF1 and if there are other 
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unique elements within USP1 which compensate for the lack of WDR20 activation are 
not known.
USP1 activity on FANCD2-Ub is well studied and the N-terminal extension of USP1 is 
important for activity on FANCD2 (Arkinson et al, 2018). DNA binding was shown to 
promote USP1-UAF1 activity on FANCD2-Ub, but in this case activation is dependent 
on a DNA binding role of UAF1 (Liang et al, 2019). Additionally, the C-terminal SUMO-
like domains (SLD) of UAF1 also play a role in the recruitment of USP1 to ubiquitinated 
substrates (Yang et al, 2011; Lee et al, 2010). In contrast, how USP1 acts on PCNA is 
not clear. Moreover, whether its activity is affected by DNA loading of PCNA-Ub has not 
been studied. This may be important for USP1 activity as it is thought to travel along 
the replicating fork where it carries out its deubiquitinating activity in crucial DNA repair 
pathways (Dungrawala et al, 2015).
In this study we demonstrate the molecular details of USP1 allosteric regulation by UAF1 
and its natural substrate i.e. DNA-loaded PCNA-Ub. We study the role of USP1 inserts 
on enzymatic activity towards substrates of increasing complexity. This reveals that 
the combined action of insert L1 and L3 inhibits USP1 catalytic activity and that this 
auto-inhibition is relieved by UAF1-dependent activation on a minimal substrate (Ub-
Rho). On PCNA-Ub we find that a PIP motif in insert L1 is crucial for activity. Finally, we 
developed a protocol to load PCNA-Ub on DNA. On this substrate, we identify a secondary 
enhancement in USP1 activity, that is only triggered upon interaction with DNA-loaded 
PCNA-Ub. Furthermore, we demonstrate that both DNA and PCNA interaction with USP1 
are important for this substrate-mediated increase in activity.
RESULTS
USP1 catalytic activity is inhibited by its inserts
To address the role of the inserts in USP1 catalytic activity, we made deletion mutants of 
USP1 that either lack each insert individually or in combinations (Fig 1a). These deletion 
mutants were successfully purified and their catalytic activities were tested against the 
minimal substrate ubiquitin-rhodamine (Ub-Rho). None of the variants lacking a single 
insert (USP1ΔL1, USP1ΔL2, USP1ΔL3) showed any change in activity compared to wild type 
USP1 (USP1WT), but when both insert L1 and L3 were removed (USP1ΔL1L3) a significant 
hyper-activation was observed (Fig 1b).
This hyper-activation was unique to this combination, as deletion of insert L1 and L2 
(USP1ΔL1L2) or insert L2 and L3 (USP1ΔL2L3) did not affect USP1 catalytic activity (Fig 
1b). The insert L3 in USP1 is located in the PK loop. In USP12 this loop is important 
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for activation, as mutation of a stretch of glycine residues within the loop leads to loss 
in activation of USP12 by either UAF1 or WDR20. In USP1, deletion of insert L3 alone 
does not affect USP1 activity but the deletion of both insert L3 and insert L1 leads to an 
increased activity of USP1.
We tested whether phosphorylation of serine 313 in insert L1 had a direct effect on USP1 
catalytic activity, since Ser313 phosphorylation was previously reported as necessary 
for UAF1 binding and its ability to activate (Villamil et al, 2012; Olazabal-Herrero et al, 
2015). We tested both the phospho-dead (Ser to Ala) and phospho-mimic (Ser to Asp) 
mutations, but neither showed an effect on activity of USP1 alone or upon binding with 
UAF1, relative to USP1WT (Fig EV2a).
We performed Michaelis-Menten kinetic analysis under increasing concentrations of 
Ub-Rho substrate (Fig 1d, Table 1) and fitted USP1WT and all the deletion mutants. As 
the reaction velocity curves for USP1ΔL1L3 did not reach saturation, the estimation of 
Vmax and subsequently KM was not reliable. To validate our findings we fitted USP1
WT 
and USP1ΔL1L3 activity data using KinTek Explorer (Johnson et al, 2009a) simultaneously, 
using all the data rather than initial rates only. Similar to our standard Michaelis-Menten 
analysis, this improved analysis again showed that the activation in USP1ΔL1L3 was mostly 
due to an increase in kcat (Fig EV2b). We conclude that insert L1 and L3 together inhibit 
the intrinsic catalytic activity of USP1.
UAF1 binding relieves insert L1 and L3 mediated auto-inhibition of USP1 
activity
UAF1 mediated activation of USP1 is primarily due to an increase in kcat (Cohn et al, 
2007) which is similar to what we observe in USP1ΔL1L3. To test whether insert L1 and L3 
mediated auto-inhibition of USP1 can be relieved by UAF1, we performed kinetic analysis 
in the presence of UAF1 on Ub-Rho (Fig 1e). We observed that the hyper-activation of 
USP1 that deletion of insert L1 and L3 had caused was lost in the presence of UAF1, as 
the catalytic activity of USP1ΔL1L3 no longer differed significantly from USP1WT, nor from 
any of the other deletion mutants. (Fig 1c, e, Table 1). These experiments also show 
that the deletion of insert L1 and insert L3 is not sufficient to completely recapitulate 
UAF1 mediated activation as UAF1 binding can still activate USP1ΔL1L3. However, our 
data suggests that one of the primary mechanisms by which USP1 is activated by UAF1 
is through relieving the auto-inhibition caused by the joint action of insert L1 and L3.
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Fig.1) UAF1 activates USP1 allosterically by relieving the insert 1 and 3 mediated auto-inhibition of USP1 cat-
alytic activity.
A) Schematic diagram of the USP1 subfamily and the USP1 deletion mutants tested in this study.
B) Single point activity assays of USP1WT and deletion mutants on Ub-Rho show signifi cantly increased activity 
in mutants where insert L1 and L3 are both deleted.
C) Single point activity assays of USP1WT and deletion mutants (± UAF1) on Ub-Rho show the loss in hyper-ac-
tivation of USP1ΔL1L3 upon addition of UAF1.
D) Michaelis-Menten analysis of USP1 deletion mutants against ubiquitin-rhodamine (Ub-Rho) shows that 
USP1ΔL1L3 has significantly higher activity compared to WT and other mutants (n=2).
E) Michaelis-Menten analysis of USP1 deletion mutants (+UAF1) against Ub-Rho shows that all deletions mu-
tants have similar catalytic activity (n=2).
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F) Comparing activity of USP1WT and USP1ΔL1L3 on a peptide substrate i.e. LRGG-AMC (100µM). USP1ΔL1L3 cleaves 
the peptide substrate more efficiently compared to USP1WT (n=2).
G) Comparing activity of USP1WT and USP1ΔL1L3 (+UAF1) on a peptide substrate i.e. LRGG-AMC (100µM). Addition 
of UAF1 allows cleavage of LRGG-AMC by both USP1WT and USP1ΔL1L3 (n=2).
Table 1 Kinetic analysis of USP1WT and deletion mutants using the Michaelis-Menten equation.
















































Based on the published structures of USP12+UAF1 and USP12+UAF1+WDR20 (Li et 
al, 2016; Dharadhar et al, 2016) we generated a homology model of USP1, that shows 
the location of the inserts of USP1 (Fig EV1b). Interestingly, Insert L3 of USP1 overlaps 
with the binding site of WDR20 in USP12 suggesting that the effect of WDR20 could be 
mimicked by a joint mechanism which involves rearrangement of both insert L1 and L3.
A defining feature of WDR20-dependent activation, is that it is necessary for the ability 
of USP12 to cleave a peptide substrate, Leu-Arg-Gly-Gly (LRGG)-AMC, since USP12-UAF1 
alone cannot cleave such a substrate (Li et al, 2016). Therefore, we analysed whether USP1 
could process this substrate. First, we compared USP1WT in the presence and absence of 
UAF1. Like USP12, USP1 alone cannot cleave the peptide substrate. However, addition of 
UAF1 is sufficient to activate USP1WT such that it can now process this substrate (Fig 1f, 
g), whereas USP12 requires WDR20 to make this happen (Fig EV2c) (Li et al, 2016). Unlike 
USP1WT, the USP1ΔL1L3 alone can cleave the peptide substrate which is in line with the idea 
that rearrangement of insert L1 brings about conformational changes in insert L3 which 
are necessary for activation of USP1 by bringing it to a WDR20 like state.
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Fig.2) Insert L1 of USP1 contains a PIP motif which is essential for activity of USP1 on PCNA-Ub.
A) Quantification of gel-based activity assays where the activity of USP1WT and deletion mutants (+UAF1) on 
PCNA-UbTAMRA is compared. The USP1ΔL1 mutant has reduced activity on PCNA-UbTAMRA compared to the other 
USP1 variants tested (n=2).
B) Multiple sequence alignment of USP1 insert L1 which highlights the conservation of the PIP and APIM motif 
in USP1 across species, the residues mutated in this region are indicated with an asterisk.
C) Quantification of gel-based activity assays where the activity of USP1 PIP mutants (+UAF1) on PCNA-UbTAMRA 
is compared. Both the PIP mutants have reduced activity on PCNA-Ub compared to USP1WT (n=2).
D) FP based binding assays of USP1 mutants (+ UAF1) with PCNA-UbTAMRA show reduced binding of USP1ΔL1 
and USP1PIP1 compared to USP1WT (n=2).
E) Quantification of gel-based activity assays where the activity of USP1WT+UAF1 on PCNA-UbWT is compared 
with PCNA-UbPIM1 shows that PCNA-UbWT is cleaved much faster compared to PCNA-UbPIM1 (n=2)
F) Comparing activity of USP1WT and USP1PIP1 (+UAF1) on PCNA-UbWT and PCNA-UbPIM1 in gel-based assays 
shows that the activity of USP1WT is severely reduced by the PIM1 mutation in PCNA, whereas USP1PIP1 activity 
is not further affected indicating that PIP1 and PIM mutation affect the same interaction (n=2).
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These results show on one hand that removal of insert L1 and L3 mediated auto-inhibition 
of USP1 brings it to a WDR20-bound-like state, and on the other hand that for USP1, 
the activation by UAF1 already achieves a state that requires WDR20 in the USP12/46 
paralogs. It seems likely that this activation is mediated by some form of UAF1-induced 
conformational change in Insert L1 and L3. When UAF1 binds, at the tip of the finger sub-
domain, this induces a cascade of rearrangements, as it does in USP12. We speculate 
that this brings about changes in insert L3, located at the base of the fingers and results 
in the removal of auto-inhibition by insert L1 and L3 (Fig EV1b). To understand how L1 
and L3 mediate their inhibition structural information will be important.
Insert L1 is necessary for USP1 activity on PCNA-Ub
To test whether the inserts of USP1 play any role in the deubiquitination of its natural 
substrate i.e. monoubiquitinated PCNA (PCNA-Ub), we carried out activity assays on 
reconstituted PCNA-Ub (Hibbert & Sixma, 2012). In these assays we used a TAMRA label 
at the N-terminus of ubiquitin for ease of quantitation (Dharadhar et al., 2019), as this 
has no effect on the rates (Fig EV2d). Comparing WT and deletion mutants, we observed 
that loss of insert L1 in USP1 severely impairs its ability to deubiquitinate PCNA-UbTAMRA 
(Fig 2a), whereas this deletion does not affect activity on a minimal substrate.
We analysed the sequence of insert L1 in a multi-sequence alignment with different 
species (Fig 2b). We identified a degenerate PCNA-interacting-peptide (PIP) box, which 
is highly conserved across vertebrates (Fig 2b). Compared to traditional PIP motifs, 
there is one phenylalanine missing in the final FF, replaced by KF. Additionally, there was 
a possible APIM-like motif just upstream of the PIP site. We made two mutants, a triple 
mutant in the PIP (PIP1: I351A, L352A and F355A) and one with additional changes in the 
APIM (PIP2: I351A, L352A and F355A; W341A, L342A and K343A). These mutants were 
co-purified with UAF1 and tested for activity on PCNA-UbTAMRA. Both USP1PIP1 and USP1PIP2 
had reduced activity on PCNA-UbTAMRA compared to USP1WT but were not affected in their 
activity on a minimal substrate (Fig 2c; Fig EV2e).
Importantly, we then analysed binding of USP1 to PCNA-Ub in a fluorescence polarization 
(FP) assay. Here we found that deletion of insert L1 (USP1ΔL1) or mutation of the PIP 
motif (PIP1) leads to a 10- and 5-fold reduction in binding to PCNA-UbTAMRA respectively 
(Fig 2d).
To validate the role of the PIP interaction between USP1 and PCNA, we made mutations 
in PCNA (PIM1: L126A and I128A; PIM2: D232A and P234A; PIM3: P253A and K254A), 
in the PIP interaction site (Eissenberg et al, 1997). USP1WT activity was substantially 
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reduced on the PCNA-Ub PIM1 and PIM2 mutant while the activity on the PIM3 mutant 
was the same when compared to PCNA-Ub (WT) (Fig EV3a). We then compared the 
activity of USP1WT and USP1PIP1 on both PCNA-UbPIM1 and PCNA-UbWT. The activity of 
USP1WT was reduced on PCNA-UbPIM1 but activity of USP1PIP1 was not further depleted 
on PCNA-UbPIM1 relative to PCNA-UbWT, indicating that both mutations affect the same 
interaction (Fig 2e, f). These binding and mutant data together confirm that insert L1 of 
USP1 contains a well conserved PIP motif which is important for USP1 interaction and 
activity on PCNA-Ub.
Purification of PCNA-Ub loaded on circular DNA
USP1-UAF1 is known to play a role in PCNA-Ub mediated translesion synthesis (Huang 
et al, 2006). Moreover, it has been suggested that USP1-UAF1 travels with elongating 
replication forks where it deubiquitinates its substrates. Removal of USP1 from this 
environment was shown to generate increased ubiquitination of proteins residing at 
the fork (Dungrawala et al, 2015). Other studies have shown that both USP1 and UAF1 
have DNA binding properties (Liang et al, 2016; Lim et al, 2018). We could confirm that 
USP1 binds DNA, and the fact that this interaction is dependent on insert L1 (Fig EV3b). 
However, we did not observe the (very small) effect on catalytic activity against a minimal 
substrate, Ub-Rhodamine (Lim et al, 2018) (Fig 3b). Nevertheless, we wondered if the 
observed interaction with DNA could affect the activity on a more natural substrate, 
PCNA-Ub loaded on DNA.
To enable analysis of USP1 activity on DNA-loaded substrate, we established efficient 
DNA loading procedures for human PCNA-Ub on circular DNA using the RFC clamp 
loader complex from yeast (Yoder & Burgers, 1991). First, we successfully purified 
PCNA-Ub where each monomer of the clamp was mono-ubiquitinated using previously 
published protocols (Hibbert & Sixma, 2012) and then we performed in vitro loading 
assays on nicked circular DNA (Fig 3a). Our results show that PCNA and PCNA-Ub 
are loaded with similar efficiency onto nicked circular DNA (Fig EV3c). We then used 
size exclusion chromatography to obtain large amounts of purified PCNA-Ub loaded on 
nicked circular DNA (Fig 3a). Due to the presence of a TAMRA label on each ubiquitin 
molecule we could measure the exact concentrations of DNA-loaded PCNA-Ub which 
allowed us to perform quantitative in vitro deubiquitination assays.
The loading and purification of DNA-loaded PCNA-Ub is technically complex since 
many factors are involved in this reaction. Moreover, the half-life of PCNA on DNA is 
approximately 25 minutes which makes downstream experiments challenging due to 
the time constraints (Zhao et al, 2017). We circumvented this problem by carrying out 
the activity assays within 20 minutes after elution from a size exclusion column.
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Fig.3) USP1 (±UAF1) has higher catalytic activity on PCNA-Ub when it is loaded on DNA.
A) Schematic representation of loading and purification of PCNA-Ub on nicked circular DNA. The DNA-loaded 
PCNA-Ub elutes in the void of the SEC column and this sample is collected and used for studying activity of 
USP1 on DNA-loaded PCNA-Ub.
B) Michaelis-Menten analysis of USP1+UAF1 with and without DNA (65bp dsDNA) shows that DNA binding 
alone has no effect on USP1 activity (n=2).
C) Coomassie stained gel of in vitro activity assay showing increased activity of USP1-UAF1 on DNA-loaded 
PCNA-Ub compared to PCNA-Ub (-DNA) and PCNA-Ub (+DNA, +RFC and not ATP).
D) Quantification of gel-based activity assays showing enhanced activity of USP1+UAF1 on DNA-loaded PC-
NA-Ub compared to free PCNA-Ub (n=3).
E) Quantification of gel-based activity assays showing enhanced activity of USP1 on DNA-loaded PCNA-Ub 
compared to free PCNA-Ub (n=3).
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Fig.4) Modelling the enhanced USP1 activity on DNA-loaded PCNA-Ub.
A) Gel based quantification of USP1-UAF1 activity on PCNA-Ub (DNA loaded and free) for three different con-
centration of enzyme and substrate.
B) FP based activity assays on free PCNA-Ub (three concentrations of USP1 and PCNA-Ub) and activity of USP1 
on increasing concentrations of Ub-Rho.
C) Kinetic model of USP1-UAF1 activity on PCNA-Ub and DNA-loaded PCNA-Ub (Ub-Rho not shown here, see 
EV 4c for full model), constants with the same colour were linked during the fitting and they share same values.
USP1 deubiquitinates PCNA-Ub more efficiently when it is loaded on DNA
We compared the deubiquitination activity of USP1 (±UAF1) on DNA-loaded PCNA-
Ub with free PCNA-Ub in a gel-based activity assay. This showed that USP1-mediated 
ubiquitin hydrolysis is much faster when PCNA-Ub is loaded on DNA (Fig 3c, d, e). In 
these experiments a minor fraction of the RFC co-eluted with DNA-loaded PCNA-Ub 
which allowed reloading of PCNA-Ub. However, this is not critical for the enhanced 
activity that we observe, as our control experiments with RFC and DNA in the absence 
of ATP do not show similar activity of USP1 (Fig 3c).
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To obtain a detailed mechanism of USP1 activity, we performed kinetic analysis and 
modelling using the KinTek explorer software (Johnson et al, 2009a). We quantified USP1 
(±UAF1) activity data under either different enzyme concentrations or different substrate 
concentrations against three different substrates, Ub-Rho, PCNA-Ub and DNA-loaded 
PCNA-Ub. We used SDS PAGE-based setup for DNA-loaded PCNA-Ub and free PCNA-Ub 
(Fig.4a, Fig EV4a). For PCNA-Ub we additionally performed fluorescence polarization 
(FP) based activity assays. Additionally, activity data of USP1 (±UAF1) on increasing 
concentrations of Ub-Rhodamine was also included (Fig 4b, Fig EV4b). The resulting data 
only fits in a model where the enhanced activity on DNA-loaded PCNA-Ub is mediated 
by an increase in affinity of USP1 (± UAF1) for the substrate with no change in catalytic 
activity. The KinTek analysis allowed us to quantify the magnitude of enhanced USP1 
activity both in the presence and absence of UAF1. We observed that loading of PCNA 
increases USP1 activity ~2-fold, but in the presence of UAF1 the increase is 5-fold (Fig 
4c). The extra increase in USP1 activity given by UAF1 was caused by an increase in 
affinity for DNA-loaded PCNA-Ub of USP1+UAF1, as the change is limited to KM. This 
observation corresponds well with previously published data which show that UAF1 
itself has DNA binding properties in the range of 400nM (Liang et al, 2019). To validate 
our kinetic modelling, we performed EMSA based binding analysis for USP1 (±UAF1) 
on DNA which confirmed that USP1-UAF1 has stronger binding compared to USP1 
alone (Fig EV4d). Altogether, our quantitative kinetic analysis shows that USP1 alone 
has enhanced activity on the natural substrate which is further strengthened when in 
complex with UAF1.
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Insert L1 is critical for enhanced activity of USP1 on DNA-loaded PCNA-Ub
To dissect how USP1 has higher activity on DNA-loaded PCNA-Ub, we compared how 
insert deletions affected the activity on DNA-loaded PCNA-Ub relative to free (unloaded) 
PCNA-Ub. The USP1ΔL2 and USP1ΔL3 showed similar activity to USP1WT in cleaving 
PCNA-Ub by loading on DNA, but the USP1ΔL1 mutant showed no increase in activity on 
the loaded substrate (Fig 5a). The activity of USP1ΔL1 on PCNA-Ub is weak, and upon 
DNA loading its activity is not enhanced, in fact the activity is slightly lowered. These 
experiments show that the insert L2 and L3 within USP1 are not involved in enhancing 
USP1 activity while insert L1 is solely responsible for achieving this substrate dependent 
increase in USP1 activity.
Since insert L1 has been previously shown to possess both PCNA and DNA binding 
properties, we tested if both these functions could be responsible for increased USP1 
activity on DNA loaded PCNA-Ub, relative to PCNA-Ub alone. To test how DNA binding 
could alter USP1 activity, we had to first identify residues involved in DNA binding so that 
we could separate the DNA and PCNA binding roles of insert L1. We analysed the insert 
L1 sequence using multiple sequence alignment and identified a region within insert L1 
with several positively charged residues, which are well conserved across vertebrates 
(Fig 5b). Insert L1 WT and three sets of triple mutants containing charge swaps were 
cloned and then purified for DNA binding studies using SPR. Our binding experiments 
showed that insert L1 can bind DNA whereas all the triple mutants almost completely 
lost DNA binding (Fig 5c), thereby highlighting the role of electrostatic interaction in 
USP1 binding to DNA.
Insert L1 mediated DNA and PCNA interactions are crucial for increasing 
USP1 activity on DNA loaded PCNA-Ub
Insert L1 of USP1 is a large insert of 200 amino acids with two distinct well conserved 
regions for which we show interaction with DNA and PCNA respectively. To gain further 
mechanistic insight into the insert L1 mediated increase of USP1 activity, we compared 
the activity of a USP1 DNA binding mutant (USP1DM1; KKK281EEE) and a USP1 PCNA 
interaction mutant (USP1PIP1) on DNA loaded PCNA-Ub with free PCNA-Ub. In both 
mutants, the increase in activity on the DNA-loaded substrate was substantially reduced 
relative to USP1WT (Fig 5d).
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Fig.5) Insert L1 mediated DNA and PCNA interactions are crucial for increase in USP1 activity on DNA loaded 
PCNA-Ub
A) Comparison of USP1WT and deletion mutants (+UAF1) for activity on DNA-loaded PCNA-Ub (solid lines) 
and free PCNA-Ub (dashed lines) shows no increase in USP1ΔL1 activity on the loaded substrate. Left panel: 
Quantification of gel-based activity assays showing percentage of cleaved PCNA-Ub at the mentioned time 
points (n=2), Right panel: Quantification of the activation fold observed in USP1WT and mutants on DNA-loaded 
PCNA-Ub versus free PCNA-Ub (n=2).
B) Multiple sequence alignment of USP1 insert L1 which highlights the DNA binding region and the conserva-
tion of the positively charged residues across species, the residues mutated in this region are indicated with 
an asterisk.
C) SPR based binding experiments show binding of insert L1 (WT) to double stranded DNA (65bp) and the 
importance of the positively charged residues (see Fig 5b) of insert L1 in DNA binding.
D) Comparison of USP1DM1, USP1PIP1 and USP1PIP1+DM1 (+UAF1) activity on DNA-loaded PCNA-Ub (solid lines) and 
free PCNA-Ub (dashed lines) shows reduced increase in activity of these mutants compared to USP1WT. Left 
panel: Quantification of gel based activity assays showing percentage of cleaved PCNA-Ub at the mentioned 
time points (n=2), Right panel: Quantification of the activation fold observed in USP1WT, USP1PIP1, USP1DM1 and 
USP1PIP1+DM1 on DNA-loaded PCNA-Ub versus free PCNA-Ub (n=2).
E) EMSA based DNA binding experiment shows that USP1PIP1 and USP1WT has similar DNA binding capability 
while USP1DM1 has lost its ability to bind DNA.
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The USP1DM1 mutant also has reduced activity on free PCNA-Ub compared to USP1WT. 
This means that we cannot fully confirm whether its loss in activity on the DNA-loaded 
substrate is due to loss of DNA interaction. To delineate this further we made a milder 
version (USP1DM2, KKK281AEA) of the original DNA binding mutant (USP1DM1). The 
USP1DM2 has similar activity on free PCNA-Ub as USP1WT but still lost DNA binding ability 
when compared with USP1WT (Fig EV5a, b). When USP1DM2 was tested on DNA loaded 
PCNA we found that it was poorly able to activate on this substrate, similar to USP1DM1 
(Fig EV5c). Taken together these mutants confirm that DNA interaction through insert 
1 is important for enhanced USP1 activity on DNA loaded PCNA-Ub.
In contrast, the PCNA-interaction mutant USP1PIP1, had retained the ability to bind DNA, 
in an electrophoretic mobility shift assay on a 65bp dsDNA (Fig 5e). This indicates that 
USP1PIP1 is only affected in PCNA interaction and the loss of activity on DNA-loaded 
PCNA-Ub in this mutant is due to the defect in PCNA interaction.
Both the USP1DM1 and USP1PIP1 mutant still show considerable increase in activity on 
DNA-loaded PCNA-Ub, although to a lesser degree than USP1WT. Therefore, we generated 
a USP1 double mutant lacking both DNA and PCNA interactions (USP1PIP1+DM1) and 
compared its activity on DNA loaded PCNA-Ub and free PCNA-Ub. This double mutant 
has a very slightly enhanced activity on both substrates, but no significant difference 
between the two, indicating that it has completely lost the ability to enhance USP1 
activity on DNA-loaded PCNA-Ub. The complete loss of substrate-mediated activity 
increase in this USP1 mutant shows that PCNA interaction and DNA interaction together 
are necessary and sufficient for the increase in USP1 activity.
Altogether, these experiments establish insert L1 as a central regulatory hub for USP1 
activity and highlight the role of various elements which play a role in allosteric regulation 
of USP1 activity. These mutations could be used for validation in vivo, but unfortunately 
the DNA-binding site overlaps with the previously assigned NLS, suggesting some 
difficulties in separating these functions out, Nevertheless, these newly identified USP1 
hotspots are important as they may serve as novel starting points for development of 
specific allosteric modulators of USP1 function.
USP1 is activated by two distinct mechanisms involving UAF1 and 
DNA-loaded PCNA-Ub
The activation of USP1 by UAF1 takes place through an allosteric mechanism where 
the catalytic turnover (kcat) of the enzyme is increased several fold (Cohn et al, 2007). 
We have shown here that this activation requires the rearrangement of insert L1 and L3 
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which auto-inhibit USP1 in the absence of UAF1 (Fig 1d, e; Table 1). In this study we also 
uncover a secondary step that enhances USP1 activity which is caused upon interaction 
with DNA-loaded PCNA-Ub.
Based on our preliminary biochemical analysis we assumed that the increase in USP1 
activity on DNA-loaded PCNA-Ub takes place solely through a change in the affinity of 
the enzyme for the loaded substrate versus the unloaded substrate, as cleavage rate 
values remained similar in individual runs. Therefore, they were linked in the final analysis 
accordingly (Fig EV4, Table 2).
Interestingly we note that not only USP1-UAF1 is activated by DNA-loading of PCNA, but 
also USP1 alone, which shows an increase in catalytic efficiency of from 2.3 mM-1 s-1 to 
4.8 mM-1 s-1. This confirms that also in the absence of UAF1 USP1 has higher activity on 
the DNA-loaded substrate. The PCNA and DNA interaction regions of Insert L1 are likely 
to play a key role in this since we have shown that mutating these two regions leads to 
no increase in activity.
Nevertheless, the increase in activity is larger in the presence of UAF1, increasing from 
178 mM-1 s-1 on PCNA-Ub to 907 mM-1 s-1 on DNA-loaded PCNA-Ub (Table 2, Fig 4c), 
primarily due to a difference in Koff. In both USP1 and USP1-UAF1, the enzyme is faster 
on DNA-loaded PCNA-Ub, but the increase in activity due to DNA-loading is higher in the 
presence of UAF1: 5-fold increase in USP1-UAF1 and a 2-fold increase in USP1 alone 
(Table 2, Fig 4c).
Recently, it has been shown that USP1 activity on Ub-FANCD2 is higher in the presence 
of DNA and this is dependent on UAF1 binding (Liang et al, 2019). This suggests that the 
DNA interaction of UAF1 may help to increase the affinity of USP1 for DNA-loaded PCNA-
Ub (Fig 4, Fig EV4). Apparently USP1 activity is regulated by two separate mechanisms, 
one which involves the change in catalytic turnover upon UAF1 binding while the other 
involves a change in affinity towards its natural substrate i.e. DNA-loaded PCNA-Ub (Fig 
6). Therefore, we propose that UAF1 activation and DNA-loaded Ub-PCNA mediated 
enhancement of USP1 activity are mechanistically independent of each other.
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Fig.6) Schematic model for USP1 activity regulation by UAF1 and DNA loaded PCNA-Ub
MATERIALS AND METHODS
Plasmids and cloning
Human USP1 and UAF1 (WDR48) constructs were obtained from Martin Cohn 
(University of Oxford). Human WDR20 (isoform 5) was subcloned from the HAP1 cell 
line (Essletzbichler et al, 2014) into pGEXNKI-GST3C-LIC vector (Luna-Vargas et al, 2011) 
for expression in Escherichia Coli. Plasmid pBL481 for overexpression of the entire 
RFC complex was a gift from Peter Burgers (Washington University, St. Louis). A 1.7Kb 
circular plasmid (RC1766) used for PCNA-Ub loading was a gift from Rafael Fernández 
Leiro (CNIO, Madrid). The USP1 constructs were all cloned in the pFastbac-HTb vector 
(N-terminal His tag) while the UAF1 construct was cloned into the pFastbac1 vector 
(N-terminal Strep tag) for expression in Spodoptera frugiperda (sf9) cells. USP1 point 
mutants were generated using QuikChange site directed mutagenesis and mutants were 
confirmed by sequencing. USP1 insert 1 (230-420) was cloned into the pGEXNKI-GST3C-
LIC vector and the CysUbiquitin construct was cloned into the pETNKI-His-SUMO2-kan 
vector for expression in Escherichia Coli (Luna-Vargas et al, 2011). Plasmids used for 
PCNA, Uba1 (E1), UbCH5C (S22R), ubiquitin and have been described previously (Hibbert 
& Sixma, 2012).
Protein expression and purification
Complexes of recombinant UAF1 with USP1 wild type and mutant proteins (USP1KKK281EEE, 
USP1PIP1,2,USP1 insert deletions) were co-expressed and co-purified from sf9 cells as 
described previously (Dharadhar et al, 2019). Complex of USP12-UAF1 protein was co-
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expressed and co-purified from sf9 cells as described previously (Dharadhar et al, 2016). 
PCNA, UBA1, ubiquitin and UbCH5c (S22R) (UBE2D3) were expressed and purified from 
Escherichia Coli as described previously (Hibbert & Sixma, 2012).
Purification of USP1
In experiments where USP1 was used without UAF1, both USP1 wild type and deletion 
mutants were expressed by Baculovirus expression in sf9 cells for 72 hours by infecting 
cells at a density of 1 X106 cells/ml. Cells were harvested in lysis buffer (50mM Tris pH 
8.0, 200mM NaCl, 5mM TCEP) with complete EDTA-free protease inhibitor (Sigma) and 
lysed by sonication. The lysed cells were spun down (53000 x g for 30 minutes) in a high-
speed centrifuge at 4°C and the supernatant was loaded on a column of Ni2+-Sepharose 
beads pre-equilibrated in lysis buffer. Once the supernatant had passed through the 
column, it was washed with 30 column volumes (CV) of wash buffer (lysis buffer + 
20mM Imidazole pH 8.0) and then USP1 was eluted with 5CV of elution buffer (lysis 
buffer + 500mM Imidazole pH 8.0). The elution fraction was diluted two-fold with 50mM 
Tris pH 8.0 and loaded on an anion exchange column (Resource Q, GE Healthcare) pre-
equilibrated with 50mM Tris pH 8.0, 100mM NaCl, 2mM DTT (IEX buffer). The column 
was washed with 3CV of IEX buffer and elution was carried out by applying a salt 
gradient of 20CV from 100mM - 1M NaCl. Fractions containing USP1 were combined and 
concentrated at 4°C in an Amicon Ultra-15 centrifugal filter unit (30 kDa cut-off; Merck) 
and then loaded on a size exclusion column (Superdex 200 10/300; GE) equilibrated in 
20mM HEPES pH 7.5, 150mM NaCl, 2mM DTT (SEC buffer). Pure USP1 fractions were 
concentrated at 4°C and stored at -80°C.
Purification of USP1 insert L1
Insert L1 wild type and mutant proteins were expressed in BL21 (E. coli) cells by inducing 
cells at an OD of 0.8 with 0.2mM IPTG followed by overnight expression at 18°C. Cells 
were harvested in lysis buffer (50mM Tris pH 8.0, 200mM NaCl, 2mM DTT) with complete 
EDTA-free protease inhibitor (Sigma) and lysed by sonication. The lysed cells were spun 
down (53000 x g for 30 minutes) in a high-speed centrifuge at 4°C and the lysate was 
loaded on a column of Glutathione Sepharose 4B beads (GE Healthcare) pre-equilibrated 
in lysis buffer. Once the lysate had passed through the column, it was washed with 
30CV of lysis buffer following which insert 1 was eluted with 5CV of elution buffer (lysis 
buffer + 50mM reduced glutathione). GST-tag was cleaved in 2 hours with 3C protease 
while dialysing against 20mM Tris pH 8.0, 100mM NaCl, 2mM DTT (Heparin buffer). 
The sample was collected from the dialysis bag and loaded on a Heparin column (GE 
Healthcare) pre-equilibrated in Heparin buffer. After sample application, the column 
was washed with 3CV of Heparin buffer and protein was eluted using a salt gradient of 
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20CV from 100mM - 1M NaCl. Fractions containing pure insert 1 were combined and 
concentrated at 4°C in an Amicon Ultra-15 centrifugal filter unit (10 kDa cut-off; Merck) 
and then loaded on a size exclusion column (Superdex 200 10/300; GE) equilibrated in 
SEC buffer. Pure insert 1 fractions were concentrated at 4°C and stored at -80°C.
Purification of GST-WDR20
GST-WDR20 was expressed in BL21 (E. coli) cells by inducing at an OD of 0.8 with 
0.2mM IPTG followed by overnight expression at 18°C. Cells were harvested in lysis 
buffer (50mM Tris pH 7.5, 200mM NaCl, 2mM DTT) with complete EDTA-free protease 
inhibitor (Sigma) and lysed by sonication. The lysed cells were spun down (53000 x g for 
30 minutes) and the clarified lysate was loaded on a column of Glutathione Sepharose 4B 
beads (GE Healthcare) pre-equilibrated in lysis buffer. The beads were incubated with the 
lysate for 30 mins at 4C and then the lysate was allowed to pass through the column. The 
beads were washed with 30CV of lysis buffer and GST-WDR20 was eluted in 5CV of lysis 
buffer with 20mM reduced glutathione. The eluted sample was then loaded on a cation 
exchange column (POROS S, GE Healthcare) pre-equilibrated with 20mM Tris pH 7.5, 
200mM NaCl, 2mM DTT (IEX buffer). GST-WDR20 eluted upon applying a salt gradient 
of 10CV from 200-1000mM NaCl. Fractions containing GST-WDR20 were combined and 
concentrated at 4°C in an Amicon Ultra-15 centrifugal filter unit (30 kDa cut-off; Merck).
Purification of PCNA-UbTAMRA
Ubiquitin with a cysteine residue introduced at the N terminus after the methionine 
at position 1 (CysUbiquitin) was labelled using maleimide linked TAMRA dye (Setareh 
Biotech). The purification of CysUbiquitin and its labelling with maleimide linked TAMRA 
has been described previously (Dharadhar et al., 2019).
The components required for the in vitro mono-ubiquitination of PCNA are UbTAMRA, 
Uba1, PCNA and UbCH5c (S22R) (UBE2D3). Once all the components were purified, the 
reaction was setup as described previously to a final reaction volume of 20 ml (Hibbert 
& Sixma, 2012). Upon completion of the reaction, the PCNA-UbTAMRA was purified from 
the rest of the components using anion exchange chromatography followed by size 
exclusion chromatography in GF buffer. The purified sample was concentrated at 4°C 
in an Amicon Ultra-15 centrifugal filter unit (10 kDa cut-off; Merck) and stored at -80°C.
Purification of RFC
The procedure for the purification of the RFC complex was adapted from a previously 
described protocol by the Burgers lab (Gomes et al, 2000). Protein was expressed in E. 
coli grown in Terrific broth (TB) medium. Cells were induced at an OD of 1.6 with 0.2mM 
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IPTG followed by overnight expression at 16°C. The cells were harvested in lysis buffer 
(30mM HEPES 7.5, 200mM NaCl, 1mM DTT, 0.5mM EDTA, 10% Glycerol, 0.5mM PMSF, 
complete protease inhibitor) and lysed by sonication. The lysed cells were kept stirring 
on ice and 0.5% Polymin P was added followed by incubation for 5 minutes. The lysed 
cells were spun down at 53000 x g for 40 mins at 4°C and the supernatant was collected. 
Ammonium sulphate (0.28 g/ml) was added to the supernatant while stirring on ice for 
30 minutes and then the precipitated proteins were collected by spinning at 12000 x g 
for 60 minutes. The proteins were resuspended in 30mM HEPES 7.5, 1mM DTT, 0.5mM 
EDTA, 10% Glycerol, 0.5mM PMSF, complete protease inhibitor followed by dialysis for 2 
hours against 30mM HEPES 7.5, 100mM NaCl, 1mM DTT, 0.5mM EDTA, 10% Glycerol. The 
dialysed sample was loaded on a cation exchange column (POROS S 6ml, GE Healthcare) 
pre-equilibrated in 30mM HEPES 7.5, 100mM NaCl, 1mM TCEP, 10% Glycerol (PorosS 
buffer). Subsequently, the column was washed with 5CV of PorosS buffer and the protein 
was eluted by applying a salt gradient from 100mM – 1M NaCl. The fractions containing 
all 5 subunits of RFC are collected and loaded on Ni2+-Sepharose beads pre-equilibrated 
in 20mM HEPES 7.5, 200mM NaCl, 10% Glycerol, 1 mM TCEP (His buffer). The column 
is then washed with 30CV of wash buffer (His buffer + 20mM Imidazole pH 8.0) and 
the protein is eluted with 5CV of elution buffer (20mM HEPES pH 7.5, 300mM NaCl, 
300mM Imidazole pH 8.0, 10% Glycerol, 1 mM TCEP, 0.05% Ampholytes). Sample was 
concentrated at 4°C in an Amicon Ultra-15 centrifugal filter unit (10 kDa cut-off; Merck) 
and then loaded on a size exclusion column (Superdex 200 10/300; GE) equilibrated 
in 20mM HEPES pH 7.5, 200mM NaCl, 10% Glycerol, 1mM DTT, 0.05% Ampholytes. 
Fractions containing the RFC complex were concentrated at 4°C and stored at -80°C.
Production of Nicked Circular DNA
The RC1766 plasmid was nicked using a nicking endonuclease, Nt.BbvCI. The nicked 
circular DNA was then loaded on a size exclusion column (Superose 6 10/300; GE) 
equilibrated in 20mM HEPES pH 7.5, 150mM NaCl, 2mM DTT. The fractions containing 
the nicked circular DNA were collected and concentrated in an Amicon Ultra-15 
centrifugal filter unit (10 kDa cut-off; Merck) up to a final concentration of 1µM.
Purification of DNA-loaded PCNA-Ub
To load PCNA-Ub on DNA, we added 10µM PCNA-Ub, 0.2µM nicked circular DNA and 
1µM RFC in 20mM HEPES pH 7.5, 150mM NaCl, 10mM MgCl2, 2mM ATP, 1mM DTT at 
a final volume of 500µl. The reaction was incubated at 4°C for 2 hours and then it was 
injected on a size exclusion column (Superose 6 10/300; GE) pre-equilibrated in 20mM 
HEPES pH 7.5, 100mM NaCl, 10mM MgCl2, 0.5mM ATP, 1mM DTT. DNA-loaded PCNA-
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Ub elutes at the void volume of the column and is ready to be used for downstream 
applications.
Ub-Rhodamine activity assays
Enzymatic activity was followed as release of fluorescent rhodamine from the quenched 
Ub-Rhodamine substrate (UbiQ; The Netherlands), providing a direct readout for DUB 
activity. The fluorescence intensity at 590 nm was measured using the Pherastar plate 
reader (BMG LABTECH GmbH, Germany). The assays were carried out in 384 well 
plates (Corning, flat bottom, low flange) at 25°C in a reaction buffer of 20mM HEPES 
pH 7.5, 150mM NaCl, 5mM DTT, 0.05% Tween-20. Single point assays were carried out 
at 1µM substrate concentration and different enzyme concentrations. The enzyme 
concentrations used are indicated in the figure. For the Michaelis Menten analysis, 100nM 
of USP1 and 10nM of USP1-UAF1 was used against different substrate concentration 
starting from 5µM to 0.1µM. The initial velocity rates were obtained from the slopes of 
the linear phase of the curve. These rates were plotted against substrate concentration 
and fitted with a Michaelis Menten model using non-linear regression in GraphPad Prism 
7 software (GraphPad Software Inc., USA). Since the reaction velocity of USP1L1L3 has not 
reached saturation, the KM values obtained by this approach are unreliable. Therefore, the 
USP1ΔL1L3 activity curves were fitted in addition using Kintek Explorer version 8.0 (Kintek 
Corporation (Johnson et al, 2009a)) alongside USP1WT to establish if there is indeed a 
real change in the KM values between the two enzymes.
Peptide substrate LRGG-AMC activity studies
Enzymatic activity was followed as a release of fluorescent AMC from the quenched 
LRGG-AMC substrate (Boston Biochem), providing a direct readout for DUB activity 
on a minimal peptide. The fluorescence intensity at 440 nm was measured using the 
Pherastar plate reader (BMG LABTECH GmbH, Germany). The assays were carried out 
in 384 well plates (Corning, flat bottom, low flange) at 25°C in a reaction buffer of 20mM 
HEPES pH 7.5, 150mM NaCl, 5mM DTT, 0.05% Tween-20. USP1 WT and mutants were 
tested at different concentrations against 100µM of LRGG-AMC, enzymes concentrations 
used are indicated in the figures.
Fluorescence Polarization based binding assay
The FP assays were carried out in 384 well plates at 25°C in a reaction buffer of 20mM 
HEPES pH 7.5, 100mM NaCl, 2mM DTT, 0.05% Tween-20. All USP1-UAF1 mutants tested 
also had their active site cysteine mutated to alanine which resulted in catalytically dead 
USP1-UAF1. These mutants were tested for binding to PCNA-UbTAMRA by measuring FP at 
varying concentrations of USP1-UAF1 (5µM-80nM) while keeping the PCNA-UbTAMRA at 
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a constant concentration of 25nM. The FP measurements were taken in the Pherastar 
plate reader (BMG LABTECH GmbH, Germany), using excitation wavelength of 540nm 
(±20) and the polarization was detected at 590nm (±20). The initial polarization of PCNA-
UbTAMRA was set at 30 mp and any increase in polarization upon binding of USP1-UAF1 
was plotted using GraphPad Prism 7 (GraphPad software Inc.,USA).
SPR based binding assay
SPR binding experiments were carried out in the Biacore T200 system (GE, USA) to test 
the binding of USP1 WT and mutants with double stranded DNA. The running buffer 
used for the SPR experiment was 20mM HEPES pH 7.5, 150mM NaCl, 2mM DTT, 0.05% 
Tween 20, 1mg/ml BSA and the DNA was immobilized on a Streptavidin chip (Sensor 
chip SA, GE) using the biotin present on the 5’ end of the DNA. The binding experiments 
were carried out in the single cycle kinetics mode with 10 sequential injections of USP1 
and USP1ΔL1 from 25µM to 0.05µM, while the insert 1 and mutants were injected from 
100µM to 0.2µM. Data from a reference flow cell (- DNA) which was run in parallel to the 
experiment was subtracted from the signal using the Biacore T200 evaluation software. 
The final analysis and figures were done in GraphPad Prism 7 software (GraphPad 
Software Inc, USA).
Electrophoretic mobility shift assays (EMSA)
USP1 binding to DNA was also tested by performing EMSA’s with native 4-12% pre-cast 
Tris-Glycine gels at 4⁰C (Life Technologies). The gels were equilibrated by running them in 
Tris Glycine buffer at 125 V for 90 mins at 4⁰C prior to the start of the actual experiment. 
USP1 and mutants were serially diluted to make a two-fold dilution series from 2.5µM 
to 0.3µM and the DNA was added to a final concentration of 0.2µM. The USP1-DNA 
samples were incubated at 4⁰C for 15 mins prior to loading in the pre-equilibrated gel 
which was then run at 125 V for 90 mins at 4⁰C. DNA bands were visualized by GelRed 
staining followed by imaging in a ChemiDoc XRS instrument (BioRad).
Gel based activity assays
PCNA-UbTAMRA cleavage assays were performed in a reaction buffer composed of 20mM 
HEPES pH 7.5, 100mM NaCl, 5mM MgCl2, 0.25mM ATP, 2mM DTT. The cleavage reaction 
was started by addition of USP1 (±UAF1) followed by incubation at room temperature 
for the specified time course. The concentration of DUB used for the kinetic modelling 
experiments was 1µM, 0.5µM, 0.25µM for USP1 and 20nM, 10nM, 5nM for USP1-UAF1. All 
the mutants tested for activity on PCNA-UbTAMRA were in complex with UAF1 and they were 
run in parallel with wild type USP1 at a concentration of 25 nM. Samples were collected 
at the indicated time points and the reaction was stopped by adding SDS loading buffer. 
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Samples were loaded on NuPAGE 4-12% Bis-Tris SDS gel (Invitrogen) and separated by 
running them at 180 V for 30 mins. The TAMRA fluorescence signal was visualized using 
a Typhoon FLA-9500 gel scanner (GE Healthcare) and the concentration of PCNA-UbTAMRA 
and ubiquitin was quantified by comparing the TAMRA fluorescence of the individual bands 
with a calibration curve of TAMRA fluorescence in the same experimental setting.
Kinetic modelling of USP1 activity on DNA-loaded and free PCNA-Ub
Kintek Explorer version 8.0 (Kintek Corporation (Johnson et al, 2009a)) was used to 
fit the reaction mechanism. Cleavage data from three different substrates i.e Ub-
Rhodamine, PCNA-Ub and DNA-loaded PCNA (Fig.4 and Sup. Fig.4) was used for the 
fitting simultaneously. The fitting presented here is based on all the data, but the model 
was built in stages. At first step, enzymatic activity assays data of USP1 and USP1-UAF1 
on minimal substrate Ub-Rhodamine was fitted to a product inhibition model. Which 
includes three steps: substrate binding, substrate cleavage and product release. The 
associations rate constants of substrate and product binding (kon) were set to diffusion 
limit approximation (100 µM-1s-1) and dissociation rate constants substrate and product 
(koff) share the same value in both reactions. The results of the fitting (kcat, KM and kcat/













kcut – cleavage rate constant
kon – substrate and product binding rate constant
koff – substrate and product dissociation rate constant
Next, the enzymatic activity FP assays data on PCNA-UbTAMRA substrate was added to 
the analysis. Same model was used and in addition to previous constrains cleavage rate 
constant (kcut) was shared same value for each enzyme, and koff shared same value in the 
reactions with same substrate. In additions concentrations of enzymes and substrates 
were allowed to vary up to 5% from the theoretical value in order to compensate for 
experimental pipetting error. At the last step of model building the data from gel base 
enzymatic activity assays on PCNA-UbTAMRA and DNA-loaded PCNA-UbTAMRA substrates 
was added to the analysis. Same model and rate constraints were used for the fitting. 
551327-L-bw-Dharadhar
Processed on: 30-12-2020 PDF page: 123
123
Insert L1 is a central hub for allosteric regulation of USP1 activity
However, it was not possible to achieve good global fit of the date unless the value of 
koff for USP1 in reaction with DNA-loaded PCNA-Ub
TAMRA was different from the value 
of koff for USP1-UAF1 in reaction with DNA-loaded PCNA-Ub
TAMRA. Solution landscape 
analysis of the fitted parameters was done using FitSpace Editor (Johnson et al, 2009b). 
It showed correlation between values of koff and kcut. Thus, only their ratios and magnitude 
are directly defined within the model, meaning that the values of kinetic efficiency (kcat/
KM) are giving the best representation of the modelling results.
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Fig EV1a) Structure based sequence alignment of USP1, USP12 and USP46 shows the relative positioning 
of inserts within USP1 which are highlighted as following, Insert 1 (red), Insert 2 (green) and Insert 3 (violet).
Fig EV1b) Homology model of USP1 (dark blue) based on the structure of USP12 (light blue) bound to UAF1 and 
WDR20 (green) highlights the positioning of USP1 inserts relative to its catalytic domain.
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Fig EV2a) Single point activity assays of USP1WT, USP1S313A, USP1S313D (+UAF1) shows no effect of these mutations 
on USP1 activity against the minimal substrate (Ub-Rho).
Fig EV2b) KinTek analysis of USP1ΔL1L3 and USP1WT activity on Ub-Rhodamine reveals that activation of USP1ΔL1L3 
is due to an increase in kcat.
Fig EV2c) Comparison of USP1-UAF1 activity on PCNA-Ub and PCNA-UbTAMRA shows that the TAMRA label does 
not affect the rate of ubiquitin cleavage (n=2).
Fig EV2d) Single point activity assays of USP1WT, USP1ΔL1 and USP1PIP mutants (+UAF1) on Ub-Rho shows similar 
activity of all mutants compared to USP1WT.
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Fig EV3a) Comparison of USP1+UAF1 activity on PCNA-UbWT and PCNA-UbPIM mutants shows lower USP1 
activity on PIM1 and PIM2 mutants.
Fig EV3b) SPR based binding experiments show that USP1ΔL1 has a reduced affinity for double stranded DNA 
(65bp) compared to USP1WT.
Fig EV3c) RFC mediated PCNA-Ub loading on nicked circular DNA has the same efficiency as loading of PCNA. 
Left Panel: Schematic representation of the purification of DNA loaded PCNA-Ub, Right panel: Coomassie 
stained gel of fractions corresponding to the first (green) and second (orange) peak from SEC of the PCNA and 
PCNA-Ub loading reactions respectively.
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Fig EV4) USP1 activity data used for KinTek analysis of USP1 on Ub-Rho, free PCNA-Ub and DNA loaded PC-
NA-Ub.
Fig EV4a) Gel based quantification of USP1 activity on PCNA-Ub (DNA loaded and free) for three different 
concentration of enzyme and substrate.
Fig EV4b) FP based activity assays on free PCNA-Ub (three concentrations of USP1 and PCNA-Ub) and activity 
of USP1 on increasing concentrations of Ub-Rho.
Fig EV4c) Full kinetic model of USP1 activity on three different substrates, constants with the same colour were 
linked during the fitting and they share same values.
Fig EV4d) EMSA based DNA binding experiment validates our KinTek modelling as it shows that USP1-UAF1 
has a higher DNA binding capacity compared to USP1 alone.
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Fig EV5a) Comparing activity of USP1 mutants on free PCNA-Ub substrate (n=2).
Fig EV5b) EMSA based DNA binding experiment shows that USP1DM2 (AEA) has reduced binding compared to 
USP1WT.
Fig EV5c) Comparing USP1 activity of DNA binding mutants and USP1WT on DNA-loaded PCNA-Ub (solid lines) 
and free PCNA-Ub (dashed lines) shows reduced activation of the DNA binding mutants compared to USP1WT. 
Left panel: Quantification of gel based activity assays showing percentage of cleaved PCNA-Ub at the mentioned 
time points (n=2), Right panel: Quantification of the activation fold observed in USP1WT, USP1DM1 and USP1DM2 
on DNA-loaded PCNA-Ub versus free PCNA-Ub (n=2).
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The genomic integrity of the cell is maintained by a host of repair pathways that employ 
enzymes from different families. Ubiquitin E3 ligases and deubiquitination enzymes 
(DUBs) are often involved in the regulation of these pathways and have emerged as 
potential drug targets in several diseases. This strategy of modulating ubiquitin 
modifying enzymes can lead to specific targeting of pathways resulting in less toxicity. 
Development of specific inhibitors for this group of enzymes has proven to be complex 
due to which most current inhibitors target the active site. Since most DUBs and E3 
ligases share identical active site grooves within their respective families the active 
site inhibitors often lack specificity. Therefore, development of compounds that target 
enzyme activity via an allosteric mechanism could lead to greater specificity and reduced 
off-target effects. Moreover, allosteric inhibitors are more likely to avoid resistance and 
they can be used in combination with more traditional inhibitors to increase their clinical 
potential (Wylie et al, 2017). In this thesis, we study the ubiquitin modifying enzymes 
involved in the translesion synthesis pathway and gain a mechanistic understanding of 
how these enzymes are regulated allosterically.
Stalling of replication forks due to damaged DNA is overcome either by repairing the 
impeding damage or by DNA damage tolerance (DDT) pathways. Translesion synthesis 
is a DDT pathway where the damaged DNA is bypassed by specialized translesion 
polymerases thereby preventing the formation of toxic DNA damage induced by fork 
stalling. Mono-ubiquitination of PCNA is an essential regulatory step of this pathway as 
it leads to the recruitment of the translesion polymerases to the replication fork (Hedglin 
& Benkovic, 2015). The E2-E3 ligase pair of RAD6-RAD18 and the DUB USP1 regulate the 
(de)modification on DNA-loaded PCNA (Hoege et al, 2002; Huang et al, 2006). Here, we 
looked at the mechanisms involved in the regulation of catalytic activity of USP1 and 
RAD18 by the substrate i.e. DNA-loaded PCNA-Ub. We also investigated the activation 
of USP1 and two closely related paralogs, USP12 and USP46 by a WD40 repeat protein 
called UAF1.
USP1, USP12 and USP46 belong to the largest family of DUBs called the Ubiquitin specific 
proteases (USPs). USP12 and USP46 are mainly composed of the USP catalytic domain 
and have a sequence similarity of 88%. They are amongst the smallest members of the 
USP family which are mostly large multi-domain proteins with a conserved catalytic 
fold. USP1 is much larger compared to USP12 and USP46 mostly due to the presence 
of several inserts within its catalytic domain but the function of these inserts is so 
far unknown. The role of inserts on USP catalytic activity has not been studied in a 
systematic manner but it is known that several USPs contain domains that are involved 
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in self-regulatory mechanisms which affect intrinsic activity or substrate recruitment 
(Nijman et al, 2005; Ye et al, 2009; Sahtoe & Sixma, 2015). In Chapter 4, we have 
investigated the role of these inserts in USP1 activity on the minimal substrate. We 
found that the large insert 1 along with insert 3 auto-inhibit USP1 activity in the absence 
of UAF1. This auto-inhibition is not observed in the presence of UAF1 suggesting that 
UAF1 binding leads to a rearrangement of insert 1 and insert 3 resulting in the loss of 
auto-inhibition.
The insert 3 of USP1 is a small insert of approximately 20 amino acid residues and is 
located on the backside of the ubiquitin binding cleft. This is a functionally intriguing 
location as USP12 and USP46 bind to their secondary activator, WDR20, in this region 
(Li et al, 2016). Unlike USP12 and USP46, USP1 does not interact with WDR20 (Kee et al, 
2010) but instead carries the insert 3 which we show plays an important role in USP1 
activity together with insert 1. We went a step further and showed that insert 1 and 3 
mediated activation in USP1 resembles the WDR20-mediated activation of USP12 and 
USP46. Moreover, our activity studies revealed that UAF1 binding to USP1 compensates 
for the lack of WDR20 binding as USP1-UAF1 reaches the same catalytic state as the 
USP12/USP46-UAF1-WDR20 complex. This compensation is brought about in part by 
the rearrangement of the insert 1 and insert 3 upon UAF1 binding. In the absence of 
any structural information of the USP1-UAF1 complex it is difficult to fully understand 
the effect of UAF1 binding but our studies have identified a defined region for allosteric 
activation in USP1. Many other USPs contain inserts (Nijman et al, 2005; Ye et al, 2009) 
whose function is still not known and a systematic approach of probing USP activity 
upon insert deletion could lead to more examples of such allosteric mechanisms.
Structural information on the USP-UAF1 complex could be vital to understand how this 
class of USPs is activated by UAF1. In chapter 3, we have solved the crystal structure of 
the USP12-UAF1 complex bound to ubiquitin and found two sites for UAF1 binding. We 
show that the USP12-UAF1 complex exists in a 1:2 stoichiometry in solution where UAF1 
binds USP12 on the finger subdomain and on the backside of the ubiquitin binding cleft 
(Dharadhar et al, 2016). We confirmed previous findings that UAF1 binding on the fingers 
of USP12 leads to catalytic activation in spite of the binding site being distant from 
the USP catalytic center (Yin et al, 2015). We did not observe any significant structural 
changes in USP12 upon UAF1 binding as the enzyme was trapped in the activated state 
with Ubiquitin Propargyl for structural studies. We tried determining the structure of the 
USP12-UAF1 complex in the absence of ubiquitin but failed to do so. However, another 
group was able to determine the structure of USP12-UAF1 without ubiquitin and also the 
structure of the USP12-UAF1-WDR20. They identified several subtle rearrangements in 
6
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USP12 upon UAF1 binding and proposed that the allosteric activation was a sum of all 
these changes (Li et al, 2016). Interestingly, one prominent location was the small helix 
and loop at the base of the fingers which is where insert 3 is located in USP1.
In Chapter 3, we also show that UAF1 binds to a second site on USP12 which does not 
have an effect on its catalytic activity. Our binding studies confirm that this two-step 
binding is also conserved in both USP46 and USP1 which could imply an important 
role that is independent of activation. In case of USP12 and USP46 this second binding 
could have a direct impact on WDR20-mediated activation as there is a partial overlap 
between the two interfaces. The binding kinetics of UAF1 for the two binding sites is 
different as the fingers binding has high affinity with low off rates while the backside 
binding has relatively low affinity with high off rates. This could indicate a more dynamic 
role in regulation of USP1/12/46 function for the backside binding but the exact function 
remains to be determined. So far, we have been unable to develop disruptive mutations 
in USP12 for the backside binding as it is dominated by backbone interactions. The lack 
of site-specific mutations has made it difficult to perform any functional studies for the 
role of backside binding but its conservation in the sub-family indicates an important 
role for USP activity.
The activation of USP12 by UAF1 is a dynamic process where several elements undergo 
small changes that allow for greater catalytic activity. This has become apparent from 
the set of USP12-UAF1 structures which show marked differences amongst themselves. 
Thus, new emerging techniques will have to be used to fully understand the UAF1 
activation mechanism as crystal structures alone will only serve as snapshots of a 
highly mobile system. In the case of USP1 this is more important since it has longer 
flexible regions which we have shown to be essential for UAF1 mediated activation of 
USP1. We know that the finger subdomain of USP1 is important for UAF1 binding and 
it is likely that the allosteric effect observed is relayed from the fingers to the rest of 
the molecule similar to what is seen in USP12. Homology models of the USP1-UAF1 
complex based on the USP12-UAF1 structures show that insert 3 of USP1 lies at the 
base of the fingers which could explain how UAF1 binding leads to the loss of the insert 
1 and insert 3 mediated auto-inhibition. Structural information of the full-length protein 
or insert 1 alone could help in obtaining more details of the activation mechanism as 
any further correlation from the USP12 structures is difficult due to the large size of the 
USP1 inserts.
Enzymatic analysis of DUBs has been mostly carried out on minimal substrates which 
leads to a limited understanding of the enzyme in several areas. One such aspect is 
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the effect of enzyme-substrate interactions on the catalytic state of the enzyme. In 
the case of USP1, the natural substrate is mono-ubiquitinated PCNA (PCNA-Ub) but 
since it carries out its role in TLS the ideal substrate should be PCNA-Ub loaded on 
DNA. In Chapter 4, we establish a workflow to purify DNA-loaded PCNA-Ub and perform 
quantitative enzymatic assays with USP1-UAF1. We show that USP1-UAF1 undergoes 
a 5-fold activation on DNA-loaded PCNA-Ub compared to free PCNA-Ub whereas USP1 
alone undergoes a 2-fold activation on the DNA-loaded substrate. The role of DNA 
binding in USP1 activity on FANCD2 has been studied before and conflicting results have 
emerged with one report claiming that FANCD2-UB is shielded by DNA leading to reduced 
deubiquitination (Twest et al, 2017) while the other reports shows that the presence of 
DNA stimulates USP1-UAF1 activity on FANCD2-UB (Liang et al, 2019). The increase in 
activity of USP1 and USP1-UAF1 complex on DNA-loaded PCNA-Ub was solely due to an 
increase in affinity for the substrate. Combining USP1 activity data from three different 
substrates allowed us to develop a comprehensive model for USP1 activity regulation 
with defined kinetic parameters. Our analysis identified two distinct mechanisms of 
USP1 activation involving UAF1 activation by increased catalytic turnover and through 
DNA-loaded PCNA by increased substrate binding.
The DNA binding ability of both USP1 and UAF1 has been described in literature before 
but their role in TLS remains to be investigated (Lim et al, 2018; Liang et al, 2019). 
In Chapter 4, we have provided an impetus to this process by identifying mutations 
that disrupt both DNA and PCNA interactions respectively. Using a combination of 
mutagenesis and in vitro activity assays we show that insert 1 of USP1 is essential for 
not only DNA binding but also for activity on PCNA. Identification of a PCNA interaction 
mutant in USP1 allows us to specifically affect USP1 function in the TLS context as 
the region that interacts with FANCD2 resides in the N-terminal extension of USP1 and 
deletion of USP1 inserts does not affect activity on FANCD2 (Arkinson et al, 2018). 
Additionally, the PCNA interaction mutant is proficient in DNA binding which allows us 
to delineate the role of DNA binding and PCNA interaction within TLS. Based on our 
enzymatic assays of these mutants on DNA -loaded PCNA-Ub, we propose that both 
the DNA and PCNA interactions of insert 1 are necessary to achieve full activation 
on DNA- loaded PCNA. The effect of these mutants in cell-based functional assays 
remains to be tested and work in this direction is currently ongoing. Insert 1 of USP1 
has emerged as a vital component for USP1 activity regulation by UAF1 and for USP1 
activation on DNA- loaded PCNA. It is a large insert of 200 amino acids and currently 
there is no structural information available but this is a promising target for development 
of allosteric inhibitors to specifically inhibit USP1 function.
6
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USP1 deubiquitination of PCNA-Ub in TLS is counteracted by the E2-E3 ligase couple 
RAD6-RAD18. It is known for more than a decade that RAD6-RAD18 mediated 
ubiquitination is more efficient (100 folds) when PCNA is loaded on DNA (Haracska 
et al, 2006) but several mechanistic questions remain unanswered. In Chapter 5, we 
uncover the molecular determinants involved in this activation and also shed light on 
the mechanism of this substrate mediated activation. Similar to insert 1 of USP1, we 
show that the SAP domain of RAD18 has both DNA and PCNA interaction regions. Our 
data confirms the presence of a previously unidentified PCNA interaction region which 
contains a PIP motif commonly found in PCNA interacting proteins. Presence of the PIP 
motif in both USP1 and RAD18 indicates the likelihood of both these enzymes competing 
with each other for access to PCNA which will be governed by factors such as local 
concentration of the enzymes and their affinity to the substrate.
In RAD18, the SAP domain is comprised of approximately 50 residues and both DNA and 
PCNA interaction regions are close to each other. We observed that all our DNA binding 
mutants which are outside the PIP motif had a severe effect on PCNA activity. However, 
we could delineate the two roles of the SAP domain as the RAD18 PIP mutant lacked any 
PCNA activity but was still proficient in DNA binding. The in-house setup for purification 
of DNA-loaded PCNA allowed us to test a large set of RAD18 mutants in quantitative 
gel-based enzymatic assays. These assays also enabled us to follow RAD18 auto-
ubiquitination and we observed that there is no change in RAD18 auto-ubiquitination 
in the presence of DNA-loaded substrate. This suggests that the observed activation 
on DNA-loaded PCNA is due to an increase in affinity for the substrate rather than an 
intrinsic activation of the RAD18 ubiquitination process. Upon testing a combination of 
DNA and PCNA interaction mutants for activity on DNA-loaded PCNA, it was apparent 
that unlike USP1, activation in RAD18 was solely due to DNA interactions of the SAP 
domain. This suggests that upon DNA binding the RAD18 molecule is arranged in such 
a manner that the RAD6-loaded ubiquitin molecule is positioned optimally for transfer to 
K164 on PCNA. It is likely that the DNA-mediated positioning of RAD18 with respect to 
PCNA allows for RAD18-PCNA interaction making the PIP mutant redundant. Overall, our 
data confirm the role of DNA binding in the activation of RAD18 on DNA-loaded PCNA.
In Chapter 5, we also investigated the mechanistic details of RING-mediated ubiquitin 
transfer in RAD18. We show that RAD18 uses a unique RING-ubiquitin interface for auto-
ubiquitination and for mono-ubiquitination on DNA-loaded PCNA. However, RAD18 needs 
the traditional charged residue interface (R76) (Densham et al, 2016) for efficient mono-
ubiquitination of free PCNA which indicates the presence of a change in mechanism 
in RAD18 between substrates. Since the PIP interaction of RAD18 is only essential for 
551327-L-bw-Dharadhar
Processed on: 30-12-2020 PDF page: 155
155
General discussion
activity on free PCNA it is possible that this interaction leads to conformational changes 
in RAD18 that engages the traditional charged interface for ubiquitin transfer. The RAD18 
interface involved in ubiquitin transfer to DNA-loaded PCNA and for auto-ubiquitination 
remains to be identified. Until now dimeric RING E3 ligases have been shown to rely on 
the “arginine lynchpin” for stabilizing the closed conformation of E2-Ub, which enables 
the efficient transfer of ubiquitin to the substrate (Plechanovová et al, 2012; Dou et al, 
2012; Densham et al, 2016). However, the RING domain of Arkadia depends on secondary 
ubiquitin-RING binding to stabilize the closed confirmation and enhance ubiquitin 
transfer (Wright et al, 2016). A similar mechanism could exist in RAD18 where the donor 
ubiquitin interacts with additional RING or non-RING elements of the E3 ligase. Further 
biochemical and structural studies would help in determining these regions within RAD18 
and also reveal details on how the nature of the substrate can alter catalytic activity by 
switching interfaces involved in ubiquitin transfer.
In this thesis, we have uncovered several molecular mechanisms involved in the 
regulation of ubiquitin modifying enzymes. The role of USP1 inserts in activation by 
UAF1 sheds light on self-regulatory mechanisms that are involved in controlling USP1 
enzymatic activity. Several other USP proteins contain inserts whose functions are still 
unknown, thus research in this direction could lead to an understanding of several such 
self-regulatory mechanisms. In addition to self-regulation of catalytic activity we have 
also uncovered mechanistic details of substrate-mediated activation in both USP1 and 
RAD6-RAD18. Biochemical characterization of these enzymes using natural substrates 
has led to the identification of molecular determinants that are involved in this activation. 
Our studies show that both USP1 and RAD6-RAD18 contain PIP interaction regions, 
this could have an important role to play in TLS pathway as both would compete for 
the same site on PCNA and depending on upstream stimuli they could dislodge each 
other from the substrate. (De)-Ubiquitination assays of other E3 ligases and DUBs with 
their respective substrates could offer several more examples of substrate mediated 
alterations in catalysis. The regions involved in the allosteric regulation of E3 ligases 
and DUBs have immense potential for the development of potent inhibitors that target 
regions other than the conserved active site of these proteins. If detailed molecular 
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DNA damage is a continuous process that needs to be countered effectively by the cell 
to ensure a healthy genome. The cell uses DNA repair pathways to remove damaged 
sites on DNA but during replication it also makes use of DNA damage tolerance (DDT) 
pathways to prevent stalling of the replication fork. Translesion synthesis is a DDT 
pathway that is regulated by the attachment and removal of a single ubiquitin molecule 
on PCNA. The E2-E3 pair RAD6-RAD18 mono-ubiquitinate PCNA at K164 residue and 
USP1 deubiquitinates the mono-ubiquitinated PCNA. The catalytic activity of both these 
enzymes is regulated by different mechanisms, especially USP1, which binds a WD40 
repeat protein called UAF1 leading to a significant increase in its activity.
Ubiquitin specific proteases (USPs) form the largest class of DUBs and many have been 
implicated in crucial cellular processes. In Chapter 2, we provide a template for studying 
Ubiquitin specific protease (USP) function in vitro. The purification of a few USP proteins 
is described here along with detailed procedures for studying enzymatic activity of USPs. 
This chapter shows how activity studies could be used to identify different layers of 
regulation in USPs, which could be mediated by internal domains, interacting modulators 
or even the substrate itself. Since, all these regulatory factors could contribute together it 
is useful to perform quantitative analysis which can tease apart individual contributions 
of different factors.
In Chapter 4, we perform quantitative analysis of USP1 activity on 3 different substrates 
of increasing complexity, i.e., Ub-Rhodamine, PCNA-Ub and DNA-loaded PCNA-Ub. We 
show that USP1 activity is stimulated on DNA-loaded PCNA compared to free PCNA-Ub. 
Our quantitative kinetic modelling of USP1 activity shows that the activation on the DNA-
loaded substrate is solely due to an increase in affinity for the substrate. Using deletion 
mutants of USP1, we identify insert L1 as the domain responsible for the activation on 
the DNA loaded substrate. We also identify regions within insert L1 which are important 
for DNA and PCNA interaction, and we show that both these interactions are important 
for stimulation of USP1 activity on DNA-loaded PCNA.
USP1 has low intrinsic activity alone but it gets activated upon binding a WD40 repeat 
protein called UAF1 which increases the catalytic turnover of USP1. Two closely related 
paralogs of USP1, i.e. USP12 and USP46 also bind UAF1 and get activated by an increase 
in catalytic turnover. In Chapter 3, we show how UAF1 binds this class of USPs by solving 
the crystal structure of the USP12-UAF1 complex with ubiquitin. We identify a conserved 
two step binding of UAF1 to USP12 and USP1 as well as confirm the presence of a 1:2 
stoichiometry of the USP12-UAF1 complex in solution. Using mutational analysis, we 
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show that the high affinity UAF1 binding on the fingers of USP12 is important for the 
activation of the enzyme whereas the low affinity backside binding does not play a direct 
role in activation. Since the backside UAF1 binding site overlaps with another activator 
of USP12 called WDR20, we propose that the backside binding of UAF1 might play a role 
in regulation of USP12 by competing with WDR20.
USP1 unlike USP12 and USP46 has several inserts whose role in USP1 function is poorly 
understood. In Chapter 4, we identify a self-regulatory mechanism in USP1 involving 
the combined action of insert L1 and insert L3. We show that insert L1 and L3 together 
auto-inhibit USP1 activity and this gets relieved upon binding of USP1 to UAF1. We 
also observe that removal of insert L1 and L3 mediated auto-inhibition brings USP1 to 
a catalytic competent state similar to what is observed in USP12/USP46 upon WDR20 
binding. Our analysis demonstrates how UAF1 binding leads to activation of USP1 by 
relieving insert L1 and L3 mediated auto-inhibition.
In Chapter 5, we uncover the mechanisms involved in RAD6-RAD18 activity on DNA-
loaded PCNA. We confirm the importance of the SAP domain in RAD18 for activity 
on both free and DNA-loaded PCNA. We identify a PCNA interaction site within the 
SAP domain and by mutational analysis show that it is important for activity of RAD18 
on free PCNA. Activity assays on DNA-loaded PCNA with RAD18 mutants show that 
RAD18 activation is entirely dependent on SAP-DNA interactions. Finally, we propose 
that RAD18 uses two different RING-ubiquitin interfaces for ubiquitin transfer depending 
upon the type of substrate. We show that RAD18 uses a common arginine residue (R76) 
for ubiquitin stabilization and transfer on free PCNA but for transfer on DNA loaded 
PCNA or RAD18 itself, it uses a unique RING-ubiquitin interface.
In Chapter 6, we discuss the results presented here in the context of existing research 
from the ubiquitin field and provide future directions for research in the regulatory 
mechanisms of DUBs and E3 ligases.
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DNA schade is een voortdurend proces dat de cel continu moet herstellen, om zo een 
gezond genoom te behouden. De cel gebruikt de DNA reparatieroutes om schade in DNA 
te verwijderen. Maar tijdens DNA replicatie, wanneer herstel te lang zou duren, wordt door 
de cel het DNA damage tolerance (DDT) mechanisme gebruikt, om te voorkomen dat de 
replicatie vork vastloopt. Een belangrijke vorm van DDT is de translesie synthese. Deze 
wordt gereguleerd door het plaatsen en verwijderen van een enkel ubiquitine molecuul op 
PCNA. Het E2-E3 paar, RAD6-RAD18, plaatst een enkele ubiquitine op lysine 164 (K164) in 
PCNA en USP1 haalt deze mono-ubiquitine weer weg. De katalytische activiteit van deze 
beide enzymen wordt op diverse manieren gereguleerd Dit geldt met name voor USP1, 
waar binding aan een WD40-repeat eiwit, genaamd UAF1, een significante activatie geeft.
Ubiqiutine-specifieke proteases (USPs) vormen de grootste klasse van de-ubiquitinerende 
enzymen (DUB), en zijn betrokken bij vele cruciale cellulaire processen. In Hoofdstuk 2, 
tonen wij een template voor het bestuderen van USP functies in vitro. De zuivering van 
een aantal USP eiwitten wordt besproken, samen met gedetailleerde procedures voor de 
bestudering van enzymatische activiteit in USPs. Dit hoofdstuk laat zien hoe activiteit-
experimenten gebruikt kunnen worden om verschillende niveaus van USP-regulatie te 
identificeren. Diverse factoren kunnen bijdragen aan de activiteit, zoals interactie met 
interne domeinen, met externe modulatoren of zelfs met het substraat zelf. Aangezien 
al deze factoren kunnen samenwerken is het belangrijk om kwantitatieve analyses uit 
te voeren waarmee de individuele invloeden van de verschillende factoren van elkaar 
gescheiden kunnen worden.
In Hoofdstuk 4, laten we kwantitatieve analyses van USP1-activiteit zien op drie 
verschillende substraten, oplopend in complexiteit; Ub-Rhodamine, PCNA-Ub en PCNA-
Ub geladen op DNA. We tonen aan dat USP1 activiteit gestimuleerd wordt door PCNA-Ub 
op DNA, vergeleken met vrij PCNA-Ub. De kwantitatieve modelering van USP1 activiteit 
laat zien dat de activatie op het DNA-geladen substraat uitsluitend komt door een 
toename in affiniteit voor het substraat. Door gebruik te maken van deletiemutanten 
van USP1, hebben we de insertie L1 geïdentificeerd als het domein dat verantwoordelijk 
is voor de activatie op het DNA-geladen substraat. Ook hebben we regio’s in insertie L1 
gevonden die belangrijk zijn voor de interactie met DNA en PCNA. We tonen aan dat deze 
interacties met DNA en PCNA belangrijk zijn voor de stimulatie van USP1 activiteit op 
het op DNA-geladen PCNA.
USP1 heeft een lage intrinsieke activiteit. Deze wordt versterkt door de binding aan 
een WD40-repeat eiwit, genaamd UAF1, door een hogere katalytische turnover. Twee 
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gerelateerde paralogen van USP1, USP12 en USP46, binden ook aan UAF1, en worden 
ook geactiveerd via een toename in de katalytische turnover. In Hoofdstuk 3, laten we 
zien hoe UAF1 deze klasse van USPs bindt door het oplossen van de kristalstructuur 
van het USP12-UAF1 complex gebonden aan ubiquitine. We hebben een geconserveerd 
twee-staps binding van UAF1 aan USP12 en USP1 geïdentificeerd, en daarnaast een 
1:2 stoichiometrie van USP12-UAF1 in oplossing. Door gebruik te maken van mutatie 
analyses, kunnen we de hoge affiniteit van UAF1 voor de ‘vingers’ van USP12 aantonen, 
en het belang hiervan voor de activatie van de enzymactiviteit. Dit terwijl de binding aan 
de ‘achterkant’ een lage affiniteit heeft en geen directe rol spelt in de activatie. Aangezien 
de ‘achterkant’ van UAF1 overlapt met een andere activator van USP12, genaamd WDR20, 
stellen we voor dat de binding met de ‘achterkant’ van UAF1 mogelijk een rol speelt in 
de regulatie van USP12 door competitie met WDR20.
USP1 heeft, in tegenstelling tot USP12 en USP46, een aantal inserties waarvan de rol 
niet volledig begrepen is. In hoofdstuk 4, hebben we een zelfregulerend mechanisme 
ontdekt in USP1, wat verzorgd wordt door de gecombineerde activiteit van inserties L1 
en L3. We tonen aan dat inserties L1 en L3 samen een automatische rem vormen op 
USP1 activiteit, en deze remming wordt opgeheven na de binding van UAF1 aan USP1. 
Ook laten we zien dat het afnemen van de automatische rem van inserties L1 en L3, USP1 
in een katalytische competente status brengt die vergelijkbaar is aan de toestand van 
USP12/USP46 na binding aan WDR20. Onze analyses tonen hoe UAF1 binding leidt tot 
activatie van USP1 door het afnemen van de automatische rem, door L1 en L3.
In Hoofdstuk 5, ontdekken we de mechanismen die betrokken zijn bij RAD6-RAD18 
activiteit op DNA-geladen PCNA. We bevestigen het belang van het SAP domein in 
RAD18 voor de activiteit op zowel vrij als DNA-geladen PCNA. We identificeren een 
bindingsplaats voor PCNA in het SAP domein, en door middel van mutaties tonen we aan 
dat deze binding belangrijk is voor de activatie van RAD18 op vrij PCNA. Activatieproeven 
op het DNA-geladen PCNA met RAD18 mutanten laat zien dat de activatie van RAD18 
volledig afhankelijk is van de interacties tussen SAP en DNA. Tenslotte poneren we de 
hypothese dat RAD18 twee verschillende RING-ubiquitine bindingsplekken heeft, die 
overdracht van ubiquitine mogelijk maken en dat het gebruik hiervan afhankelijk is van 
het type substraat. We laten zien dat RAD18 een bekende arginine (R76) gebruikt voor 
het stabilisaties van ubiquitine op de E2 en katalyse van de overdracht naar vrij PCNA 
maar voor dit proces, op DNA-geladen PCNA of op RAD18 zelf, gebruikt het een unieke 
bindingsplaats op het RING-ubiquitine oppervlak.
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In Hoofdstuk 6, plaatsen we de resultaten in de context van bestaande literatuur van 
het ubiquitine-veld. Daarnaast geven we voorstellen voor toekomstig onderzoek naar 
mechanismen van DUBs en E3-ligases.
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1. UAF1 binding to the finger sub-domain of USP12 leads to increased catalytic activity 
while the second binding event does not affect catalytic activity on a minimal 
substrate. (this thesis)
2. The primary mechanisms by which USP1 is activated by UAF1 is through relieving 
the auto-inhibition caused by the joint action of insert L1 and L3. (this thesis)
3. USP1 deubiquitinates PCNA-Ub more efficiently when it is loaded on DNA and this 
effect is strengthened when in complex with UAF1. (this thesis)
4. Insert L1 is an important regulatory hub within USP1 necessary for both substrate 
mediated activity enhancement and allosteric activation upon UAF1 binding. (this 
thesis)
5. RAD18 employs two distinct interfaces for ubiquitin transfer on free PCNA and DNA 
loaded PCNA respectively. (this thesis)
6. Successful in vitro characterization of de(ubiquitination) enzymes requires pure 
and stable protein.
7. Quantitative analysis of enzymatic activity on natural substrates is essential for 
mechanistic understanding of enzyme function and regulation.
8. Structural information alone is not enough to understand dynamic regulatory 
systems involving flexible elements.
9. A lot of good scientific research is lost due to a lack of time to pursue unexpected 
results.
10. While differing widely in the various little bits we know, in our infinite ignorance we 
are all equal. (Karl R. Popper)
11. We must accept finite disappointment, but never lose infinite hope. (Martin Luther 
King, Jr)
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